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ABSTRACT 
Treatment of mental illness differs between races. Many reports, investigations, public 
enquiries and surveys have been conducted documenting differences in referral to 
specialist mental health services, admission rates to hospital, detention under the Mental 
Health Act and seclusion whilst in hospital. These differences are particularly marked 
for black patients compared with white.  
 
Concerns about these differences, in addition to research (predominantly from the 
United States) showing differences in prescribing of antipsychotics for ethnic 
minorities, have prompted United Kingdom studies investigating any prejudicial 
prescribing of antipsychotics. Identified differences include use of high doses, more 
frequent use of older drugs and depot formulations, especially for black compared with 
white patients. Most of these UK studies were older, had small sample sizes and 
controlled for few, if any, confounding factors affecting antipsychotic prescribing. A 
large, multi-centre, cross-sectional survey of antipsychotic prescribing by ethnicity, 
collecting over 20 potential confounding factors, was undertaken to measure dose, high 
dose, polypharmacy, type of antipsychotic, cost of antipsychotic, clozapine use and 
route of administration. The null hypothesis was that black patients receive 
antipsychotic drug treatment of equal dose, type, number, cost and route to white 
patients. Data were analysed (using regression methods) for black and white patients 
alone (as these are the two ethnicities with the most reported differences in medication 
use), for all ethnicities (to see if any differences for other ethnic groups not only black 
and white), by individual centre (to determine if prescribing by ethnicity differs by 
location) and also to determine which factors predicted outcomes. Medical prescriber 
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attitudes to prescribing by ethnicity were assessed using a case vignette and 
questionnaire method. 
 
Analysis by ethnicity did not find differences between black and white patients (n=938) 
in dose (adjusted percentage difference 0.97 [95% confidence interval (CI) -4.28, 6.22], 
p=0.72); high dose (adjusted odds ratio [AOR] 0.98 [CI 0.63, 1.51], p=0.92); use of first 
generation antipsychotics (AOR 1.25 [CI 0.87, 1.79], p=0.22); polypharmacy prescribed 
(AOR 1.15 [CI 0.87, 1.51], p =0.33); polypharmacy administered (AOR 1.08 [CI 0.78, 
1.49], p=0.66); or cost of antipsychotic treatment (adjusted effect size 1.75 [CI -9.81, 
13.31], p=0.77). Re-analysis including all ethnicities and inclusion of two other 
outcomes (route of administration and clozapine use), also did not find differences by 
ethnicity although many variables were associated with the outcomes. Some of these 
relationships were unexpected, for example the use of lower doses and first generation 
antipsychotics, but most could be explained rationally.  
 
Analysis of data by the different sites involved revealed differences in prescribing by 
ethnicity, particularly for one centre. These effects included higher doses, 
polypharmacy, greater use of 1st generation antipsychotics and higher costs 
predominantly for black compared with white patients. Unfortunately for some of these 
outcomes it was not possible to adjust results for potential confounders because of some 
centres’ small sample sizes and missing data.  
 
After dissemination of findings, ethnic minority prescribers reported that they were very 
surprised with the results of these studies on antipsychotics and ethnicity. They said 
they purposely prescribed higher doses for black patients as they were more severely ill 
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on admission to hospital. To test the validity of these comments all medical prescribers 
at one NHS trust were surveyed using a case vignette and questionnaire. Differences 
were not found in antipsychotic prescribing by ethnicity for percentage maximum dose 
(47.7% black, 50.9% white, p=0.57), high dose (1.67% black, 3.33% white, p=0.68), 
type (1.6% black, 2.5% white, p=0.10), polypharmacy (3.3% black, 6.5% white, 
p=0.37) and route of administration (intramuscular 0.8% black, 0% white; oral black 
44.7%, white 45.5%; oral or intramuscular black 3.3%, white 5.7%; p=0.53) outcomes. 
 
The study was, at the time it was undertaken, the largest UK study of antipsychotic 
prescribing in black and white patients and the most geographically diverse. Overall 
clinical and theoretical studies described in this thesis did not show differences in 
antipsychotic prescribing by ethnicity. Some individual centres may have poorer 
prescribing by ethnicity that requires remedial action, although such differences were 
infrequently observed. Nevertheless, for all of these studies significant limitations, 
including in design and analysis, may have affected these results. 
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CHAPTER 1 INTRODUCTION - ETHNICITY AND PRESCRIBING 
1.1 RACE AND ETHNICITY  
What is race? The Oxford English Dictionary defines race as ‘each of the major 
divisions of humankind, having distinct physical characteristics’. Confusingly it also 
describes race as ‘a group of people sharing the same culture, history, language, etc.; an 
ethnic group’ and has six further definitions. Ethnicity, however, is described as ‘the 
fact or state of belonging to a social group that has a common national or cultural 
tradition’.  In practice the two terms are often used interchangeably, for example when 
requesting patients’ race or ethnic group on hospital admission. As we have seen, 
neither are simple or precise terms. 
 
Use of the word ‘race’ has been problematic as it is associated with historical attempts 
to categorise people by their skin colour and other physical characteristics. These 
categories have, in the past, been used to defend the use of eugenics and social 
Darwinism but are a social and political rather than a biological construct.  The term 
‘ethnic group’ (United Nations Educational Scientific and Cultural Organiszation, 1950) 
is sometimes suggested as a preferred term as it includes cultural groups of various 
kinds and also white people. It is important to use the term ‘ethnic group’ rather than 
‘ethnic’ as in some cultures, particularly the United States, ethnic is sometimes used to 
refer to black communities. 
 
When we use the term ‘race’ we may assume others understand our meaning. 
Anthropologists study of the term has found that the public say race is based on 
biological differences, is relatively unchanging and races are easily distinguishable from 
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each other (MacEachern, 2011). Likewise organisations and Acts of Parliament 
concerned with equality have traditionally used the term ‘race’, for example the 
Commission for Race Equality and the Race Relations Act 2000. These have been 
renamed respectively as the Equality and Human Rights Commission and repealed for 
the Equality Act 2010. 
 
How is ethnicity measured in the UK? The largest data collection of ethnicity comes 
from the UK census. From 1841 census data collected information on country of birth 
only for persons born outside England and Wales. A question on parents’ country of 
birth was added in 1971 and it was not until the 1991 census that race/ethnicity data 
were collected in the UK but still not in Northern Ireland (Office for National Statistics, 
2006). Respondents were asked about their ethnic group rather than ethnic origin. The 
categories used then were white, black-African, black-other, Indian, Pakistani, 
Bangladeshi, Chinese, any other ethnic group.  This categorisation was criticised as it 
did not separate white respondents into any groups and did not allow people to describe 
themselves as British. By 2001 Northern Ireland was included (white, mixed and Irish 
Traveller options) and British, Irish, other white and mixed were added.  The options 
then were white (British, Irish, any other white background), mixed (white and black 
Caribbean, white and black African, white and Asian, any other mixed background), 
Asian/Asian British (Indian, Pakistani, Bangladeshi, any other Asian background), 
black/black British (Caribbean, African, any other black background), Chinese or other 
ethnic groups (Chinese, any other). Furthermore a question on religion was included as 
for some this is a more important signifier of identity than ethnicity. In the most recent 
census in 2011 Gypsy/Irish Traveller and Arab were added and Chinese was reclassified 
to Asian. Categories were as in Appendix 1. The 2011 census also asked a question 
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about ‘national identity’ allowing respondents to express which country or countries 
they were most affiliated to (Office for National Statistics, 2011), allowing 
classification to become more complex and nuanced. 
 
The Office for National Statistics Ethnic Group Classification 2015 recommends using 
a very similar classification system to the 2011 census (Office for National Statistics, 
2015) for data collection. It emphasises the importance of self-identification and 
allowing respondents to see all possible options available before selection. The UK 
NHS still uses the 2001 census classification as the national standard for mandatory 
ethnicity data collection (Department of Health, 2001) so lags behind in its modernity. 
Scotland recently started using the 2011 classifications.  
 
We can see, over a 20-year period, the subtle changes and increased sophistication of 
ethnicity classification. Even with these changes critics describe what is being measured 
as still predominantly race, as opposed to ethnicity.  A person’s ethnicity is based as 
much on subjective factors as the practicalities of place of birth etc. A pragmatic 
solution has to be reached that incorporates enough variation to allow respondents to 
feel their ethnicity is accurately described but also allows large enough samples in each 
group for statistical analysis. Researchers need to be aware of the heterogeneity and 
limitations of their classifications (Mathur, 2013) as people may be racially similar but 
culturally distinct. Higher level groupings can mask heterogeneity that is important - for 
example white groups include the Irish, people from eastern European whilst Asian 
includes people from Pakistani, Indian, Bangladeshi and since the 2011 census Chinese. 
These groups can vary in health outcomes because of different socioeconomics and 
levels of education. For instance, coronary artery bypass graft surgery rates by ethnicity 
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– worst for Bangladeshi, better for Pakistani and best for Indian people. Grouping these 
people together as Asian loses these important distinctions. Collapsing ethnic minority 
groupings risks finding false negative results. 
1.2 ETHNICITY AND RESEARCH 
1.2.1  PARTICIPATION IN RESEARCH 
Participation in research studies by minority ethnic groups is crucial so that trial data 
can be generalised to the populations that are being treated. In addition if the results of 
research studies are not reported by ethnic group we do not know if treatments are 
ineffective, intolerable or require adjustment. Inclusion of ethnic groups in research is a 
core component of ensuring health equality.  
 
National guidelines from the NIH in the US now stipulate that minority ethnic groups 
must be recruited into clinical trials in adequate numbers (National Institutes of Health, 
2001).  The NIH Revitalization Act of 1993 (National Institutes of Health, 1993) 
directed the NIH to produce guidelines to include women and minorities in research, 
making researchers legally bound to recruit and report data on these groups. This 
guidance does not specify what proportion of minorities should be included in a study 
but instead gives advice depending on whether or not previous studies suggest 
significant or equivocal differences. It also states that when earlier studies suggest there 
are, or there could be, differences by gender or ethnicity proposals ‘must include a 
description of plans to conduct analyses to detect significant differences in intervention 
effect by sex/gender, racial/ethnic groups, and relevant subpopulations’. 
 
All clinical trial research in the UK is currently conducted under the EU Clinical Trials 
Regulation (The European Parliament, 2014).  These regulations are a legal requirement 
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and EU member states must comply with them. Clinical Trials Regulations recently 
replaced the EU Clinical Trials Directive, but these new regulations do not mandate the 
recruitment of minority groups into research in the EU as legislation does in the US. 
 
In the UK, as well as EU regulation, the Research Governance Framework for Health 
and Social Care (Department of Health, 2005b) states in standard 2.2.7 ‘Research, and 
those pursuing it, should respect the diversity of human society and conditions and the 
multicultural nature of society. Whenever relevant, it should take account of age, 
disability, gender, sexual orientation, race, culture and religion in its design, 
undertaking, and reporting. The body of research evidence available to policy makers 
should reflect the diversity of the population.’ This does not legally bind researchers, as 
in the US, nor does it stipulate what proportions of minorities should be included. A 
new research framework for the UK is currently being updated and is at the consultation 
stage. It is worth noting that in countries where policies compel ethnic minority 
participation there is greater reporting of data by ethnicity and inclusion of these groups 
(Rochon et al., 2004). The UK framework has been described as unsophisticated by 
merely ensuring minorities are present in samples (Allmark, 2004). Critics suggest that 
researchers need to identify studies where ethnicity matters (for example where 
treatment effects differ) and also analyse by ethnicity.  
 
When minorities are included in research studies, in what proportions should they be? A 
logical suggestion is that the proportions of each ethnic group included in the study 
mimic that of the population studied. Minorities are included in research so that any 
differences in treatment can be determined by subgroup analysis. These differences may 
be in equality of service provision or be used as a proxy for clinical diversity. Reflecting 
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population proportions does not always ensure adequate numbers for statistical analyses 
particularly for ethnic groups with smaller representations. This means that larger 
numbers of patients may need to be recruited at that start of the study and costed for 
during study planning. Also as race and ethnicity are not biological constructs, 
including and analysing by race or ethnicity means that we may be unintentionally 
perpetuating stereotypes as we are assuming that race/ethnicity indicates a specific 
genetic/disease/clinical characteristic (Rathore & Krumholz, 2003; Smart et al., 2008). 
This is less important when studying issues such as equality of healthcare provision but 
can be crucial when attempting to determine biological differences to a treatment. 
 
Studies and reports examining participation of minority groups in research are 
conflicting (Braunstein et al., 2008; Federal Drugs Administration, 2013; Wendler et al., 
2005). The perceived reluctance of minority groups to participate in research is 
described in several medical specialities including oncology, infectious diseases and 
cardiology (el-Sadr & Capps, 1992; Federal Drugs Administration, 2013; Murthy et al., 
2004; Newman et al., 2006; Ranganathan & Bhopal, 2006; Shavers et al., 2002; Stewart 
et al., 2007). Most data describes studies from the US with some information from the 
UK. Other studies, however, report high or as expected rates of participation by 
proportion of the population (Fisher & Kalbaugh, 2011; Wendler et al., 2005).  
 
Interestingly when examining participation of minorities by phase of clinical trial, 
representation of black and minority ethnic groups differs. Phase I studies are safety 
studies in healthy volunteers and phases II and III are in those with the condition 
needing treatment. Minority groups are overrepresented in phase I studies (Fisher & 
Kalbaugh, 2011) and the reasons for these differences are unclear. Financial rewards for 
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exposure to the risks of phase I studies can be an incentive with some people making a 
career from participation. Some authors have suggested that if minority groups are 
underrepresented in research this means that the majority population are undertaking 
disproportionate risks and this is ethnically indefensible. Analysis of participation by 
phases of research study for ethnic minorities shows this idea to be more complex than a 
brief examination would suggest. 
 
In order to participate in research minorities need to be invited to take part - willingness 
is only one aspect of their inclusion. There are many other obstacles to participation; 
distrust of the medical community; poor access to primary care (minorities are 
predominantly treated in emergency rooms in the US) with the resultant loss of a 
consistent relationship with a medical provider; fewer minority health care 
professionals; not actively recruiting minority participants in places where minorities 
are geographically located; language difficulties; medical eligibility; prescriber 
preconceptions of minorities (including perceived reduced intelligence, likelihood of 
poor adherence to treatment and appointments) and lack of knowledge about clinical 
trials (Corbie-Smith et al., 2002; Fisher & Kalbaugh, 2011; Shavers et al., 2002; van 
Ryn & Burke, 2000; Wendler et al., 2005).  
 
The often-cited reason for these concerns is the infamous Tuskegee Syphilis Study. This 
was a US medical research study, started in 1932, of the natural course of untreated 
syphilis. The study included approximately 600 black men (numbers quoted vary) - 399 
with syphilis and 201 uninfected and continued until 1972 despite effective treatment 
for syphilis being available in the 1940s. The subjects in the study were assumed to 
consent by volunteering for the study and were actively deceived by the researchers and 
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the government into being given treatments known to be inactive. Rigorous efforts were 
made to keep subjects in the study until after their death so that their condition could be 
confirmed by post-mortem. The full degree of the systematic deception that occurred 
has been described in detail (Brandt, 1978) and President Clinton apologised to the 
survivors of the study and the families of the deceased (Centers for Disease Control and 
Prevention, 1997). It would be expected that such gross deception and abuse would 
have a major impact on participation in clinical trials by black people. Some studies 
support this but there is limited direct evidence (Corbie-Smith, 1999; McCallum et al., 
2006). Surveys have found that despite black people being more aware than whites of 
both the Tuskegee study and the Clinton apology, they are as likely or more likely to 
participate in research (Brandon et al., 2005; Brown & Topcu, 2003; Katz et al., 2009; 
Katz et al., 2008). It has also been reported that distrust of the medical and scientific 
community predates the Tuskegee study and has it origins in the medical experiments 
conducted on slaves (Gamble, 1997). 
 
Improving minority participation in research can be done by improving access to 
research opportunities rather than changing mindsets. Trust can be improved in many 
ways; minorities need to be involved in the planning and management of the study from 
the start; community and church leaders can promote and recruit subjects; researchers 
need to develop long-term relationships with the communities from which they are 
trying to recruit. Practical suggestions also have beneficial effects on recruitment such 
as informing and inviting minorities though public presentations; providing translators 
where language barriers exist; offering childcare and travel expenses; recruiting 
minority researchers whose patients are mostly minorities; involve minority physicians 
in study design and improving researchers training and experience of working with 
minority ethnic groups (Swanson & Ward, 1995; Thompson et al., 1996; Wendler et al., 
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2005).  Participation rates of minorities in phase I clinical trials, where many of these 
suggestions have been implemented, show they are clearly effective.  
 
1.2.2 MEASUREMENT OF RACE AND ETHNICITY IN RESEARCH 
An essential component of measuring race and ethnicity in research is that it must be 
self reported and identified. Race, as discussed earlier, is not anthropologically or 
genetically derived; it is a social and political construct. As such the National Institutes 
of Health in the US recommend measuring both race and ethnicity. Ethnicity is 
measured as Latino/Hispanic or non-Latino/non-Hispanic then race as American Indian 
or Alaska Native, Asian, black or African American, Native Hawaiian or other Pacific 
Islander, and white. Each of these ethnic and racial groups are clearly described.  
 
The accurate measurement of race/ethnicity in research is important so that health 
services are truly equitable and disparity can be investigated.  In the past ethnicity was 
assigned by the interviewer rather than respondent. As ethnicity is a complex concept 
and can vary by questioner, location and over time, it should be self-assigned. The NHS 
in England uses the 2001 census classification and the patient is asked ‘what is your 
ethnic group?’ then shown a printed list of options to choose from.  If this is not 
possible e.g. for telephone contacts, then a series of questions are asked that guide the 
respondent through the available categories. The Office for National Statistics produces 
its own guidance, most recently in 2015, on monitoring of ethnic groups. It also gives 
advice on merging of categories when they have changed with each census. This is 
important so that changes over time can be measured against each other. 
 
If we are going to record and analyse information about race and ethnicity then it must 
be accurate and complete. Recording of ethnicity in the 1990s in NHS primary and 
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secondary care was poor and it was not until 2006, when financial incentives were 
introduced, that data collection began to be systematically obtained for newly registered 
patients in both sectors of the health service.  The completeness of ethnic group 
recording in the NHS since these changes has improved, particularly when primary and 
secondary care data are combined (Mathur, 2014). Results from studies examining the 
accuracy of the data collected are conflicting. In one study, where self-recorded 
ethnicity in hospital records versus a cancer survey was compared, overall ethnicity was 
correctly recorded in almost 95% of cases but when examined further white ethnicity 
was broadly correct (over 97%) but for ethnic minorities over 40% of data were found 
to be incorrect (Saunders et al., 2013). Mathur and colleagues describe highly accurate 
ethnicity classifications when comparing hospital vs. census data but they examined 
total data not by ethnic group (Mathur, 2014). Inaccurate recording of ethnicity has also 
been described in other countries particularly for ethnicities with the smallest 
proportions in the population. In the US this is more likely if not black or not white 
(Gomez & Glaser, 2006; Waldo, 2004) whilst in New Zealand, Maori, Pacific groups 
and Asian ethnicity are poorly recorded (Swan et al., 2006).  
1.3 ETHNICITY AND HEALTH 
There is a long history of inequality in provision of health care services to ethnic 
minorities.  There have been many reports and analyses, from the Poor Laws through to 
the introduction of the welfare state and the NHS, into social inequalities and health. 
The seminal report into the issue was the infamous Black report in 1980 (Black, 1980). 
This examined health inequalities and why they had, inexplicably, worsened since the 
introduction of the NHS. Black showed that the poorest had the greatest risk of ill health 
and death and that the reasons for this were social inequalities i.e. diet, occupation, 
education, housing and environment. It was difficult to examine ethnicity and health 
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inequality at the time as data collection of ethnicity was in its infancy (country of birth 
was the only measure available) and had not yet been included in censuses. Whilst 
ethnic minorities were more likely to have a lower occupational class (used as a proxy 
for wealth and social class in the report) this alone did not explain inequality. Using 
standardised mortality ratios (SMR = observed deaths/expected deaths x 100) produced 
some unexpected results. Immigrant workers’ SMRs compared favourably with their 
British-born equivalents.  Black suggests that this may be because healthier people are 
more likely to migrate as they expect to survive and flourish in a new country. But when 
SMRs for causes of death for ethnic minorities are compared with number of deaths in 
rank order very different patterns of disease emerge (Senior & Bhopal, 1994). This is 
because SMRs compare diseases common in the comparison population whereas rank 
order of deaths emphasises diseases that are common independent of comparison.  So it 
can be seen the importance of measuring ethnicity, ill health and death and that the 
methods used can have variable results.  
 
Internationally the WHO made an assessment of health inequality in thirteen developed 
countries (Crombie, 2005). This found that health inequalities existed in all of the 
countries studied and because poverty and health are interlinked, health and social 
justice policies should be unified. A WHO target since 1985 has recommended a 25% 
reduction of inequality between countries and between groups within countries (World 
Health Organization, 1985). 
 
Since the Black report there have been numerous attempts to measure, analyse and 
make recommendations to improve health equality. These include the Whitehall I and II 
studies of staff grade (a proxy for socioeconomic position or social class) and mortality 
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in the British Civil service (Marmot et al., 1991; Reid et al., 1974). These studies found 
that, even after controlling for risk factors, the lower the grade of staff the higher the 
rate of cardiovascular disease. The reasons for this finding are unclear but an increase in 
stress owing to a lack of control of work, low self-esteem and lower salaries have all 
been suggested. Unfortunately both these studies of health equality did not collect data 
on ethnicity. The Black report’s recommendations were not accepted or implemented by 
the government of the time because it had been commissioned and supported by the 
previous administration and of the financial costs involved. Despite this the report 
prompted an explosion of research. It was updated by the Heath Research Council 
(Townsend, 1992), further investigated by the King’s Fund (Benzeval, 1995) and 
eventually a later government (Variations Sub-group of the Chief Medical Officer's 
Health of the Nation Working Group, 1996). It was not until the 1990s that the issue of 
health equality was revisited by a public inquiry (Acheson, 1998) and government 
policy (Department of Health, 1999b). All these reports essentially made the same 
major argument. Ill health and socioeconomic disadvantage were inextricably related 
and variations in health services were not the prime reason for variations in health 
(Marmot, 2001).  
 
The Acheson report (Acheson, 1998) investigated health equality including the effect of  
ethnicity. He found that for almost all minority ethic groups’ mortality ratios were 
higher than average and that cause of death varied by country of birth. Ethnicity was 
measured by country of birth on death certificates so only migrant data were analysed, 
missing many self-identified ethnic minorities born in the UK. For infant mortality only 
mother’s country of birth was recorded on birth certificates at the time making analysis 
difficult, but mothers from the Caribbean and Pakistan had infant mortality rates about 
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double the national average. Additionally he described many indications of poorer 
health for ethic minorities, for example higher rates of limiting long-standing illness for 
those of Pakistani or Bangladeshi origin than white people. Moreover ethnic minority 
groups were more likely to live in areas of geographic and economic deprivation that 
contributed to both between and within ethnic minority group health inequality. In this 
respect minority groups have more similarities than differences with the majority ethnic 
group.  
 
Acheson described specific differences in care received by minority groups. For 
instance use of primary care was similar to the white majority but difficulty in 
physically accessing their GP, longer waiting times at the surgery, less satisfaction with 
outcomes and lower referral rates to secondary care were reported. Some of these 
differences may be because of communication difficulties and lack of cultural 
competency (i.e. the ability to provide services to patients with different cultural beliefs, 
attitudes and behaviours and the use of multi-cultural staff in policy development, 
administration and provision of services). He cites an example of lower rates of cervical 
screening in South Asian women improved by culturally sensitive explanation of the 
purpose and procedures of the test.  
 
The Acheson report recommended that ethnic minorities should be present on decision 
making/advisory panels about health; their needs specifically considered in the 
development and implementation of policies aimed at reducing socioeconomic 
inequalities; that data on ethnic minorities needed to improve to monitor inequalities in 
health. After so many reports and investigations into health inequalities Sir Donald 
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Acheson wrote in the foreword to the King’s Fund report ‘today the question is not 
whether the facts are valid but who cares and what can be done about them’. 
 
More recently the Marmot review of 2010 (Marmot, 2010) was charged with proposing 
evidence–based strategies for reducing health inequality in England. He once again 
found that socioeconomic status and worse health outcomes were associated for some 
but not all ethnic groups. 
 
The 2011 UK census asked two questions about health, one about general health 
(options; very good, good, fair, bad, very bad) and a second about long-term disability 
(are your day to day activities limited because of a health problem or disability which 
has lasted, or is expected to last, at least 12 months? Include problems related to old 
age. Options; yes limited a little, yes limited a lot or no). These data show us ethnicities 
with the highest proportions of limiting long-term illness (compared with white) 
differed by gender and were Pakistani and Bangladeshi women, mixed white-black 
Caribbean men, white Irish men, black Caribbean men, white Gypsy and Irish Traveller 
(new category for the 2011 census) men and women and particularly those of older age. 
Conversely Pakistani, Bangladeshi, Arab and Chinese men had lower rates of limiting 
long-term illness than whites (Becares, 2013). These effects were not replicated in the 
question on general health where poorer health was reported. Better rates of limiting 
long-term illness were reported for other white, black African and Chinese.  
 
Geographically London had the most severe health inequalities by ethnicity in England 
and Wales. We can see that the results are complex and differences occur by ethnic 
group with gender (see Figure 1 and 2 below, age-standardised ratios of limiting long-
term illness for ethnic minority groups compared to white British by gender). 
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Measurement of ethnicity data allows us to determine if any inequalities exist between 
ethnic minorities and the majority population. The importance of collecting these data 
has been strengthened most recently by the Equality Act 2010 which legally ensures 
that public bodies must provide equitable health services. The NHS must publish data to 
show that they are adhering to the legislation and, if not, has to show what steps are to 
be taken to achieve equality of provision.  
 
We can see that significant health inequality occurs within minority ethnic groups and 
between them and the majority population. This difference is not wholly explained by 
lower socioeconomic status in minorities.  
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1.3.1 ETHNICITY AND PHYSICAL HEALTH 
Specific differences in the provision of health services to minority ethnic groups have 
been consistently found across a wide range of medical disciplines. US studies of 
treatment by ethnicity highlight many areas of poorer quality health services. African 
Americans are less likely than the majority to receive optimal cardiac medication; 
coronary artery bypass surgery; cancer testing, treatments and pain relief; stroke care; 
rehabilitation and nursing home services (Ball & Elixhauser, 1996; Goel et al., 2003; 
Johnston et al., 2001; Sander et al., 2009). They are also more likely to receive some 
surgical procedures such as orchidectomy (Bjurlin et al., 2012) and amputations 
(Feinglass et al., 2005). This is even after controlling for factors such as health 
insurance, age, symptoms, disease severity, under/over use of services and patient 
income. These differences are, unsurprisingly, associated with higher mortality rates for 
African Americans. 
 
Perceptions of treatment and the reality of care are at odds with each other. Surveys in 
the US show people think that ethnic minorities do not receive different treatment from 
the white majority (Lillie-Blanton et al., 2000). The reasons for these differences are 
partly but not completely explained by poverty and poorer access to care as there are 
other factors that may be contributing such as discrimination and stereotyping. 
Suggested solutions include increasing proportions of ethnic minorities among health 
care professionals, improving access to speciality care, allowing appeals for denials of 
care, enforcing equality rights legislation, promoting use of evidence-based guidelines, 




In the UK we would perhaps expect healthcare to be different. The NHS is a 
government-funded equitable healthcare system where treatment is given on the basis of 
need and not ability to pay. It has a well-developed primary care and public health 
system, unlike in the US, which aids prevention, detection and treatment of disease 
earlier. Nevertheless there are still health inequalities by ethnicity. Specifically these 
include lower rates of cervical cancer screening and coronary angioplasty for minorities 
(particularly South Asian populations (Feder et al., 2002; Webb et al., 2004)) and 
significantly higher rates of infant mortality in Caribbean and Pakistani communities 
(Gray et al., 2009).  Rates of certain health conditions also differ by ethnicity in the UK. 
Mortality ratios for lung cancer are higher for Scottish and Irish groups but lower for 
black African, black Caribbean and South Asians; Bangladeshi and Pakistani people 
have higher rates of coronary artery disease; South Asians and Caribbean people are 
more likely to have type 2 diabetes; lifestyle differences in fruit and vegetable intake, 
physical activity, smoking, alcohol use and obesity rates are worse for some but not all 
minority groups in the UK (Aspinall & Jacobson, 2004). 
 
1.3.2 ETHNICITY AND MENTAL HEALTH 
1.3.2.1  RECENT HISTORY 
Treatment of mental illness in minority ethnic groups differs from the majority 
(Department of Health, 2003; 2005a). There have been many reports, investigations and 
recommendations detailing large differences in referral, admission, seclusion and 
detention rates for different ethnicities – particularly when data from black and white 
patients are compared.  
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Modernisation and reform of mental health services was planned through the National 
Service Framework for Mental Health for adults (Department of Health, 1999a). This 
described evidence-based national standards, their aims, development, delivery and 
performance measurement. Research on ethnicity and mental health was examined as 
part of their process and reported: 
• In black compared with white patients - higher rates of psychotic illness, referral to 
mental health services through the criminal justice system rather than GPs or social 
services, admission to hospital under the Mental Health Act, treatment with physical 
rather than psychological therapies and admission to secure services. (Davies et al., 
1996; Koffman et al., 1997; McKenzie et al., 1995; Nazroo, 1998) 
• Depression diagnosed less frequently in Asian people compared with white despite 
higher rates of suicide in Asian women (NHS Centre for Reviews and 
Dissemination, 1996). 
• Stigma because of mental illness worsened by racism, ethnicity affects access to 
treatment (Commander et al., 1997). 
• Mental health assessments are often not sensitive to ethnicity (McKenzie et al., 
1995). Staff need skills in cultural competence and the NHS must attract and retain 
staff from BME communities. 
• Ethnicity monitoring not satisfactory in the NHS and needed to improve. 
Unfortunately the NSF-MH, despite reporting these differences by ethnicity, did not set 
standards for mental health services specifically for minority ethnic groups. 
 
After the NSF-MH in 1999 an amendment was made to the Race Relations Act in 2000 
that forced all public bodies, including the NHS, to eliminate racism in public services. 
Two reports, ‘Breaking the Circles of Fear’ (Keating et al., 2002) and ‘Inside Outside’ 
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(Department of Health, 2003), were produced as result of this change. ‘Breaking the 
Circles of Fear’ was a qualitative study that examined the relationship between mental 
health services and African and Caribbean communities. Key themes were the sources 
(perceptions, attitudes, diagnosis, hospital experiences) and consequences (limited trust 
and engagement, delays in seeking help) of fear of mental health services. The study 
concluded that these fears affect access to services resulting in delays in treatment and 
coercive care. 
 
‘Inside Outside’ examined the inequalities in provision of mental health services for 
ethnic minorities and set targets to reduce and eliminate these differences and improve 
services. The report stated that ethnic minorities were more likely to experience 
institutional and coercive care, that individual patients needs were not given priority and 
that institutional racism existed in mental health care. It described the evidence for 
disparities in mental health care for ethnic minorities by using the seven national 
standards and five key areas i.e. health promotion (including discrimination and social 
exclusion), primary care and access to care, effective services, carers and suicide of the 
NSF-MH. These standards and the reports findings are outlined below: 
Standard 1: Mental Health Promotion. Health and social services should provide mental 
health for all, combat discrimination and promote social inclusion. 
• Racism and stigma affect psychiatric morbidity.  
• Individuals from black and minority groups are at 
o greater risk of developing mental health problems than the majority. 
o increased risk of hospital admission and coercive care (especially African 
Caribbean and Irish people). 
o elevated risk of suicide (especially for the Irish and South Asian women). 
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o greater risk of readmission (especially for black patients). 
 
Standard 2: Primary Care. Patients who contact primary care with a mental health 
problem should have this identified, assessed, treated and, where necessary, referred to 
specialist care. 
• Research suggests GPs may be less likely to recognise psychiatric disorder in ethnic 
minority patients. 
• Consultation rates for anxiety and depression may be reduced for some groups 
(especially for South Asians and the Chinese) but increased in others (the Irish). 
• Language and cultural barriers affect assessment. 
• Recognition of mental health problems (particularly for black and South Asian 
patients) and referral to specialist services is affected by ethnicity. 
• Lack of involvement of patients’ GPs associated with compulsory admission and 
police involvement. 
 
Standard 3: Access to Services: individuals with a mental health problem should be able 
to make contact with local services 24 hours a day. 
• There are barriers to ethnic minority groups successfully accessing services and they 
are less satisfied with these services after contact. 
• Cultural stereotyping may affect access to services e.g. Irish people stereotyped as 
having alcohol problems prevents treatment for mental illness. 
• Ethnic minorities are likely to access care through coercion, compulsory admission 




Standard 4 and 5: Effective services for people with severe mental illness. Patients with 
severe mental illness should receive the treatment and services they need. Crises should 
be prevented where possible and if they do occur treated quickly and efficiently in a 
hospital bed near home. Ethnic minorities  
• are more likely than the majority population to be misdiagnosed, prescribed drugs 
and ECT and less likely to be referred for psychotherapy. 
• have higher readmission rates, longer hospital stays and are less likely to have their 
social and psychological needs addressed. 
• rights and health care needs are taken less seriously than for white patients on acute 
psychiatric units. 
• are more likely to be assessed as needing medium and high secure psychiatric care 
and, particularly for African Caribbean people, are overrepresented in forensic 
services. 
• are less satisfied with mental health services but are more satisfied with newer 
treatment services such as home treatment, crisis resolution and early intervention 
but, for African Caribbean patients, not intensive case management. 
 
Standard 6: Caring about carers: health and social services must assess the needs of and 
provide care for carers of people receiving specialist mental health services. There is 
little research available about carers’ experience of mental health services for ethnic 
minorities. Concerns reported through surveys and stakeholder events: 
• Carers of black patients feel unable to make treatment decisions and find 
community services and they are also concerned about doses of antipsychotic 
medication. 
• Carers want information about mental illness and how best to support relatives and 
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also want to be listened to and involved in care decisions. 
• Advocates that are culturally appropriate are needed. 
 
Standard 7: Preventing Suicide. Health and social care services aim to achieve the target 
of a reduction of national suicide rate by one fifth by 2010 (Saving Lives: Our Healthier 
Nation (Department of Health, 1999b)). 
• Suicide by ethnicity is not recorded at inquests or on death certificates (this is still 
the case now as death certificates record place of birth only). 
• Women of South Asian and East African origin and Irish people have higher suicide 
rates than those born in England and Wales. 
 
After documenting these mental health inequalities by ethnicity the report describes 
changes needed both inside services and outside within communities. The objectives 
and changes were as follows: 
i. To reduce and eliminate ethnic inequality in mental health service experience 
and outcome by consulting with mental health agencies and stakeholders in the 
community and ensuring accountability and change through clinical governance 
(i.e. standards of care). 
ii. To develop a culturally capable service i.e. ethnic minorities should receive the 
same treatment as the majority through: developing a diverse and culturally 
sensitive workforce; ensuring the voluntary sector works with the NHS to 
develop services for minority groups; mental health services that are flexible and 
adaptable to working with different cultures; improving access to translation 
services for people. 
iii. To set national standards to improve access, care experience and outcome. They 
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proposed to do this by: collection of ethnicity data; training GPs in cultural 
awareness; assessing patients mental state in their own language; auditing 
referrals to specialist mental health services and psychotropic drug use annually; 
reducing coercive care by access to crisis teams, crisis care plans and audit of 
Mental Health Act use by ethnicity; mental health assessments should be carried 
out with family/carers and interpreter or advocate; care plans to include cultural, 
religious or spiritual beliefs; ensuring families and carers have information on 
legal, advocacy, second opinion rights; ensuring NHS trusts have an Equality 
Framework for audits. 
iv. To enhance the cultural relevance of research and development by developing 
research methods for use in minority ethnic groups and including these groups in 
all research. 
 
In the same year as the ‘Inside Outside’ report there was a public inquiry into the death 
of David Bennett (Norfolk Suffolk & Cambridgeshire Strategic Health Authority, 
2003). David Bennett was a black patient who died of positional asphyxia during a 
restraint at a medium secure mental health unit in Norfolk in 1998. This was not the first 
time a public inquiry into the death of a black patient in a mental health unit had been 
undertaken. In 1993 there had been a public inquiry (Prins, 1993) into the deaths of 
three black patients at Broadmoor hospital, namely Michael Martin in 1984, Joseph 
Watts in 1988 and Orville Blackwood in 1991. All three patients died after being 
restrained and given injections of antipsychotic drugs. The report described how black 
people were more likely to be brought into hospital by police; detained under the 
Mental Health Act; kept on locked wards; be transferred from prison to secure units; 
receive medication and less likely to receive psychotherapy. The recommendations of 
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the report were to introduce training in the management of violent incidents without 
restraint; monitor and research diagnosis of Afro-Caribbean patients; training for staff in 
resuscitation; black appointee to advise on race awareness and equal opportunities and 
development of a procedure for informing relatives of the death of a patient. 
 
At around the same time as the Orville Blackwood inquiry, the Ritchie inquiry (Ritchie, 
1994) investigated the care and treatment of Christopher Clunis, a black patient who 
stabbed and killed a man on the London Underground in 1992. Christopher had 
schizophrenia, was unwell at the time of the attack and not taking medication. The 
inquiry found that the many services that were involved in his care (mental health 
services, the police, primary care, social services, the Crown Prosecution Service) did 
not communicate and share information with each other and so his risk of violence was 
not properly recognised. Lack of resources meant that he was not managed by a forensic 
service and his medication was not reviewed. He was treated with depot antipsychotics 
and, on one admission, very large doses of antipsychotic medication (chlorpromazine 
2000mg regularly plus up to 1600mg when required daily). The inquiry examined the 
effect of ethnicity on Christopher’s treatment and found that there was no 
discrimination or prejudice against him. But they did report that staff were too willing to 
accept that he misused street drugs and diagnose him with drug-induced psychosis. In 
reality he did not misuse street drugs but had schizophrenia. The report comments also 
on the overrepresentation of black patients with schizophrenia in mental health services 
and detained under the Mental Health Act.  
 
The inquiry into the death of David Bennett, five years later, described in detail the 
circumstances leading up to, during and after his death. He had been restrained by 
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several nurses (between three and five - testimonies were confused) in the face down or 
prone position for somewhere between 15 and 25 minutes. On the night of his death he 
had taken his oral regular medication as usual and was not administered any medication 
during the restraint. David was taking large doses of several medications concurrently 
i.e. clozapine 700mg, haloperidol 40mg, sulpiride 200mg and valproate 200mg (to 
prevent seizures). The total percentage maximum dose (i.e. calculating each dose as a 
proportion of the BNF maximum dose and then multiplying by 100), using the doses 
that were licensed at that time, was approximately 106%. If current maximum doses 
were used this would be 286%. This is because the maximum dose of haloperidol was 
200mg and has been repeatedly reduced to the current maximum oral dose of 20mg. 
The pathologist did not consider that David’s medication was the cause of his death and 
his post-mortem blood results were normal (but levels of medication in a body after 
death are notoriously difficult to interpret (Taylor et al., 2015)). But David was 
receiving high dose antipsychotic polypharmacy, as had Orville Blackwood before him 
(fluphenazine decanoate 150mg IM single dose with promazine injection 150mg given 
to manage violent behaviour: 125% percentage maximum dose). Using high doses and 
more than one antipsychotic confers an increased risk of a range of side effects 
including movement, anticholinergic, metabolic, seizures, sedation, neuroleptic 
malignant syndrome, QT prolongation, arrhythmia and sudden cardiac death. 
 
Other failings in David Bennett’s treatment included the lack of availability of a doctor 
on site (it took 1½ hours for a doctor to get to the unit) and that his family were not 
notified of his death until the next morning. Many of the 22 recommendations of the 
David Bennett enquiry had been previously made by the Orville Blackwood enquiry. 
Recommendations included training in cultural awareness, control and restraint, CPR 
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and first aid; assessment of ethnic minorities mental state; acknowledgement by the 
government of institutional racism in mental health services; appointment of a National 
Director of Mental Health and Ethnicity; policy for racist abuse in mental health 
services; care plans to detail ethnicity and cultural needs; workforce should be 
ethnically diverse; restraints in the prone position should be for a maximum of 3 
minutes; collection of data on deaths of psychiatric inpatients by ethnicity and use of 
control and restraint; research into the management of treatment-resistant schizophrenia; 
access to second opinion in mental health for all patients; detention in secure hospital 
only when necessary; review of financial assistance for patients leaving hospital; 
movement of patients between hospitals justified in writing; families of deceased 
psychiatric patients to be given care and support; medication in mental health to be used 
within maximum doses. The need to translate good intentions and recommendations 
into actions was highlighted. 
 
Controversially the David Bennett inquiry reported, as had ‘Inside Outside’ 
(Department of Health, 2003) and ‘Delivering Race Equality in Mental Health Care’ 
(Department of Health, 2005a), that mental health services were institutionally racist. 
The term was original described in the Macpherson report (Macpherson, 1999) into the 
Metropolitan police handling of the death of Stephen Lawrence, a black teenager who 
was stabbed to death in a racially motivated attack in 1993. He said “Institutional racism 
is the collective failure of an organisation to provide an appropriate and professional 
service to people because of their colour, culture, or ethnic origin. It can be seen or 
detected in processes, health systems, attitudes and behaviour which amount to 
discrimination through unwitting prejudice, ignorance, thoughtlessness and racist 
stereotyping, which disadvantage minority ethnic people”.  Some commentators state 
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institutional racism is about systems and policies that affect outcomes for minority 
groups rather than direct racism (McKenzie & Bhui, 2007)	but this has been 
vociferously disputed (Singh, 2007).	Other researchers have also described mental 
health services as institutionally racist, quoting higher rates of admission and 
involuntary admissions and longer stays as evidence. They argue that while incidence 
rates may be higher for black people it is prevalence that is reflected in hospital 
admission data (McKenzie & Bhui, 2007) and community prevalence rates do not differ 
by ethnicity (Nazroo, 1997). These views have been rejected by some (Fearon & 
Murray, 2007) contending that community prevalence studies using the same data 
report high rates of hallucinations (Johns et al., 2002) and psychotic symptoms (King et 
al., 2005) in ethnic minorities. Others report higher admission rates are because of 
higher rates of psychosis in black patients (Singh & Burns, 2006). They argue that rates 
of psychosis are higher in all immigrant groups globally including for Western 
minorities and that detention rates are higher because fewer referrals for black patients 
come from GPs and more from the police. This was because families of black patients 
are more likely to contact the police rather than medical services when a member of 
their family is ill for the first time and argue that this does not reflect institutional 
racism, as there has been no prior contact with mental health services. They attribute the 
difference in method of referral to the stigma of mental illness in these communities, 
with behavioural problems requiring legal rather than medical help (Singh & Burns, 
2006). Differences in involuntary admission rates they explain are because of referral 
through the courts or police (Murray & Fearon, 2007), presentation to services without a 
family member in attendance (carers seek help earlier), living alone, higher rates of 
unemployment, low levels of social support, growing up in the inner city, being 
separated from a parent or suffering physical abuse in childhood and racist experiences - 
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all factors that are more likely for black, and particularly for black Caribbean, patients.  
They argue that accusations of institutional racism damage research into the reasons for 
these marked differences for black people and those working in mental health services 
do not operate in isolation - education, employment, housing, social services and the 
criminal justice system all combine to affect risk of admission (McKenzie & Bhui, 
2007). Others contend that under and delayed treatment of patients is where the problem 
lies and that suggestions of a need for separate services for minority ethnic groups are 
themselves racist and a form of psychiatric apartheid (Murray & Fearon, 2007; Singh, 
2007). There is also concern that those who deny mental health services are 
institutionally racist and that they too will be deemed racists (Murray & Fearon, 2007). 
Confusingly the UK government accepted direct and indirect discrimination by 
ethnicity did occur (Department of Health, 2005a), but now the Department of Health 
says that the NHS is not institutionally racist (Murray & Fearon, 2007). 
 
The government’s response to the Bennett inquiry and accusations of institutional 
racism were the introduction of the NHS Race Equality Action plan (listing actions and 
those responsible for health services, outcomes and developing people) and the 
publication of Delivering Race Equality in mental health care, an action plan for reform 
inside and outside services (Department of Health, 2005a). The DRE report planned 
more appropriate and responsive services (action to develop organisations and the 
workforce), community engagement (engage communities through 500 new 
Community Development Workers) and better information (improved monitoring of 
ethnicity, better dissemination of information and good practice, census of mental health 
patients). The plan was for a service for ethnic minorities of less fear and increased 
satisfaction; reduced rates of admission to hospital; reductions in violence and 
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seclusion; prevention of deaths after physical intervention; better states of recovery; 
greater access to talking treatments; more active role in training of professionals; 
development of policy; a culturally competent workforce. Ultimately it should deliver 
equality of access, experience and outcome for ethnic minorities. The government 
accepted the recommendations of the Bennett inquiry in DRE with some minor 
variations - stating the prone position of restraint should be used as a last resort rather 
than it should be used for a maximum of 3 minutes and that services should not be 
discriminatory rather than saying services are institutionally racist. One of the major 
recommendations was that an annual census be undertaken of inpatients in mental 
health and learning disability services. 
 
The Count Me In Censuses of mental health and learning disabilities services (Care 
Quality Commission, 2010) began in 2005 and continued until 2010. They were 
designed to collect accurate data on the ethnicity of users and enable health services to 
achieve the goals of DRE by tracking progress using this data. Overall there was little 
change in the 6 years in admission and detention of ethnic minorities. This may not be 
surprising given that 31% of patients had been in hospital for more than a year (the 
censuses overrepresent long-stay admission and underrepresent short-stay admissions). 
In 2010 the census collected information on 32,799 inpatients in 261 NHS and 
independent healthcare organisations in England and Wales or outpatients under a 
community treatment order. The key findings are as described in Table 1. Differences in 
rates refer to statistically significant differences from national rates.  
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For learning disability services the main differences were in rates of admission – lower 
for other white, Indian, Pakistani, other Asian, black African, Chinese and other groups 
and two to threefold higher for white and black Caribbean, mixed, black Caribbean, 
other black and other mixed groups. Other notable differences were that two thirds of 
patients had been in hospital for one year or more and almost a third for five years. 
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Changes over the 6 years were few for mental health: 
• Overall number of inpatients fell by 12%. 
• Proportion in independent hospitals rose from 10 to 16% i.e. by 60% or 6 
percentage points. 
• Proportion of patients from minority ethnic groups increased from 20 to 23% i.e. 
by 15% or 3 percentage points (population of ethnic minorities also rose by 8% 
from 2005 to 2007). 
• Admission rates remained similar: 
o Lower than average for white British, Indian and Chinese groups. 
o Average for Pakistani and Bangladeshi groups. 
o Higher than average for black and white/black mixed (more than two 
times average), other black ‘exceptionally high rate of admissions’. 
• Rates of referral from GPs and community mental health teams were lower in 
black and white and black groups, referral from the criminal justice system was 
higher. 
• Increase in number of patients detained under the Mental Health Act (40% in 
2005, 49% in 2012). 
• Rates of self-harm lower among black and South Asian groups. 
• Few differences in hands-on restraint, physical assault, accidents. 
 
DRE goals for minority ethnic groups were: 
• A decline in admission rates – two or more times higher for black and 
white/black mixed, six times higher for other black groups, lower for Indian, 
Chinese. 
• To reduce detention rates - higher in all six censuses for black Caribbean, black 
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African, other black, almost consistently higher for black and white Caribbean 
and other white groups. Higher than average detention under section 37/41 
(criminal courts use section 37 to refer patients to hospital instead of prison, 
section 41 allows a court to place restrictions on discharge (this order added if 
risk to public as Ministry of Justice as well as psychiatrist control admission)) 
for black Caribbean and other black groups. 
• To reduce seclusion - higher for black and white, black mixed groups and other 
white groups in three of the six censuses. 
 
The next step after ‘Count me in’ was to move on from counting patients in hospital to 
understanding the factors that result in variations in rates and routes of admission to 
hospital for ethnic minorities. The Care Quality Commission recommended that mental 
health services worked with other statutory agencies including police, the criminal 
justice system, voluntary groups and minority communities to prevent and intervene 
earlier in mental ill health. They emphasised the importance of good quality data 
collection after these censuses. The data are collated for both hospital and community 
mental health services by the NHS Information Centre in the Mental Health Minimum 
Data Set and so provides a larger sample size and more detailed information as most 
patients (more than 90%) are located in the community. 
 
A review of DRE (Melba, 2010) found that the sheer number of recommendations (78 
in total) made it difficult for organisations to focus on them all. Progress was made in 
many areas but lack of organisational understanding of what was required, variable data 
collection and quality meant that, for some recommendations, outcomes were difficult 
to assess. 
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The government’s new strategy for mental health, after DRE, was No Health without 
Mental Health (Department of Health, 2011). This aimed to reduce the socioeconomic 
risks of mental ill health, reduce inequalities and improve outcomes – very similar aims 
to DRE. Key objectives included ‘parity of esteem’ of mental to physical health and 
integration of mental and physical health services. The report mentions, once again, 
equality and fairness and highlights the need to collect data on suicide, differences in 
rates of mental illness, admission and detention rates of minority ethnic groups.  
 
Recent data from 2015 for mental health and learning disability analysed from MHMDS 
has still found major differences for some ethnic minorities (Health and Social Care 
Information Centre, 2015). 
 
• ‘The black or black British group had the highest proportion of people who had 
spent time in hospital in the year, which meant that 12.7 people per 100 who 
were in contact with mental health and learning disability services from this 
ethnic group spent at least one night in hospital in the year. This is higher than 
the figure for any of the other ethnic groups and more than double the figure for 
the white ethnic group.’ 
• ‘People from the black or black British ethnic group were more likely than other 
ethnic groups to be detained, with 56.9 detentions per 100 inpatients.’ 
• ‘The black or black British ethnic group had the highest percentage of people 
who were cared for under Care Programme Approach (a national system which 
sets out how mental health and learning disability services should help people 
with mental illnesses and complex needs) in the year at 37.2%, which is much 
higher than the number for all ethnic groups.’ 
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Analysis suggested these figures could be related to greater or more complex needs 
once in contact with services for these ethnic groups.  
 
We have seen through numerous reports and inquiries that inequalities exist in mental 
health services. The risk factors and potential causes of these differences are complex 
but may be related to diagnosis, pathways to care and different rates of mental illness in 
some ethnic groups. 
1.3.2.2  DIAGNOSIS AND RATES OF PSYCHOSIS AND SCHIZOPHRENIA IN 
ETHNIC MINORITIES 
Rates of psychosis and schizophrenia are much higher for black patients in the UK than 
white (Bhugra et al., 1997; King et al., 1994; Van et al., 1996). What are the reasons for 
these differences and are they to do with racism by mental health services or are other 
factors important? 
 
There have been concerns that ethnic minorities, particularly black patients, are more 
likely than whites to be diagnosed with schizophrenia (Neighbors et al., 1989; 
Sashidharan, 1993; Sashidharan & Francis, 1999; Schwartz & Blankenship, 2014).  
These differences have occurred even after using standardised diagnostic criteria and 
interview (Neighbors et al., 1989) and have been suggested to include clinician bias 
owing to cultural stereotyping and Eurocentric diagnostic practice (Mukherjee et al., 
1983; Singh & Burns, 2006), under-diagnosis of depression and bipolar disorder 
(Barnes, 2008), language difficulties (Department of Health, 2003), ethnic differences 
in presentation (Mukherjee et al., 1983) and clinicians’ own ethnicity (Trierweiler et al., 
2006).   
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Other research studies examining diagnosis have repudiated these causes. A case 
vignette diagnosis and treatment study, in which only one detail (ethnicity) varied, 
found British psychiatrists, regardless of which country they were trained, were less 
likely to diagnose schizophrenia in black patients compared with white (Lewis et al., 
1990). In addition a study comparing the diagnoses of a Jamaican and a British 
psychiatrist for UK patients found they diagnosed a similar proportion with 
schizophrenia but disagreed as to exactly which patients had the condition (Hickling et 
al., 1999). Diagnosis in black people may also be affected and confused by differing 
symptoms that UK psychiatrists recognise as schizophrenia, for example hallucinations 
may be more frequent and culturally more acceptable in non-Western countries (Johns 
et al., 2002). Black people may also have a different illness course with more relapse, 
remission and social disturbance but fewer negative and persistent symptoms (Sharpley 
et al., 2001). 
The incidence of schizophrenia has been found to be similar in people in the West 
Indies as in the UK (Sharpley et al., 2001) but much higher for black people in the UK 
(Kirkbride et al., 2006), particularly for the siblings of black second-generation patients 
with schizophrenia. This indicates that environmental factors are affecting risk and 
vulnerability (Hutchinson et al., 1996).  
Some social risk factors disproportionately affect the black community such as being 
the child of a single parent, separation from parents, and being brought up in the care 
system. Cannabis is a risk factor for psychosis particularly when use is heavy and with a 
high potency product (Di Forti et al., 2015; Marconi et al., 2016). Data are contradictory 
about whether use is similar in black and white patients – reportedly the same in those 
with psychosis but lesser for black immigrants than white native populations (Cantwell 
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et al., 1999; Sharpley et al., 2001; Veen et al., 2002). However other more recent studies 
suggest use is greater in black populations (UK Drug Policy Commission, 2010). Urban 
environments are stressful and black people are more likely to live in inner cities where 
social isolation, living in areas with a low population of your ethnic origin, overcrowded 
housing, overstimulation, crime, pollution and living alone can be more common 
(Bhugra & Bhui, 2001).  
Ways of accessing mental health services i.e. ‘pathways to care’ can help us understand 
further why rates of hospital admission are higher for minority groups. Black patients 
are more likely to be referred to services by police, less likely to be referred by GPs, and 
more likely to be admitted compulsorily. What causes these differences? Delays in help-
seeking results in use of emergency services, stereotypes of black men as more 
dangerous and violent, unemployment, living alone, residing in social housing are all 
risk factors for compulsory admission (Pipe et al., 1991). 
Severity of psychosis has been reported to be worse for some ethnicities e.g. Chinese 
and South Asian patients in Canada (Chiu et al., 2016), African Americans in the US 
(Arnold et al., 2004). But other studies have found no such differences (Connolly & 
Taylor, 2008; Kim et al., 2014) and, in the UK, have instead focussed on measuring 
diagnostic incidence, inpatient admission and detention rates as indirect measures of 
illness severity (Kirkbride et al., 2006; Mann et al., 2014). 
Black and white patients and relatives have similar rates of satisfaction with mental 
health services but black patients are more likely to see services as racist, and 
specifically second-generation black patients, are less satisfied than older first- 
generation blacks and whites. Interestingly the greater the number of previous 
admissions the more likely patients are to be less satisfied, indicating that dissatisfaction 
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develops over time and may be a factor delaying seeking help from mental health 
services (Parkman et al., 1997). 
Can racism against ethnic minorities cause mental illness? Studies in the US have found 
that minor daily discrimination can lead to ill health and that unfulfilled aspirations and 
obstruction of opportunity cause psychological stress. Moreover the psychological 
effects of racism include external attributions of negative events (owing to a negative 
view of self) resulting in paranoia and delusions (Sharpley et al., 2001). The impact of 
racism on the development of psychosis is unknown but some studies have found an 
association between the two (Janssen et al., 2003; Karlsen et al., 2005). 
A key question is why are these social factors associated with psychosis but not 
depression and anxiety? Possible explanations include reduced help-seeking behaviour 
in ethnic minorities; GPs failing to notice psychiatric symptoms because of patients’ 
somatic presentation to avoid the stigma of mental illness; avoidance of the effects of 
racism being defined as anxiety or depression. Nevertheless studies show similar or 
greater prevalence of depression and anxiety in black compared with white people. So 
why is psychosis not so markedly elevated in South Asian populations? Acculturation is 
a stressful experience and so living an insular life with ones own community may be 
protective. Rates of unemployment are lower in South Asian populations than black so 
improved socioeconomic status and upward mobility may be protective factors. 
Could migration be a factor? The seminal study by Ødegaard (Ødegaard, 1932) found 
that Norwegian immigrants to the US were more likely to develop schizophrenia than 
Americans born in the US or native Norwegians. He hypothesised that people who 
migrate are themselves at greater risk of schizophrenia but later studies showed this to 
be incorrect as it would not explain the higher risk for second-generation migrants 
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(Cantor-Graae et al., 2003; Selten et al., 2002). Other studies in the UK, Denmark and 
the Netherlands have found similar results to Ødegaard (Cantor-Graae et al., 2003; 
Cantor-Graae & Selten, 2005; Selten et al., 2001). Results are not uniform for all 
migrants. For instance Turkish migrants to the Netherlands, unlike other migrant 
groups, do not have an elevated risk of schizophrenia (Selten et al., 2001). A systematic 
review and meta-analysis of migration and schizophrenia found a relative risk of 2.7 
(95% CI 2.3, 3.2) for first-generation migrants and 4.5 (95% CI 1.5, 13.1) for second-
generation migrants (Cantor-Graae & Selten, 2005). Risks were greater for those 
migrating from developing vs. developed countries and from areas where the majority 
population is black (vs. white or not black or white). The reasons for this are unclear but 
were suggested to be an increased risk of schizophrenia in the country of origin and 
environmental risk factors in Western society. When the incidence of schizophrenia was 
studied both in the WHO ten-country study (Jablensky et al., 1992) (Colombia, 
Czechoslovakia, Denmark, India, Ireland, Japan, Nigeria, the USSR, the UK, and the 
US) and in a separate study in Barbados (Mahy et al., 1999) no significant differences 
by country were found. It is worth noting that black men are one group that are less 
likely to be counted in UK national censuses and some authors have suggested this may 
affect incidence calculations by as much as 10-30%. So raised incidence in country of 
origin and in people who choose to migrate are unlikely to be causes of increased rates 
of schizophrenia. This suggests risks are environmental, for example living in an urban 
environment and the degree of this urbanicity. Research is still some way behind in 
explaining these differences adequately.  
In summary, higher rates of diagnosis of schizophrenia and admission to mental health 
units for ethnic minorities have complex social and environmental not genetic causes. 
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What is clear is that the reasons for these differences have not been fully elucidated and 
further hypotheses and testing are required to provide an explanation. 
1.3.2.3  ETHNICITY AND PSYCHOLOGICAL TREATMENT 
There are concerns that access to psychological treatments for ethnic minorities are 
poor. Commitments made to monitor and improve the situation are stated in DRE and 
the government’s Improving Access to Psychological Treatments programme 
(Department of Health, 2005a; 2009).  Even after the introduction of IAPT, Asian, black 
and other groups are underrepresented in initial assessment statistics for psychological 
therapy. These differences represent low referral rates to these services (Glover et al., 
2010). As well as poor access, ethnic minorities are less likely to receive psychotherapy, 
particularly black vs. white patients (OR 0.33, 95% CI  0.16, 0.71) (Department of 
Health, 2003; Mays, 1985; McKenzie et al., 2001).   
 
Studies of CBT for schizophrenia show that black patients have higher dropout rates 
and poorer outcomes (Rathod et al., 2005). Various reasons have been proposed for 
these differences including: difficulty in engagement; cultural stereotyping as ‘not 
psychologically minded’; attitudes of professionals; and lack of understanding of other 
cultures (Rathod et al., 2005). The reasons for termination of psychotherapy include a 
negative attitude towards the therapist and lack of belief in effectiveness of treatment. 
Cultural adaptation of CBT for minority groups could improve these results (Rathod et 
al., 2010). 
 
Having psychology professionals that represent the minority ethnic groups they serve is 
an important factor in enhancing trust and acceptance of psychological therapies 
(Department of Health, 2009). Matching client and therapist by ethnicity may improve 
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numbers of completed sessions and reduce drop-out rates (Flaskerud & Liu, 1991). Data 
are difficult to locate on the proportion of psychology professionals by ethnicity in the 
UK, but examining access to postgraduate clinical psychology courses can serve as a 
proxy measure. In 2016 17% of those accepted to a place on these courses were from an 
ethnic minority (University of Leeds, 2015). This compares with 14% of the UK 
population being from an ethnic minority in the 2011 census, thus indicating a diverse 
population of trainees. Examining membership of the British Society of Psychologists 
in 2016 reveals, of members who declared ethnicity, only a tiny proportion were non-
white i.e.1.7% were black and 6.7% other (British Psychological Society, 2016). Thus 
the diversity of psychologists in the UK does not reflect the UK population. This has 
important cultural implications as people from ethnic minorities may wish to see a 
therapist with a similar cultural and linguistic background to themselves. 
 
Access to and receipt of psychological treatment by ethnicity are important issues to 
monitor but so to is acceptance of treatment after it has been offered. There are concerns 
that some black patients may be more likely to refuse the offer of CBT treatment. Trust 
in services, the stigma of mental illness and therapist ethnicity are important factors 
affecting ethnic minorities acceptance of psychological therapies (Gary, 2005; Shea & 
Yeh, 2008; Thompson & Alexander, 2006).  
1.3.2.4  ETHNICITY AND METABOLISM OF PSYCHOTROPIC MEDICATION 
Most psychotropics are not excreted unchanged in the urine – they have to be 
metabolised by the body to make them more polar and less lipid soluble so they can be 
removed by the kidney. This metabolism occurs in several organs but most takes place 
in the liver which contains pockets of enzymes called microsomes. Drug metabolism 
occurs in two stages to make drugs more polar and usually inactive. Phase I is when 
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oxidation, reduction or hydrolysis occurs and phase II joins drugs or their metabolites to 
another substance for example through glucuronidation, acetylation, sulfation, 
methylation and glutathione conjugation (Preston, 2015). 
 
Liver microsomes contain an enzyme system called cytochrome P450, a family of 
enzymes that oxidise many psychotropics. The CYP450 enzymes were evolved in 
animals over billions of years to detoxify plant poisons and consist of over forty 
different isoenzymes. Only eight of these isoenzymes are responsible for 90% of the 
metabolism of commonly used drugs. These are CYP3A4, CYP2D6, CYP2C9, 
CYP1A2, CYP2C8, CYP2C19 and to a lesser extent CYP2B6 and CYP2E1. There are a 
few other enzymes involved in phase I reactions e.g. functional monoamine oxidases. 
Phase II conjugation reaction enzymes are less well understood with glucuronidation by 
UDP-glucuronyltransferases the subject of much research. Drugs may be removed by 
and induce or inhibit transporter proteins such as the efflux pump P-glycoprotein. This 
may affect absorption, distribution and elimination of medication and cause drug 
interactions. 
 
Genetic variation can affect the metabolism of psychotropics as some of the CYP450 
enzymes are subject to ‘genetic polymorphism’, i.e. some people may have variants of 
these isoenzymes with different activity.  People may be poor metabolisers, 
intermediate metabolisers, normal metabolisers (confusingly described as extensive 
metabolisers) or ultra rapid metabolisers. A person’s metabolising status is genetically 
determined and can vary by ethnic group. 
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The CYP450 enzymes that metabolise antipsychotics are predominantly CYP1A2, 
CYP2D6 and CYP3A4 (Preston, 2015; Taylor et al., 2015). Details are in Table 2. 
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Ethnic differences in CYP450 activity have been identified for all three of the major 
enzymes that metabolise antipsychotics i.e. CYP1A2, CYP2D6 and CYP3A4 (McGraw 
& Waller, 2012). This means that some populations may metabolise psychotropics more 
slowly or quickly than others resulting in higher or lower plasma levels of these drugs.  
 
Determining the effects of genetic polymorphism on CYP450 enzymes is difficult. 
Ethnicity, as discussed earlier, is in itself challenging to classify and can erroneously 
combine people in a category who are very different. This means that inter-ethnic as 
well as between ethnic differences in metabolising capacity can be marked. The 
increasing movement of peoples means ethnic isolation has been replaced by ethnic 
diversity making genotypes less predictable. 
 
CYP1A2 is active mostly in the liver and accounts for approximately 15% of the 
activity of CYP450 enzymatic hepatic system (Wynn et al., 2008). Environmental 
factors are also important as smoking and some foods (e.g. cruciferous vegetables, 
charcoal grilled foods) can also induce CYP1A2. PMs of CYP1A2 are 5% of 
Australians, 14% of Japanese, 5% of Chinese with lower activity also reported for South 
and East Asian and African populations compared with Caucasians (Perera et al., 2012; 
Relling et al., 1992; Yang et al., 2012; Zhou et al., 2009). The activity of CYP1A2 has 
clinically significant effects on the elimination of olanzapine and clozapine (Murray, 
2006).   
 
CYP2D6 is probably the best studied of the CYP450 enzymes to be investigated for its 
effects on drug interactions. It is a low-capacity, high-affinity enzyme i.e. will 
metabolise drugs in low concentrations but if concentrations rise then CYP3A4 or 
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CYP1A2 (high capacity, low affinity enzymes) will clear the drug. This means 
CYP2D6 PM status may be compensated for by other enzymes (Wynn et al., 2008). 
CYP2D6 is found in the brain, prostate, bone marrow and heart as well as in relatively 
small amounts in the liver (2-4% of CYP450 total liver content).  
 
CYP2D6 is polymorphic. PMs of CYP2D6 number approximately 1% in South and 
East Asians, 5-10% in whites and 0-19% in blacks (Bernard et al., 2006; McGraw & 
Waller, 2012). Interethnic variation can be pronounced e.g. black PM of CYP2D6 
comprise 1.8% of Ethiopians compared with 19% of black South Africans (Bernard et 
al., 2006). Ultra-extensive and intermediate metabolisers also exist and proportions of 
these do vary by ethnicity, for instance 60% of East Asian people are intermediate 
metabolisers of CYP2D6 whilst 21% of Saudi Arabians and 29% of Ethiopians are UM 
(Bernard et al., 2006; Wynn et al., 2008). 
 
CYP3A4 accounts for 30% of CYP450 activity in the liver and 70% in the small 
intestine. It is a high-capacity, low-affinity enzyme so where there are low 
concentrations of a drug metabolised by CYP3A4 other CYP450 enzymes may be 
active. If CYP3A4 is inhibited it may be difficult for the other low-capacity, high-
affinity enzymes to cope with metabolism so drug levels can rise.  There are many 
polymorphisms of CYP3A4 but their effect on metabolic activity is as yet unknown and 
there is high inter-individual variability in activity between the different isoforms 
(Hsieh et al., 2001; McGraw & Waller, 2012; Wandel et al., 2000). CY3A4 
polymorphisms are associated with several diseases including breast and prostate 
cancers, secondary leukaemias, diabetes and hyperlipidaemia (Zhou et al., 2006). 
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So overall whilst one would expect that genetic polymorphism of CYP450 enzymes 
would have an important effect on dosing of psychotropics for Asians (antipsychotic 
dose reductions of 20% have been suggested in expert opinion surveys for East Asian 
people (Gardner et al., 2010)) it would not explain differences in prescribing between 
other ethnic groups.  That is not to say that metabolising ability has no effect on dosing 
or adverse effects of medication (indeed PM of CYP2D6 have a greater risk of 
developing tardive dyskinesia and extrapyramidal side effects) but that an individual’s 
own metabolising ability may be more important than their ethnicity alone (Wynn et al., 
2008). Currently in the UK determining CYP450 polymorphisms is prohibitively 
expensive through laboratory genotyping or response to a probe (substance metabolised 
by the CYP450 enzyme in question e.g. for CYP1A2 caffeine, CYP2D6 
dextromethorphan, CYP3A4 midazolam) and is usually only possible within a clinical 
trial. Technological developments mean there are now commercially available tests e.g. 
the AmpliChip that can quickly and easily detect metaboliser status for CYP2D6 and 
CYP2C19. In time the UK may be able to test all patients routinely, as is done in some 
other countries (Mrazek, 2010). 
 
Of course CYP450 metabolism is not the only method of drug metabolism. Acetylation 
by N-acetyltransferases is a phase II conjugation reaction and is subject to genetic 
polymorphism and ethnic difference. Some individuals are slow acetylators and can 
experience greater toxicity with some drugs e.g. hydralazine, isoniazid, procainamide 
and sulfasalazine but not as yet for antipsychotics (Ackenheil & Weber, 2004; Preston, 
2015). Other methods of drug interaction possibly affecting antipsychotics are drug 
transporter proteins which carry drugs across biological membranes. The most studied 
is P-glycoprotein, an efflux pump that pushes drugs out of cells and is subject to genetic 
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polymorphism. It can be induced or inhibited by drugs but is mostly important for 
metabolism of cancer and HIV drugs and is not thought to affect or transport 
antipsychotics (Preston, 2015). It is worth noting that P-glycoprotein and CYP3A4 
operate in a coordinated way. In the intestine P-glycoprotein increases the time a drug is 
exposed to CYP3A4 reducing bioavailability whilst the reverse occurs in the liver. The 
interplay between the two systems is under research. Other drug transporters also exist 
but their effects on antipsychotics are not known. 
1.3.2.5  ETHNICITY AND ANTIDEPRESSANT TREATMENT 
Data on the prevalence of depression in ethnic minorities are conflicting. Some authors 
have found that depression is more common in certain ethnic minorities whilst others 
have found the opposite (Acheson, 1998; Riolo et al., 2005; Sprotson K, 2002; Williams 
et al., 2007). This may be because these people with depression are less likely to access 
care and treatment, resulting in a more severe and chronic condition (Alegria et al., 
2008; Williams et al., 2007). 
 
Antidepressant treatment may vary by ethnicity. Black and Asian patients (but not 
Hispanic (Sleath et al., 2001)), especially those living in areas of high ethnic density, 
are less likely than whites to be prescribed an antidepressant (Alegria et al., 2008; 
Gonzalez et al., 2008; Walters et al., 2008). Even in vascular disease, where depression 
is associated with higher mortality, rates of antidepressant use are much lower in black 
compared with white patients even after adjustment for depression severity (Waldman 
et al., 2009). Conversely a study of psychiatrists’ assessments of video vignettes of late 
life depression that differed by gender and ethnicity (African American or white) found 
no differences in diagnosis or treatment (Kales et al., 2005). This suggests that factors 
other than ethnic bias are also important. Racial differences in acceptability of use of 
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antidepressants have been cited as a potential cause of these findings (Cooper et al., 
2003) with ethnic minorities preferring counselling and prayer as treatments for 
depression (Givens et al., 2007a). However antidepressant stigma appears to be greater 
in white compared with black patients (Givens et al., 2007b).  
 
When ethnic minority groups do take antidepressants there appear to be few differences 
in the speed of response and remission rates compared with the majority population 
(Lesser et al., 2007; Lesser et al., 2010) as long as an effective dose is prescribed 
(Cornwell & Hull, 1998). This is despite polymorphic differences in serotonin and 
noradrenaline transporters genes, which can differ by ethnicity, affecting antidepressant 
response (Kim et al., 2006). 
 
1.3.2.6  ETHNICITY AND ANTIPSYCHOTIC TREATMENT 
Are there differences in prescribing of psychotropics in minority ethnic groups that 
relate to prejudice rather than metabolism? Patients and carers think so (Department of 
Health, 2003; South London and Maudsley NHS Trust, 2005) and, after the inquiry into 
the death of David Bennett (Norfolk Suffolk & Cambridgeshire Strategic Health 
Authority, 2003), the issue needed investigation (Department of Health, 2005a).  
 
Most of the studies examining psychotropic use by ethnicity have been completed in the 
US. Differences in antipsychotic treatment by ethnicity include; an increased likelihood 
of receiving an antipsychotic (Delbello et al., 2000; Flaskerud & Hu, 1992; Szarek & 
Goethe, 2003) (refuted by a meta-analysis (Puyat et al., 2013)), higher doses (Diaz & 
De Leon, 2002; Segal et al., 1996; Walkup et al., 2000), older drugs (Daumit et al., 
2003; Fleck et al., 2002) and more frequent use of depot formulations (Kuno & 
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Rothbard, 2002). Again these differences are pronounced for black compared with 
white patients. These studies analysed mostly large US databases and adjusted for only 
a few confounding factors affecting the prescribing of antipsychotics (see Appendix 2 
for list of studies and confounders). The healthcare systems of the UK and US differ 
markedly and have a profound effect on access to and receipt of treatment. Many of the 
US studies did not adjust for health insurance status.  
 
There are few UK studies examining ethnicity and antipsychotic use. One survey (Lloyd 
& Moodley, 1992) found no significant differences (after adjustment for five 
confounding variables) in overall doses of antipsychotics taken by black and white 
patients, but black patients were more likely than whites to be receiving a depot and at a 
significantly higher dose. My cross-sectional surveys of antipsychotic prescribing and 
ethnicity have included large numbers of patients from three NHS trusts and accounted 
for multiple confounding factors (Connolly et al., 2007; Connolly & Taylor, 2008). 
Overall these surveys found did not find significant differences between black and 
white patients for antipsychotic dose, high dose (>100% of maximum dose) or type 
prescribed (FGA or SGA), even after adjustment for over 20 different confounding 
factors. But both higher costs of antipsychotic medication and polypharmacy (more than 
one antipsychotic prescribed) were significantly more likely in black patients (Connolly 
& Taylor, 2008).  
 
A detailed literature review of antipsychotic prescribing by ethnicity is described in 
Appendix 3 and summarised in Appendix 4.  The outcomes from Appendix 4 are 
summarised in Table 3 below. Overall there are, broadly, a larger number of prescribing 
studies that show worse outcomes for black patients (vs. white or non-black or 
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Hispanic), non-white (vs. white), Hispanic (vs. white or non-Hispanic) and Maori (vs. 
non-Maori) patients. However studies of Asian ethnicities have mostly better (or 
similar) outcomes than other ethnicities, although the number of studies are few. 
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TABLE 3 ANTIPSYCHOTIC PRESCRIBING AND ETHNICITY STUDIES - NUMERICAL SUMMARY OF STUDY OUTCOMES 
 
Ethnic comparison Outcome Results (number of studies) 
Worse No difference Better Total 
 
















Antipsychotic use 9 11 5 25 
Antipsychotic prescribed 0 1 0 1 
Antipsychotic administered 0 0 1 1 
Dose 8 18 4 30 
High dose 4 8 0 12 
Polypharmacy 6 10 2 18 
PRN antipsychotics 0 1 0 1 
Depot use 11 3 0 14 
Route 0 1 0 1 
Type of antipsychotic (FGA) 3 1 0 4 
Type of antipsychotic (SGA) 14 10 0 24 
Oral SGA 1 0 0 1 
Oral FGA 1 0 0 1 
Depot SGA 0 0 1 1 
Depot FGA 1 0 0 1 
Clozapine use 7 0 0 7 
Clozapine cessation 0 1 0 1 
Cost 1 1 1 3 
Length of treatment 1 1 0 2 
Anticholinergic agent use 1 0 0 1 
‘Off label’ SGA use 0 0 1 1 
Stimulant and SGA use 1 0 0 1 
Service user choice of antipsychotic 0 1 0 1 
Written information provided 0 1 0 1 
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Benefits/side effects explained 0 1 0 1 
Total 69 70 15 154 
Ethnic comparison Outcome Results (number of studies) 
Worse No difference Better Total 
 
Black vs. non-black 
(reference) 
Antipsychotic use 1 2 0 3 
Dose 2 2 0 4 
Depot use 5 0 0 5 
Type (FGA) 2 1 0 3 
Type (SGA) 4 2 1 7 
Clozapine use 1 0 0 1 
Polypharmacy 0 1 0 1 
Anticholinergic agent use 1 0 0 1 
Antipsychotic injection number of doses 1 0 0 1 
Low dose (< 300mg CPZe) 1 0 0 1 
Stimulant and SGA use 0 1 0 1 
Antipsychotic plasma levels 1 0 0 1 
Total 19 9 1 29 
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Ethnic comparison Outcome Results (number of studies) 
Worse No difference Better Total 
 
White vs. non-white 
(reference) 
Antipsychotic use 2 6 4 12 
Dose 0 3 1 4 
High dose 0 0 3 3 
Depot use 0 3 3 6 
Length of treatment 0 1 0 1 
Anticholinergic agent use 0 0 1 1 
Clozapine use 0 3 1 4 
Low dose (< 300mg CPZe) 1 0 0 1 
Type (FGA) 0 1 1 2 
Type (SGA) 0 8 4 12 
Polypharmacy 1 4 1 6 
Cost 1 0 0 1 
‘Off-label’ SGA use 0 0 1 1 
Antipsychotic indication 0 1 0 1 
Total 5 30 20 55 
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Ethnic comparison Outcome Results (number of studies) 
Worse No difference Better Total 
Asian vs. white (reference) Antipsychotic use 0 2 2 3 
Dose 0 2 5 7 
Polypharmacy 1 3 0 3 
Type of antipsychotic 0 1 0 1 
High dose 0 1 0 1 
Depot use 0 1 0 1 
Clozapine use 0 1 0 1 
Service user choice of antipsychotic 0 1 0 1 
Written information provided 0 1 0 1 
Benefits/side effects explained 0 1 0 1 
Anticholinergic agent use 0 1 0 1 
Switching from FGA to SGA 0 1 0 1 
Total 1 14 7 22 
Asian vs. black (reference) Dose 0 2 1 3 
Polypharmacy 0 2 0 2 
Total 0 4 1 5 
Asian vs. Hispanic (reference) Dose 0 2 1 3 
Anticholinergic agent use 0 1 0 1 
Total 0 3 1 4 
Asian vs. non-Asian 
(reference) 
Dose 0 0 2 2 
Anticholinergic agent use 1 0 0 1 
Total 1 0 2 3 
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Ethnic comparison Outcome Results (number of studies) 
Worse No difference Better Total 
 
Mixed vs. white (reference 
category) 
Antipsychotic use 0 1 0 1 
Type of antipsychotic  0 1 0 1 
Depot use 0 1 0 1 
Clozapine use 0 1 0 1 
High dose 1 0 0 1 
Polypharmacy 0 1 0 1 
Service user choice of antipsychotic 0 1 0 1 
Written information provided 0 1 0 1 
Benefits/side effects explained 0 1 0 1 
Total 1 8 0 9 
 
Chinese/other vs. white 
(reference category) 
Antipsychotic use 0 1 0 1 
Type of antipsychotic  0 1 0 1 
Depot use 0 1 0 1 
Clozapine use 0 1 0 1 
High dose 0 1 0 1 
Polypharmacy 0 1 0 1 
Service user choice of antipsychotic 0 1 0 1 
Written information provided 0 1 0 1 
Benefits/side effects explained 0 1 0 1 
Total 0 9 0 9 
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Ethnic comparison Outcome Results (number of studies) 
Worse No difference Better Total 
 
Hispanic vs. white (reference) 
Antipsychotic use 2 3 2 7 
Dose 2 5 3 10 
High dose 0 1 0 1 
Polypharmacy 0 5 1 6 
Type (SGA) 5 2 0 7 
Type (FGA) 0 1 0 1 
Clozapine use 4 0 0 4 
Depot use 0 1 0 1 
Cost 0 0 1 1 
Anticholinergic agent use 0 1 0 1 
‘Off-label’ SGA use 0 0 1 1 
Total 13 19 8 40 
 
Hispanic vs. black (reference) 
Dose 1 1 1 3 
Polypharmacy 0 0 2 2 
Type (SGA) 0 0 1 1 
Total 1 1 4 6 
 
Hispanic vs. non-Hispanic 
(reference) 
Antipsychotic use 0 1 0 1 
Dose 0 1 1 2 
Polypharmacy 1 0 1 2 
Type (SGA) 3 0 0 3 
Total 4 2 2 8 
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Ethnic comparison Outcome Results (number of studies) 
Worse No difference Better Total 
Mexican American vs. white 
(reference) 
Type (SGA) 1 2 0 3 
Total 1 2 0 3 
American Indian vs. white 
(reference) 
Antipsychotic use 0 1 1 2 
Total 0 1 1 2 
Maori vs. non-Maori 
(reference) 
Antipsychotic dose (CPZe) 0 1 0 1 
Depot use (FGA) 1 1 0 2 
Type (SGA) 1 1 0 2 
Clozapine use 0 0 1 1 
Total 2 3 1 6 
Asian, Maori and Pacific 
Islanders vs. non-ethnic 
minority (reference) 
Antipsychotic use 0 1 0 1 
Total 0 1 0 1 
Hawaiian or multiracial vs. 
white 
Antipsychotic use 0 0 1 1 
Total 0 0 1 1 
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1.4 RATIONALE FOR RESEARCH 
There have been calls from reports into mental health services and ethnicity for annual 
audits of psychotropic drug use (particularly antipsychotics) and ethnicity (Department 
of Health, 2003; 2005a). This is to establish if there are any differences in prescribing 
(i.e. dose, route, type, number, cost) by ethnicity. There are inequalities in mental health 
care and, from my extensive review in Appendices 3 and 4, evidence of differences in 
prescribing by ethnicity. Such differences require investigation. 
 
The Department of Health’s ‘Delivering Race Equality in Mental Health Care: An 
action plan for reform inside and outside services’ (Department of Health, 2005a) and 
the Government’s response to the Independent inquiry into the death of David Bennett 
(Norfolk Suffolk & Cambridgeshire Strategic Health Authority, 2003) in 2005 state; 
- ‘Organisations should have information capable of being analysed by ethnicity on 
factors such as medication. If an organisation finds, for example, that average doses 
of antipsychotic medications are higher for African-Caribbean men, or that novel 
antipsychotic prescribing is lower, it should investigate why. If there is no clinical 
reason for the variation, then the organisation should act to reduce it.’ 
- ‘Commissioners and service providers should consider whether it would help local 
service development to monitor ethnicity in relation to specific aspects of treatment 
and care, for example using different categories of medication – novel antipsychotics, 
high dose prescribing etc.’ 
 
The undertaking of larger pharmacoepidemiological (e.g. computer database) studies is 
precluded by the need to collect data on, and correct for, numerous potential confounders 
of prescribing practice (although the effects of overadjustment need to be considered). 
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This extent of data collection is best undertaken in inpatient units where data can be 
readily and accurately recorded.  In the present study the aim was to examine the influence 
of ethnicity on antipsychotic prescribing practice in inpatient units serving populations 
with the largest proportions of black and minority ethnic group people in the UK.  
 
This thesis will investigate differences in prescribing practices according to ethnic origin 
while attempting to account for influences of other variables. Mental Health trusts provide 
services to a wide range of service users from diverse ethnic backgrounds.  Results should 








The purpose of the study is to discover if non-white patients receive different doses (dose, 
high dose) or treatment (type, number, cost) of antipsychotics compared with white 
patients.  
 
1.4.3 OBJECTIVES  
• To describe antipsychotic prescribing by ethnicity.  
• To collect multiple confounding factors that may be affecting the outcomes. 
• To compare prescribing by black and white ethnicity to determine if ethnicity 
influences any of the outcomes (i.e. dose, high dose, type of antipsychotic, 
polypharmacy, cost of antipsychotic). 
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• To analyse the data for each centre involved in the study by black and white ethnicity 
to determine if individual centres affect prescribing. 
• To analyse the data for other minority ethnicities to determine the relationship with 
outcomes. 
• To determine which clinical variables predict study outcomes. 
• To investigate the effect of ‘when required’ dosing on polypharmacy rates. 
• To investigate the effect of prescriber attitudes to prescribing by ethnicity. 
 
1.4.4 STUDIES CONTAINED IN THIS THESIS 
• Study 1, Chapter 2 - cross-sectional survey of antipsychotic prescribing (i.e. dose, 
high dose, type of antipsychotic, polypharmacy, cost of antipsychotic) by black and 
white ethnicity. This study will investigate prescribing of antipsychotics in black and 
white patients and collect variables that may be affecting the outcomes to establish if 
there are any differences in prescribing of antipsychotics by these ethnicities. It fulfils 
calls from reports into ethnicity and mental health services to investigate prescribing 
practices in the UK because of differences found in research studies (see Table 3). 
Most studies and concerns about prescribing have been in black compared with white 
patients. These are the two ethnic groups with the largest proportions of inpatients in 
UK NHS mental health trusts so this analysis was done first. 
• Study 2, Chapter 3 - analysis of antipsychotic prescribing by black and white ethnicity 
for each centre involved in the study. This study analyses data for black and white 
patients for each individual centre alone and then all data combined with centre 
included as a variable. Study 2 builds on study 1 by investigating variation in 
prescribing practice between NHS Trusts for black and white patients not just within 
these ethnic groups. 
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• Study 3, Chapter 4 - predictors of antipsychotic prescribing for all ethnicities. This 
study investigates prescribing of antipsychotics for people of all ethnicities not just 
black and white patients. It builds on study 2 by investigating a larger sample, 
including proportionally smaller ethnic groupings, to discover if prescribing varies by 
these ethnicities.  
• Study 4, Chapter 5 - case vignette questionnaire study analysing prescribers attitudes 
to antipsychotic prescribing by ethnicity.  This study of theoretical prescribing 
intention for a black or white patient investigates prescribing by ethnicity using a 
different method to those used in studies 1, 2 and 3. It builds on these earlier studies 
by exploring antipsychotic prescribing by ethnicity with a different research design.
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CHAPTER 2 ANTIPSYCHOTIC PRESCRIBING BY BLACK AND WHITE 
ETHNICITY 
2.1 GENERAL INTRODUCTION 
People of black and minority ethnic groups are overrepresented in mental health 
services in the UK compared with their white counterparts (Department of Health, 
2005a). There are many suggested reasons for this including: delays in seeking help 
from mental health services; routes of access to these services (Bhui et al., 2003); 
differences in diagnosis (e.g. overdiagnosis of black people with schizophrenia) 
(Barnes, 2004); exposure to risk factors for mental illness (e.g. substance misuse) and 
institutional racism in mental health services (Kirkbride et al., 2006; McKenzie & Bhui, 
2007).  
 
Antipsychotic prescribing varies by ethnicity in many countries and has been studied 
particularly in the US. As discussed extensively in the introduction to this thesis, there 
are numerous studies examining the pharmacokinetic, pharmacodynamic and 
prescribing of psychotropics in people of different ethnicities (see Appendices 3 and 4). 
A small proportion of antipsychotic prescribing variability may be explained by 
pharmacokinetic differences for some ethnicities, for example differences in 
metabolism by Asian people (Oesterheld, 2009). This programme of work examines 
antipsychotic prescribing specifically rather than other aspects of biological variability 
in order to test the effect of patient ethnicity, rather than inter-ethnic pharmacokinetic 
and pharmacodynamic differences, on prescriber decisions. 
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As well as research studies finding differences in prescribing of antipsychotics by 
ethnicity, reports and investigations into ethnicity and mental health in the UK have also 
recommended analysis. Most concern is reported for differences in prescribing for black 
compared with white patients. This is because these are the two ethnic groups are the 
largest proportions of inpatients in mental health hospitals and black patients are an 
overrepresented group. This study addresses these concerns by measuring antipsychotic 
prescribing by ethnicity for black and white patients. 
 
2.1.1 BACKGROUND 
Antipsychotic prescribing by ethnicity had been previously studied firstly in my own 
NHS trust, the South London and Maudsley, and then in neighbouring trusts, South 
West London and Saint George’s and Oxleas. A cross-sectional survey method was 
used and data collected using a data collection form, from patient interviews, case-notes 
and prescription charts. These two initial studies were important development steps in 
the design and analysis of the third multicentre study. Without these preliminary studies 
there would not have been an understanding, with the benefit of hindsight and peer 
review, of the strengths and limitations of the study methods.  
 
Ethnicity is only one of many influences affecting how antipsychotics are prescribed, so 
the study design needed to collect a range of factors to control for these variables, and 
allow any differences in prescribing because of ethnicity alone to be statistically 
isolated.  
 
The initial data collection form was developed using three methods. Firstly a list of all 
the possible factors that could affect prescribing of antipsychotics was devised. This 
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was undertaken following the completion of a literature review (using Medline, Embase 
and Google Scholar citation databases) of antipsychotic prescribing by ethnicity. The 
research studies identified were examined for variables that had been collected by 
previous researchers and this information was collated into a table (Appendix 2). This 
enabled previous work to be replicated and to further develop the area of study through 
collection of additional factors affecting prescribing of antipsychotics by ethnicity. 
Lastly expert opinion was sought from clinical colleagues to determine the relevance 
and appropriateness of these factors to allow review and refinement. 
Information from these methods was then examined to determine if data could be 
feasibly collected on these factors. Finally all the information was collated and 
incorporated into an antipsychotics and ethnicity data collection form number 1 
(Appendix 5).  
 
The peer review process of publication during the first antipsychotic prescribing and 
ethnicity study highlighted limitations with the data collection. Data on severity of 
illness was not collected, a factor which could obviously affect prescribing of 
antipsychotics. This variable was included in the data collection form (Appendix 7) and 
notes (Appendix 8) for the second study of SLaM, SWLaSG and Oxleas prescribing by 
ethnicity (Appendix 9) (Connolly & Taylor, 2008).  
 
The first study collected data on patients who had taken an antipsychotic for 3 weeks or 
longer. This was to exclude periods of dose titration or switching of medication. On 
reflection it was realised that data should be collected for all patients prescribed an 
antipsychotic, regardless of treatment length. This was because high doses could have 
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been used on initiation of treatment for different ethnicities and that excluding these 
patients could be missing important data. 
 
Patients were interviewed individually for the two initial studies for several reasons. 
They were asked their own ethnicity, parental ethnicity, smoking status, educational 
level, employment status, first language, if they had been given a choice of 
antipsychotic treatment and if the pros and cons of their antipsychotic treatment had 
been explained.   
 
Ethnicity is usually self-ascribed (Office for National Statistics, 2003) however the 
study tested prescribers perception of a patient’s ethnicity at the point of prescribing of 
an antipsychotic, rather than the individual’s preferred description. This meant self-
ascription of ethnicity was not essential. Initially parental ethnicity was collected to 
determine if patients were black or white or of mixed ethnicity. It was realised that this 
again was inaccurate as ethnicity is derived over many generations and does not only 
result from parental ethnicity. Mixed ethnicity patients were not included in these two 
initial studies. This was for two reasons. Firstly collection of data for only black or 
white patients would make results clearer and secondly black and white ethnicities were 
the largest inpatient groups.  In this study data were collected on all ethnicities including 
mixed so that a full examination of prescribing in each group could be undertaken (see 
Chapter 4 for all ethnicities analysis). 
 
Again the peer review process of the second study made suggestions for improvement 
of data collection. As the study was cross-sectional in design, collection of the severity 
of illness measure occurred on the day of data collection, not on the date of starting an 
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antipsychotic. This rendered this data unrepresentative, as it was often some time since 
the antipsychotic had been started or the dose increased. Because of this the severity of 
illness factor was not collected for this final study.  
 
Both initial studies allowed greater testing of the modified data collection form and 
important insights into how to improve the methods. The final data collection form is in 
Appendix 12 and accompanying notes for data collection are in Appendices 10 and 11. 
 
2.1.2 FUNDING 
Our initial study (Connolly et al., 2007) was funded, after a call for applications for 
research, by a grant from the Health Services Research Committee at the SLaM NHS 
trust. The second larger study (Connolly & Taylor, 2008) was then funded after 
application to the trustees of the charitable fund of the SLaM NHS trust. Publication and 
dissemination of the results of these earlier studies through conference presentations 
resulted in an approach with funding for this national study from the Equality and 
Human Rights Commission (previously the Commission for Racial Equality). 
2.2 METHOD 
2.2.1 STUDY DESIGN AND SETTING 
The study was a cross-sectional survey of antipsychotic prescribing in black and white 
inpatients prescribed one or more regular antipsychotics on the day of the data 








• All adult inpatients (aged 18 and over) on acute general psychiatry wards, 
including psychiatric intensive care units. 
• Prescribed one or more regular antipsychotics on the day of the data collection 
(or had received a when required/ PRN dose in the last 24 hours).  
Exclusion criteria: 
• All suitable patients within each trust were included over a three-month period: 
none were excluded except for reasons above. 
Recording of ethnicity is mandatory for all inpatients (Department of Health, 2007) and 
patients were classed as white (white British, white Irish, white other), black (black 
British, black African, black Caribbean, black other), mixed (white and black 
Caribbean, white and black African, white and Asian, mixed other), Asian (Asian 
British, Asian Indian, Asian Pakistani, Asian other) or Chinese/other ethnic group 
according to their medical notes (as categorised by the Office for National Statistics 
(Office for National Statistics, 2001)). As discussed in Chapter 1, classification of 
ethnicity aims to include the variability and complexity of people but research requires 
categorisation. The ethnic groups used by the Office for National Statistics contain 
diverse collections of people. Collapsing of ethnic categories loses heterogeneity and 
can ultimately affect results.  
 
This study differed from the previous ones in that data were collected on all ethnicities 
not only black or white patients (Connolly et al., 2007; Connolly & Taylor, 2008). 
Analysis of the data in this chapter is for black and white patients only – the two largest 
ethnic groups in the population sample. 
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2.2.3 DATA COLLECTION 
Ten mental health trusts were approached to take part in this survey of antipsychotic 
prescribing and ethnicity. These trusts were chosen because they served populations 
known to have the largest proportions of BME patients in the UK. Data from the ‘Count 
me in Census’ by the Care Quality Commission (Care Quality Commission, 2009) (see 
Chapter 1 for discussion of this document) were used to determine which UK mental 
health trusts had the most ethnically diverse patient population (see Appendix 13). 
Multiple efforts were made to contact and encourage these trusts to contribute to the 
data collection. Trusts were initially invited to take part by written contact with their 
chief pharmacist. Those who did not reply were contacted once again by letter and then 
by telephone. Finally if there was still no reply the funding agency supporting the 
research (Equality and Human Rights Commission) was contacted so that they could 
follow up non-responding trusts through their regular meetings with NHS trust Chief 
Executives. Contact with each trust highlighted the benefits of engaging in the study 
which included: 
• Analysis of data on antipsychotic prescribing and ethnicity for their trust. 
• Comparison of their results with other English mental health trusts. 
• A financial contribution towards the cost of data collection. 
• Assistance and support with engaging in multicentre audit. 
• Suggestions on how to improve equality of prescribing practice. 
The funding from the Equality and Human Rights Commission was used to provide 






Prescribing outcomes have been well studied in psychiatry. Quality standards have been 
set nationally in the UK by the Prescribing Observatory for Mental Health and are 
audited regularly (Paton et al., 2008). There here have been many studies of 
antipsychotic prescribing and ethnicity completed worldwide (see Chapter 1). The 
quality standards from POMH-UK and other studies of ethnicity and antipsychotics 
were used as outcome measures. 
The main outcomes of the study were:  
• Dose - expressed as a percentage of the BNF licensed maximum dose (British 
Medical Association and Royal Pharmaceutical Society of Great Britain, 2008). 
• High dose - being prescribed antipsychotic medication above maximum BNF doses 
i.e. at more than 100% of the BNF maximum dose (British Medical Association and 
Royal Pharmaceutical Society of Great Britain, 2008). 
• Polypharmacy prescribed - more than one antipsychotic prescribed regularly or 
when required. 
• Polypharmacy administered - more than one antipsychotic prescribed and 
administered in the last 24 hours. 
• Type of antipsychotic - categories of FGA and SGA from the BNF (British Medical 
Association and Royal Pharmaceutical Society of Great Britain, 2008). 
• Cost - 28 days of medication (Monthly Index of Medical Specialities, December 
2008). 
2.2.5 INSTRUMENTS AND PERSONNEL  
Data were collected by pharmacists or doctors working within each NHS trust during 
normal working hours, as part of routine clinical care. Each data collector was visited in 
person and trained by the researcher on how and where to collect the data from and an 
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explanation of data collection definitions provided. This information was also provided 
in written form (Appendices 10, 11 and 12) and telephone contact support for the data 
collectors was also offered. 
 
Potential confounders were predetermined from previous research (see Appendix 2), 
previous studies I have conducted and published in peer-reviewed journals and expert 
opinion (medical and pharmacist colleagues experienced in ethnicity research 
methodology and statistics) as described above and are listed in Table 4. The 
confounders were defined for the data collectors as in Appendix 10. They were 
determined by reference to casenotes, prescription charts and to standard reference texts 
for dose, type and cost (British Medical Association and Royal Pharmaceutical Society 
of Great Britain, 2008; Monthly Index of Medical Specialities, December 2008). 
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TABLE 4 POTENTIAL CONFOUNDERS 
 
Type of data Confounder  
Demographic Age, gender, education, employment status, forensic history 
(previous conviction or currently charged with an offence), 
language spoken, smoking status, ethnicity of patient’s 
consultant. 
Clinical Current legal detention status, current substance misuse, 
diagnosis, duration of illness, length of current admission, 
number of previous admissions, history of or current non-
compliance, weight. 
Medication-specific Previous antipsychotic treatments, previous treatment with 
current antipsychotic medication, anticholinergic prescribed 
regularly, length of current antipsychotic treatment, route of 
administration. 
Outcome-based Dose, high dose, polypharmacy prescribed, polypharmacy 
administered, type of antipsychotic, cost of antipsychotic. 
 
2.2.6 SAMPLE SIZE  
A ‘power’ calculation was performed before starting the study to avoid a false negative 
type II statistical error (Jones et al., 2003). A sample size of 788 was calculated to be 
required to have an 80% chance of detecting a 5% (55% vs. 50%) absolute difference 
for the main outcome (percentage maximum dose) between black and white patients 
(assuming a standard deviation of 25). Estimates of dose and standard deviation were 
taken from previous studies on ethnicity and prescribing (Connolly et al., 2007; 
Connolly & Taylor, 2008). 
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2.2.7 STATISTICAL ANALYSIS 
The aim was to compare the six outcomes between the two groups (black and white 
patients) and to adjust the resulting comparisons for the effect of confounding variables. 
Although the trust caring for the patient was not included as a confounder in this data 
analysis it was used in later analyses to compare how prescribing practice varied by 
centre (see Chapter 3). Data collection forms were quality assured for accuracy and 
completeness before entry onto a database and then the database was again checked 
against paper records after all the data had been entered. 
 
Baseline demographic and clinical characteristics were analysed by ethnicity. A linear 
regression model was then used to investigate whether there was a difference between 
black and white patients for the continuous outcomes of dose and cost of treatment. 
Confounding variables to be included in the model were selected using a stepwise 
forward selection procedure with a selection criterion of 10% and removal criterion of 
20%. Where the relationship between continuous potential confounding variables and 
the outcomes could not be assumed to be linear (a requirement for regression modelling 
(Field, 2013)) and transforming variables did not induce a linear relationship, restricted 
cubic splines were applied. The fit of each model and the influence of observations were 
examined. This modelling produced an adjusted effect size (i.e. median percentage 
difference for dose and median cost difference) for ethnicity for the outcomes of dose 
and cost. A similar approach was used for the binary outcomes of high dose, 
polypharmacy prescribed, polypharmacy administered and prescribing of FGA drugs, 
but using logistic regression modelling. This modelling allowed the calculation of 
adjusted odds ratios. Identification of confounding variables was as described above. 
The fit of each model was examined using residual analysis. 
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Initially a complete case analysis was performed for each of the regression models i.e. 
where only patients with complete covariate data were included in the model. Excluding 
patients without full information may result in biased estimates. Consequently values 
were imputed for patients with missing covariate data using a multiple imputation 
method. For each variable an appropriate regression model was specified. Five datasets 
containing imputed values were created then each data set was analysed and the relevant 
parameters were averaged across the data to give a single estimate. The analysis was 
performed using the function ICE in Stata version 10.  The adjusted results reported are 
for the imputed data sets.  
 
2.2.8 ETHICAL COMMITTEE APPROVAL  
Individual trust approvals were sought and obtained for the study through local clinical 




The null hypothesis was black patients are prescribed the same total dose of 
antipsychotics as white. 
 
2.2.10 AIM 
The purpose of the study was to discover if black patients receive different doses (total 
dose, high dose) or treatment (type, number, cost) of antipsychotics compared with 





2.2.11 OBJECTIVES  
• To complete a study of antipsychotic prescribing and ethnicity  
• To collect multiple potentially confounding factors that may be affecting the 
outcomes 
• To analyse the black and white ethnicity data statistically to determine if ethnicity 
influences any of the study’s outcomes 
2.3 RESULTS 
2.3.1 PRIMARY OUTCOME-COMPLETE CASE ANALYSIS 
Nine trusts agreed to take part and eight (Barnet, Enfield and Haringey, Camden and 
Islington, Central and North West London, East London and City, Manchester Mental 
Health and Social Care Trust, North East London, Nottinghamshire Healthcare, South 
London and Maudsley) completed the data collection. Data relating to 938 patients 
across eight centres was collected of which 541 (57.7%) were white and 397 (42.3%) 
black. The demographic data, including clinical information, and numbers recruited 
from each centre are displayed in Tables 5 and 6. The largest number of patients came 
from SLaM, most were male, middle-aged, unemployed, had completed their secondary 
education, spoke English as a first language and smoked cigarettes. Clinically a greater 
number had schizophrenia, weighed more than 77kg, were compulsorily detained in 
hospital, did not have a forensic history, had had two or more hospital admissions, a 
duration of illness of at least 8 years, a length of admission of more than 8 weeks, a 
history of non-compliance with medication and were not misusing substances. Most had 
a consultant of white ethnicity and a third of senior doctors were from a minority ethnic 
group. For the medication-specific confounders most patients had taken their current 
antipsychotic before and two or more antipsychotics previously, were taking treatment 
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orally, had been on their current treatment for 40 days or more and were not taking an 
anticholinergic medicine.  
 
Not all confounder data were available for all subjects at the time of the survey. Total 
missing data proportions by centre are listed in Table 7. The proportion of primary 
outcome-complete confounder data were 94.6% (18627 complete data points) and main 
outcome data (percentage maximum dose) 100%; missing data were imputed as 



















TABLE 5 DEMOGRAPHIC AND CLINICAL CATEGORIES BY ETHNICITY 
 
Variable (n = complete) White n=541(%) Black n=397 (%) 
Centre (938) 
SLaM 88 (44.2) 111 (55.8) 
CNWL 91 (61.5) 57 (38.5) 
ELC 45 (37.2) 76 (62.8) 
BEH 51 (46.8) 58 (53.2) 
C&I 59 (60.2) 39 (39.8) 
NEL 68 (72.3) 26 (27.7) 
Manchester 73 (82) 16 (18) 
Nottingham 66 (82.5) 14 (17.5) 
Gender (938) 
Male 323 (59.7) 267 (67.3) 
Female 218 (40.3) 130 (32.7) 
Employment (921) 
Unemployed 475 (90.5) 360 (90.9) 
Employed 22 (4.2) 18 (4.5) 
Student 5 (0.9) 16 (4) 
Retired 23 (4.4) 2 (0.5) 
Education (858) 
Primary 67 (13.9) 48 (12.7) 
Secondary 276 (57.3) 205 (54.1) 
6th form/to 18 years 95 (19.7) 91 (24) 
University 44 (9.1) 35 (9.2) 
Language (916) 
Not English 41 (7.9) 48 (12.2) 
English 481 (92.1) 346 (87.8) 
Smoking status (896) 
Smoker 389 (76.9) 265 (67.9) 
Non-smoker 117 (23.1) 125 (32.1) 
Diagnosis (875) 
Schizophrenia 314 (64.3) 306 (79.1) 
Other 174 (35.7) 81 (20.9) 
Ethnicity of Consultant (912)  
White  358 (67.5) 254 (66.5) 
Mixed 6 (1.1) 4 (1) 
Asian  75 (14.2) 45 (11.8) 
Black 60 (11.3) 56 (14.7) 
Chinese/other 31 (5.8) 23 (6) 
Previous treatment with current antipsychotic (841) 
Yes 292 (62.4) 248 (66.5) 
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Variable (n=complete) White n=541(%) Black n=397 (%) 
Legal Status (934) 
Informal 199 (37.1) 92 (23.2) 
Sectioned (compulsorily detained in 
hospital) 338 (62.9) 305 (76.8) 
Forensic History (863) 
Yes 179 (37.1) 191 (50.1) 
Previous antipsychotics (812)  
None 92 (20.5) 86 (23.6) 
1 116 (25.9) 71 (19.5) 
2 to 5 203 (45.3) 181 (49.7) 
≥ 6 37 (8.3) 26 (7.1) 
Previous admissions (871) 
None 46 (9.5) 48 (12.4) 
1 48 (9.9) 44 (11.3) 
2 to 5 172 (35.6) 151 (38.9) 
≥ 6 217 (44.9) 145 (37.4) 
Non-compliance history (874) 
Yes 373 (76.1) 322 (83.9) 
Route (938) 
Oral 432 (79.9) 280 (70.5) 
Intramuscular 109 (20.1) 117 (29.5) 
Regular anticholinergic use (918) 
Yes 86 (16.3) 65 (16.6) 
Substance misuse (892) 
Yes 216 (43) 188 (48.2) 
 
TABLE 6 CONTINUOUS DEMOGRAPHIC AND CLINICAL CATEGORIES BY 
ETHNICITY 
 
Variable (n=complete) White (n=541) Black (n=397) 
Median age in years (95% 
confidence interval (CI)), n=938 42 (40, 43) 35 (33, 37) 
Median duration of illness in days 
(95% CI), n=840 3950 (3387, 4380) 2920 (2190, 3285) 
Median weight in kilograms (95% 
CI), n=833 77 (75, 79) 80 (78, 83) 
Median length of admission in 
days (95% CI), n=926 57 (49, 62) 58 (50, 67) 
Median length of treatment with 
current antipsychotic in days 
(95% CI), n=831 40 (31, 46) 40 (35, 51) 
 100 
TABLE 7 TOTAL MISSING DATA BY CENTRE 
 
Centre Complete data 
cases (%) 
Cases with at least one 
variable missing (%) 
Total cases (%) 
SLaM 190 (95.5) 9 (4.5) 199 (21.2) 
CNWL 94 (63.5) 54 (36.5) 148 (15.8) 
ELC 107 (88.4) 14 (11.6) 121 (12.9) 
BEH 100 (91.7) 9 (8.3) 109 (11.6) 
C&I 91 (92.9) 7 (7.1) 98 (10.4) 
NEL 29 (30.8) 65 (69.2) 94 (10) 
Manchester 11 (12.4) 78 (87.6) 89 (9.5) 
Nottingham 78 (97.5) 2 (2.5) 80 (8.5) 
Total 700 (74.6) 238 (25.3) 938 (100) 
 
Outcomes (with histograms where appropriate) are described in Figures 3 through to 12. 
Both percentage maximum dose and cost outcomes were skewed so median values were 
used in preference to mean for accuracy. There significant differences were not found in 
any outcome by ethnicity. 
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Unadjusted percentage difference 2.28 (CI -3.04, 7.61), p=0.4 
 
FIGURE 6 PROPORTION RECEIVING HIGH DOSE (>100% MAXIMUM DOSE) 
 
 






















(CI 53.1, 63.5) 
 
50.0%  













Adjusted odds ratio 0.98 
(CI 0.63, 1.51), p=0.92 
 
Adjusted percentage 
difference 0.97  
(CI -4.28, 6.22), p=0.72 
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  Unadjusted odds ratio 1.41 (CI 1.08, 1.83), p=0.01 
 
FIGURE 8 PROPORTION ADMINISTERED POLYPHARMACY  
 
 


































Adjusted odds ratio 1.15  
(CI 0.87, 1.51), p=0.33 
Adjusted odds ratio 1.08 
(CI 0.78, 1.49), p=0.66 
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FIGURE 9  PROPORTION PRESCRIBED A FIRST GENERATION 
ANTIPSYCHOTIC 
 
Unadjusted odds ratio 1.44 (CI 1.06, 1.94), p=0.02 
 
 





















Adjusted odds ratio 1.25  
(CI 0.87, 1.79), p=0.22 
 105 









Unadjusted cost difference in pounds 1.08 (CI -10.6, 12.8), p=0.86 
Key for Figures: * calculated as percentage maximum dose; CI = 95% confidence interval; ratios expressed as black compared 
with white (reference category). 








Adjusted cost difference in pounds 1.75 
(CI -9.81, 13.31), p=0.77 
 106 
Each outcome model was adjusted for multiple confounders. The final models are 
displayed in Tables 8 through to 13. 
 
The unadjusted values quoted on the graphs for dose (Figure 5) and cost (Figure 12) 
represent the regression coefficients from the fitted linear regression models. These are 
median values. The differences between adjusted and unadjusted values are because of 
the outcome data being skewed. The residuals of the regression model were deemed to 
be normally distributed. 
 
TABLE 8 LINEAR REGRESSION MODEL FOR MEDIAN TOTAL PERCENTAGE 
MAXIMUM DOSE (PRIMARY OUTCOME-COMPLETE, N=938) 
 
Variable  Coefficient Standard 
Error 
p value 95% CI 
Ethnicity: black 0.97 2.67 0.72 -4.28, 6.22 
Previous treatment with 
current antipsychotic: yes 
12.80 3.00 <0.001 6.90, 18.70 
Legal status: sectioned 5.04 2.85 0.08 -0.56,10.64 
Previous admissions: more 
than 5 
3.37 1.51 0.03 0.40, 6.34 
Gender: female -7.80 2.77 0.005 -13.24, -2.37 
Length of admission (log) 4.84 0.97 <0.001 2.93, 6.74 
Route: intramuscular -2.78 3.10 0.37 -8.86, 3.31 
Weight 1 0.16 0.34 0.63 -0.51, 0.84 
Weight 2 1.17 1.11 0.30 -1.05, 3.40 
Weight 3 -5.85 3.78 0.13 -13.37, 1.67 
Ethnicity of consultant: black 10.20 20.52 0.62 -30.69, 51.10 
 
Some variables violated an assumption of linear regression that there must be a linear 
relationship between outcome and confounder. These were transformed and included in 
the model using the log scale for the length of admission in days and restricted cubic 
splines (a third order polynomial equation) using four knots (where polynomial sections 
join) equally spaced for the weight variable. 
 
 107 
Variables with significant influence on dose were: patients who had previously received 
treatment with their current antipsychotic had a 12.80% higher dose; those who had 
more than five previous hospital admissions had a 3.37% higher dose; females had a 
7.8% lower dose and those with a longer length of hospital stay had a 1.58% (i.e. log 
4.84) higher dose.  
 
TABLE 9 LOGISTIC REGRESSION MODEL FOR HIGH DOSE (PRIMARY 
OUTCOME-COMPLETE, N=938) 
 




p value 95% CI 
Ethnicity: black 0.98 0.22 0.92 0.63, 1.51 
Weight (kg)* 1.01 0.01 0.06 1.00, 1.02 
Education: A level/up to age 18  0.54 0.17 0.06 0.29, 1.01 
Diagnosis: not schizophrenia 0.55 0.19 0.09 0.28, 1.10 
Ethnicity of consultant: black 2.29 0.56 0.001 1.42, 3.69 
Legal status: sectioned 1.08 0.26 0.77 0.66, 1.74 
Previous treatment with current 
antipsychotic: yes 
2.70 0.80 0.001 1.50, 4.86 
*OR for 1kg weight change 
For prescribing of high dose, patients whose consultant’s ethnicity was black had more 
than twice the odds of receiving a high dose compared with white consultants. In 
addition those previously treated with their current antipsychotic also had more than 
twice the odds of receiving a high dose compared with those who had not had their 








TABLE 10 LOGISTIC REGRESSION MODEL FOR POLYPHARMACY 
PRESCRIBED (PRIMARY OUTCOME-COMPLETE CASES, N=938) 
 




p value 95% CI 
Ethnicity: black 1.15 0.16 0.33 0.87, 1.51 
Age (years)* 0.98 0.01 0.002 0.97, 0.99 
Legal status: sectioned 1.61 0.24 0.001 1.20, 2.16 
Route: intramuscular 1.42 0.22 0.02 1.05, 1.94 
Previous treatment with 
current antipsychotic: yes 
1.84 0.27 <0.001 1.39, 2.46 
Ethnicity of consultant: black 1.03 0.21 0.87 0.69, 1.55 
Employment: student 0.47 0.22 0.11 0.19, 1.18 
*OR for change per increase in years 
Each year increase in age reduced the odds of being prescribed polypharmacy by 2%. 
Being detained under the Mental Health Act, receiving an intramuscular antipsychotic 
and having previously been treated with their current antipsychotic increased the odds 
of prescribed polypharmacy.  
 
TABLE 11 LOGISTIC REGRESSION MODEL FOR POLYPHARMACY 








p value 95% CI 
Ethnicity: black 1.08 0.18 0.66 0.78, 1.49 
Age (years)* 0.98 0.007 0.001 0.96, 0.99 
Education: secondary 1.70 0.29 0.002 1.22, 2.38 
Legal status: sectioned 1.18 0.22 0.38 0.82, 1.69 
Previous admissions: more 
than 5 
1.25 0.13 0.04 1.02, 1.55 
Route: intramuscular 1.82 0.32 0.001 1.28, 2.57 
Previous treatment with 
current antipsychotic: yes 
2.02 0.46 0.004 1.28, 3.20 
*OR for change per increase in years 
Each year increase in age reduced the odds of being administered polypharmacy by 2%. 
Being educated to secondary level (compared with primary), a higher number of 
previous admissions, receiving an intramuscular antipsychotic and having previously 
been treated with their current antipsychotic all increased the odds of administered 
polypharmacy.  
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TABLE 12 LOGISTIC REGRESSION MODEL FOR FIRST GENERATION TYPE  
OF ANTIPSYCHOTIC (PRIMARY OUTCOME-COMPLETE CASES, N=938) 
 







Ethnicity: black 1.25 0.23 0.22 0.87, 1.79 
Route: intramuscular 10.75 2.01 0.001 7.45, 15.51 
Anticholinergic use: no 0.24 0.05 0.001 0.16, 0.37 
Previous treatment with 
current antipsychotic: yes 
1.33 0.27 0.16 0.89, 1.96 
Ethnicity of consultant: black 0.52 0.16 0.03 0.28, 0.95 
 
Receiving an intramuscular antipsychotic was associated with a ten-fold increase in 
odds of taking a FGA. Not taking an anticholinergic and having a consultant of black 
ethnicity reduced the odds of taking a FGA. 
 
TABLE 13 LINEAR REGRESSION MODEL FOR MEDIAN COST (PRIMARY 
OUTCOME-COMPLETE CASES, N=938)  
 





Ethnicity: black 1.75 5.89 0.77 -9.81, 13.31 
Weight 1 0.04 0.71 0.96 -1.38, 1.45 
Weight 2 2.92 2.30 0.21 -1.61, 7.44 
Weight 3 -13.92 7.85 0.08 -29.35, 1.50 
Previous admissions: more 
than 5 
6.64 3.33 0.05 -0.10, 13.19 
Anticholinergic use: no 25.93 7.86 0.001 10.51, 41.35 
Previous treatment with 
current antipsychotic: yes 
17.16 6.69 0.01 3.98, 30.34 
Length of admission (log) 9.36 2.16 0.001 5.12, 13.60 
Ethnicity of consultant: 
black 
6.62 44.44 0.88 -81.41, 94.66 
 
As with the dose outcome, some variables violated an assumption of linear regression 
that there must be a linear relationship between outcome and confounder. These were 
transformed and included in the model using the log scale for the length of admission in 
days and restricted cubic splines (a third order polynomial equation) using four knots 
(where polynomial sections join) equally spaced for the weight variable. Variables with 
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significant influence on cost were those patients who were not taking an anticholinergic 
who had a 25.93% higher cost; those who had previously received treatment with their 
current antipsychotic had a 17.16% higher dose; those with a longer length of admission 
had a 2.24% (i.e. log 9.36) higher cost.  
 
2.3.2 COMPLETE CASE ANALYSIS 
TABLE 14 LINEAR REGRESSION MODEL FOR MEDIAN TOTAL PERCENTAGE 
MAXIMUM DOSE (COMPLETE CASES N=790) 
 
Variable Coefficient Standard 
Error 
p value 95% CI 
Ethnicity: black 0.16 2.85 0.96 -5.43, 5.75 
Previous treatment with 
current antipsychotic: yes 
15.09 3.06 <0.001 9.07, 21.10 
Legal status: sectioned 6.84 3.11 0.03 0.73, 12.96 
Previous admissions: 
more than 5 
3.78 1.59 0.02 0.67, 6.89 
Gender: female -6.60 3.01 0.03 -12.51, -0.70 
Length of admission (log) 5.20 1.05 <0.001 3.14, 7.25 
Route: intramuscular -5.12 3.34 0.13 -11.68, 1.45 
Weight 1 0.27 0.33 0.41 -0.37, 0.91 
Weight 2 1.18 1.13 0.30 -1.05, 3.40 
Weight 3 -6.04 3.77 0.11 -13.45, 1.36 
Ethnicity of consultant: 
black 
-2.32 20.94 0.91 -43.44, 38.79 
 
Variables with significant influence on dose were those patients who had previously 
received treatment with their current antipsychotic had a 15.09% higher dose; were 
detained under the Mental Health Act had a 6.84% higher dose; who had more than five 
previous hospital admissions had a 3.78% higher dose; who were female had a 6.6% 





TABLE 15 LOGISTIC REGRESSION MODEL FOR HIGH DOSE (COMPLETE 
CASES, N=762) 
 




p value 95% CI 
Ethnicity: black 0.89 0.21 0.62 0.55, 1.42 
Weight (kg)* 1.02 0.01 0.01 1.01, 1.03 
Education: A level/up to 
age 18  
0.57 0.19 0.09 0.30, 1.08 
Diagnosis: not 
schizophrenia 
0.51 0.17 0.04 0.27, 0.97 
Ethnicity of consultant: 
Chinese/other 
2.40 0.66 0.002 1.40, 4.11 
Legal status: sectioned 1.62 0.47 0.10 0.92, 2.85 
Previous treatment with 
current antipsychotic: yes 
2.99 0.91 <0.001 1.64, 5.45 
*OR for 1kg weight change 
 
For the prescribing of high dose, each 1 kg increase in weight was associated with a 2% 
increase in the odds of receiving a high dose. Patients without schizophrenia have 
approximately half the odds of receiving a high dose and those whose medical 
consultants ethnicity is Chinese/other have twice the odds of being prescribed a high 
dose compared with those patients with a white consultant. Patients who have 
previously been treated with their current antipsychotic have approximately three-times 
the odds of receiving a high dose. 
 
TABLE 16 LOGISTIC REGRESSION MODEL FOR POLYPHARMACY 
PRESCRIBED (COMPLETE CASES, N=813) 
 







Ethnicity: black 1.06 0.16 0.70 0.79, 1.43 
Age (years)* 0.98 0.006 0.001 0.97, 0.99 
Legal status: sectioned 1.54 0.25 0.008 1.12, 2.13 
Route: intramuscular 1.31 0.22 0.12 0.94, 1.83 
Previous treatment with 
current antipsychotic: yes 
1.94 0.30 0.001 1.43, 2.63 
Ethnicity of consultant: black 1.32 0.30 0.22 0.85, 2.06 
Employment: student 0.41 0.21 0.08 0.15, 1.13 
*OR for change per increase in years 
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For this outcome, each year increase in age reduced the odds of being prescribed 
polypharmacy by 2%. Being detained under the Mental Health Act and having 
previously been treated with their current antipsychotic increased the odds of prescribed 
polypharmacy.  
 
TABLE 17 LOGISTIC REGRESSION MODEL FOR POLYPHARMACY 
ADMINISTERED (COMPLETE CASES, N=803) 
 







Ethnicity: black 1.08 0.18 0.66 0.78, 1.49 
Age (years)* 0.98 0.007 0.001 0.96, 0.99 
Education: secondary 1.70 0.29 0.002 1.22, 2.38 
Legal status: sectioned 1.18 0.22 0.38 0.82, 1.69 
Previous admissions: more 
than 5 
1.25 0.13 0.04 1.02, 1.55 
Route: intramuscular 1.82 0.32 0.001 1.28, 2.57 
Previous treatment with 
current antipsychotic: yes 
2.02 0.46 0.004 1.28, 3.20 
*OR for change per increase in years 
Each year increase in age reduced the odds of being administered polypharmacy by 2%. 
Being educated to secondary level (compared with primary), a higher number of 
previous admissions, receiving an intramuscular antipsychotic and having previously 
been treated with their current antipsychotic all increased the odds of administered 
polypharmacy.  
 
TABLE 18 LOGISTIC REGRESSION MODEL FOR FIRST GENERATION TYPE 










Ethnicity: black 1.10 0.22 0.63 0.74, 1.63 
Route: intramuscular 12.16 2.52 0.001 8.11, 18.25 
Anticholinergic use: no 0.21 0.05 0.001 0.13, 0.34 
Previous treatment with 
current antipsychotic: yes 
1.44 0.31 0.09 0.95, 2.20 
Ethnicity of consultant: black 0.47 0.16 0.03 0.24, 0.93 
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Receiving an intramuscular antipsychotic was associated with a twelvefold increase in 
odds of taking a FGA. Not taking an anticholinergic and having a consultant of black 
ethnicity reduced the odds of taking a FGA. 
 
TABLE 19 LINEAR REGRESSION MODEL FOR MEDIAN COST (COMPLETE 
CASES, N=790) 
 





Ethnicity: black 2.03 6.26 0.75 -10.25, 14.31 
Weight 1 0.22 0.71 0.76 -1.18, 1.63 
Weight 2 2.85 2.53 0.26 -2.12, 7.81 
Weight 3 -13.92 8.41 0.10 -30.43, 2.59 
Previous admissions: 
more than 5 
6.68 3.49 0.06 -0.17, 13.52 
Anticholinergic use: no 28.20 8.55 0.001 11.41, 44.99 
Previous treatment with 
current antipsychotic: yes 
20.77 6.84 0.002 7.35, 34.20 
Length of admission 
(log)* 
10.17 2.30 0.001 5.65, 14.68 
Ethnicity of consultant: 
black 
-15.70 45.90 0.73 -105.80, 74.39 
*OR for change in 100 days 
 
Variables with significant influence on cost were those patients who were not taking an 
anticholinergic who had a 28.20% higher cost; those who had previously received 
treatment with their current antipsychotic had a 20.77% higher cost; those with a longer 
length of admission had a 2.32% (i.e. log 10.17) higher cost.  
 
2.3.3 ROUTE OF ADMINISTRATION 
Injectable preparations accounted for approximately a quarter of those prescribed. black 
patients were more likely than white to receive an intramuscular antipsychotic (chi-
squared test, p=0.001). Route of administration by ethnicity was analysed using logistic 
regression in Chapter 4. 
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2.3.4 INDIVIDUAL ANTIPSYCHOTICS  
Risperidone (oral plus intramuscular) and olanzapine were prescribed most frequently 
and zotepine the least (see Table 20). Clozapine use accounted for 10% of the frequency 
of prescribing of antipsychotics and did not differ by ethnicity for black and white 
patients (chi-squared test, p= 0.287) (see Chapter 4 also).  
 
TABLE 20 FREQUENCY OF ANTIPSYCHOTICS PRESCRIBED 
 
Antipsychotic  Ethnicity Frequency (%) 
White Black 
Risperidone oral 78 77 155 (15.9) Total 
243 (25) Risperidone long-acting injection  43 45 88 (9.1) 
Olanzapine oral 154 83 237 (24.4) 
Clozapine 61 36 97 (10) 
Quetiapine  60 25 85 (8.7) 
Haloperidol oral 23 24 47 (4.8) Total 
71 (7.3) Haloperidol decanoate injection 8 15 23 (2.4) 
Haloperidol aqueous injection 0 1 1 (0.1) 
Zuclopentixol decanoate injection 30 26 56 (5.9) Total 
59 (6.2) Zuclopentixol oral 2 1 3 (0.3) 
Aripiprazole 26 18 44 (4.5) 
Pipotiazine palmitate injection 16 19 35 (3.6) 
Amisulpride 19 8 27 (2.8) 
Flupentixol decanoate injection 13 12 25 (2.6) 
Flupentixol oral  2 0 2 (0.2) 
Chlorpromazine 8 7 15 (1.5) 
Trifluoperazine 6 5 11 (1.1) 
Fluphenazine decanoate injection 5 4 9 (0.9) 
Sulpiride 5 4 9 (0.9) 
Zotepine 3 0 3 (0.3) 
Total 562 410 972 
 
2.4 DISCUSSION 
2.4.1 MAIN FINDINGS 
In this multicentre study of antipsychotic prescribing practice in black and white 
patients, involving a large cohort drawn from across the UK, significant differences 
were not found between the two groups for dose, high dose, polypharmacy, type, route 
and cost of treatment, after adjustment for multiple confounding factors. The numerous 
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associations found between potential confounders and outcomes confirms the 
importance of adjustment for these factors. Nonetheless significant limitations may have 
affected these results. 
 
2.4.2 POPULATION  
Our population were inpatients in acute psychiatric care in mental health trusts with 
high proportions of black and minority ethnic groups in England. Thus results could be 
applied to the larger population of UK inpatients. Community patients were not 
included which may have affected the results. Patients not in hospital are usually less 
acutely unwell and so are likely to be on stable doses of medication for longer periods. 
If community patients had been included in the study they may have provided more 
accurate data on dose, high dose and the true extent of polypharmacy because PRN 
prescribing for rapid tranquillisation would have been eliminated. Indeed a recent study 
of antipsychotic use by ethnicity in a large community sample (Das-Munshi et al., 2018) 
found that black patients, compared with white, were more likely to be prescribed depot 
antipsychotics and were less likely to be prescribed clozapine. Mixed patients were 
more likely than white to receive high dose antipsychotic treatment. 
 
2.4.3 VARIABLES ASSOCIATED WITH EACH OUTCOME 
The two different data sets analysed (primary outcome-complete and complete cases) 
produced broadly similar results. Each outcome was adjusted for different variables. 
These are discussed in detail below. 
 
Primary outcome-complete data for dose found the biggest increases were associated 
with previous treatment with a patient’s current antipsychotic. This reflects use of an 
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antipsychotic with assumed previous efficacy but in larger doses given the likelihood of 
more severe symptoms in an acute subsequent episode (Taylor et al., 2015). A greater 
number of previous admissions and longer length of admission, both measures of 
severity and chronicity of illness, were also associated with higher doses. Interestingly 
women received lower doses than men possibly because of pharmacokinetic or weight 
differences (mean weight for females was 64.8kg vs. males 73.1kg) (Perry, 2001; 
Rummel-Kluge et al., 2010). Complete case data produced similar results but also 
included being sectioned under the Mental Health Act as a significant factor for a larger 
dose. This, like number and length of admissions, is a reflection of illness severity as 
those patients who are detained involuntarily often have more serious illness. Ethnicity 
was not associated with any significant differences in dose in both primary outcome-
complete and complete case analyses. 
 
High dose (more than 100% of BNF maximum dose) primary outcome-complete data 
found consultant psychiatrists of black ethnicity, compared with white, were more likely 
to prescribe high dose antipsychotics. Consultant psychiatrists of Chinese/other 
ethnicity were associated with high do117se prescribing in the complete case analysis. 
These associations were unexpected but after dissemination of findings of earlier studies 
on antipsychotics and ethnicity, ethnic minority prescribers reported informally that 
they were very surprised by the results. They said they purposely prescribed higher 
doses for black patients as they were more severely ill on admission to hospital. These 
comments have been explored further in a later study in Chapter 5. Having previously 
been treated with their current antipsychotic was associated with high doses in both 
analyses. Again, as with percentage maximum dose, high doses could be used when 
restarting a previously effective antipsychotic treatment in an acutely unwell inpatient. 
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Weight was associated with high doses in the complete case analysis as body size may 
affect prescribers’ perception of a need for larger doses. This could of course be an 
incidental finding as many antipsychotics are commonly known to cause weight gain 
(Rummel-Kluge et al., 2010). Lower odds of high doses were associated in the complete 
case analysis with not having schizophrenia, possibly because antipsychotics are often 
used for psychiatric conditions where lower doses may be required e.g. in patients with 
autism or personality disorders (Barnard et al., 2002; Black et al., 2014). 
 
As patients aged they were less likely to be prescribed more than one antipsychotic. 
This may reflect a greater severity of illness and/or a greater risk of violence in younger 
patients (Hodgins & Riaz, 2011; National Institute for Health and Care Excellence, 
2015). Then again there have been concerns that young, black patients are perceived 
stereotypically as more violent than other ethnic groups possibly accounting for these 
results(Prins, 1993). Interestingly when data for all ethnicities (white, black, other) was 
analysed in Chapter 4, increasing age was associated with a greater risk of antipsychotic 
polypharmacy. Most polypharmacy occurs through ‘when required or PRN’ use of 
antipsychotics (Paton et al., 2008). When required antipsychotics are used for 
behavioural disturbance or rapid tranquillisation so may reflect a greater prevalence of 
this conduct in younger patients (National Institute for Health and Care Excellence, 
2015). Polypharmacy could be a proxy measure of illness severity so it would be 
expected that being involuntarily detained would be associated with being prescribed 
more than one antipsychotic. Previous use of current treatment increased the odds of 
being administered more than one antipsychotic. This perhaps reflects a chronic or 
treatment-resistant illness course resulting in addition of further medication (Barnes & 
Paton, 2011). Use of intramuscular antipsychotics increased the risk of being on more 
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than one antipsychotic in the primary outcome-complete case analysis only. This could 
have been because patients switching to depot medication remained on oral treatment 
during the transfer. Co-prescription of depot with oral medication is commonplace 
despite the illogical nature of the combination (Barnes et al., 2009). 
 
For polypharmacy administered complete case and primary outcome-complete case 
analyses produced similar results. As with polypharmacy prescribed, as patients aged 
they were less likely to be administered more than one antipsychotic. Again this may 
reflect illness severity or violence risk in younger patients. The odds of receiving more 
than one antipsychotic were greater in those who had completed secondary school 
compared with only primary. This association is difficult to explain as higher 
educational attainment usually predicts lower rates of psychotic symptomatology 
(Geddes et al., 1994). As such one would expect those who had received secondary 
level education, compared with primary, to have a lower risk of polypharmacy 
administered. Having a chronic illness, as reflected in number of previous admissions, 
was, unsurprisingly, associated with taking more than one antipsychotic. As with 
polypharmacy prescribed use of intramuscular antipsychotics and previous use of 
current treatment increased the risk of being administered more than one antipsychotic.  
 
Factors associated with prescribing of a first generation type of antipsychotic were the 
same for both complete and primary outcome-complete case analyses. Anticholinergic 
medications are usually used with FGAs to treat EPSE so the association of not taking 
an anticholinergic and having a lower odds of being prescribed a FGA was as expected. 
However having a consultant psychiatrist of black ethnicity was associated with a lower 
odds of being prescribed an older antipsychotic. Again as with the association with 
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ethnic minority psychiatrist and high dose antipsychotic use, the relationship between 
prescriber ethnicity and antipsychotics is explored in a further study in Chapter 5. Most 
intramuscular forms of antipsychotics are available as depots. The odds of receiving a 
FGA were ten to twelvefold higher if receiving an intramuscular form. This is 
unsurprising as, at the time of data collection, there was only one SGA available as a 
depot formulation i.e. risperidone long-acting injection (British Medical Association 
and Royal Pharmaceutical Society of Great Britain, 2008). Short-acting injectable 
antipsychotics are usually used for rapid tranquillisation. The only short-acting SGA 
available at the time was olanzapine. This formulation is rarely prescribed (as reflected 
by results in Table 20) as it cannot be administered concurrently with lorazepam 
injection, an agent commonly used for behavioural disturbance (Datapharm 
Communications Ltd, 2016). Indeed olanzapine short-acting injection has since become 
unavailable in the UK. 
 
Confounders associated with cost were the same for primary outcome-complete and 
compete case analyses. Antipsychotic costs were higher for those not taking an 
anticholinergic medication. SGAs are, in general, more expensive than FGAs (Monthly 
Index of Medical Specialities, December 2008) and anticholinergics are usually 
prescribed to treat extra-pyramidal adverse effects of the latter. Thus patients taking 
newer agents are less likely to be on an anticholinergic and so costs would be expected 
to be higher. Higher costs were associated with having had their current antipsychotic 
treatment before. Previous treatment with a patient’s current antipsychotic and a longer 
length of admission were also associated with total dose so higher costs may reflect 
higher doses.  
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Route of administration was not an a priori outcome and post-hoc analysis found black 
patients were more likely than white to receive an antipsychotic via the intramuscular 
route.  However a logistic regression analysis, controlling for all confounding factors, 
found ethnicity was not associated with route (see Chapter 4). Previous studies have 
found that black patients are more likely than white to have been prescribed a depot 
antipsychotic (Kreyenbuhl et al., 2003; Lloyd & Moodley, 1992; Shi, 2007; Woods et 
al., 2003). These studies did not control for multiple confounding factors and may 
account for the differing results.  
 
2.4.4 WHICH ANTIPSYCHOTICS DID PRESCRIBERS USE? 
As well as the six prescribing outcomes the individual antipsychotic choice of 
prescribers was examined. The most frequently prescribed antipsychotics were 
risperidone (oral and long-acting injection) and oral olanzapine. This pattern of 
antipsychotic prescribing replicates efficacy and effectiveness outcomes of randomised 
controlled trials and meta-analyses (Leucht et al., 2009; Lieberman et al., 2005) which 
consistently rank olanzapine and risperidone as the most effective agents in non 
treatment-resistant psychotic illness (Stroup et al., 2006). At the time of data collection, 
oral risperidone was available as a generic product at a reduced cost which is likely to 
have increased the frequency of prescribing. Conversely risperidone long-acting 
injection was the only SGA available as a long-acting formulation at the time of the data 
collection and, despite its high cost, was still the most frequently prescribed injectable 
preparation. 
 
Clozapine use was not an a priori outcome and, unexpectedly, its use did not differ by 
ethnicity. Regular full blood count testing is mandatory when taking clozapine as it can 
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cause neutropenia and agranulocytosis.  If levels of white cells fall below specified 
values then clozapine must be stopped. Black patients are more likely than white to 
develop neutropenia on clozapine so limiting its use in black people (Whiskey et al., 
2011). A ‘benign ethnic neutropenia’ classification from a haematologist allows lower 
FBC parameters to be used for some black patients. These results may reflect an 
awareness and use of the BEN system thus allowing greater use of clozapine in black 
patients. 
 
2.4.5 COMPARISON WITH PREVIOUS STUDIES 
Most of the studies examining antipsychotic use by ethnicity have been completed in 
the US. Differences in antipsychotic treatment in black and white patients included; a 
greater likelihood of receiving an antipsychotic (Delbello et al., 2000; Flaskerud & Hu, 
1992; Szarek & Goethe, 2003), higher doses (Diaz & De Leon, 2002; Segal et al., 
1996), older drugs (Daumit et al., 2003; Fleck et al., 2002) and more frequent use of 
depot formulations (Kuno & Rothbard, 2002). These studies adjusted, unlike the present 
study, for only a few confounding factors affecting the prescribing of antipsychotics. 
Outcomes from these studies may not be comparable with ours because of differences in 
design and other factors related to healthcare settings and practices in different countries 
at different times.  
 
There are few UK studies examining ethnicity and antipsychotic use. One survey (Lloyd 
& Moodley, 1992) found no significant differences (after adjustment for five 
confounding variables) in doses of antipsychotics taken by black and white patients. But 
black patients were more likely than white to be receiving a depot and at a significantly 
higher dose. The findings of this study differ from these earlier results, after adjustment 
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for confounders, for route of administration. Other UK studies, which were not designed 
to specifically examine prescribing by ethnicity, have not found an effect of ethnicity on 
antipsychotic high dose use (Paton et al., 2008) and polypharmacy (Lelliott, 2002). The 
earlier cross-sectional surveys of antipsychotic prescribing and ethnicity included 
several hundred patients from three NHS mental health trusts and again accounted for 
multiple confounding factors (Connolly et al., 2007; Connolly & Taylor, 2008). A 
recent study of antipsychotic use by ethnicity in a large, multicentre sample of 
community patients (Das-Munshi et al., 2018) found that black patients, compared with 
white, were more likely to be prescribed depot antipsychotics and were less likely to be 
prescribed clozapine. Mixed patients were more likely than white to receive high dose 
antipsychotic treatment. Overall the older surveys were undertaken on inpatients. They 
found few differences between black and white patients for the same outcomes used in 
this study although higher costs of antipsychotic medication and polypharmacy were 
significantly more likely in black patients. For full details of previous studies of 
antipsychotic prescribing and ethnicity see Chapter 1. 
 
2.4.6 LIMITATIONS 
Limitations of the study include the cross-sectional design, which allows examination of 
prescribing practice at only a single time point. This design is cost effective but cannot 
confirm causation. Other researchers have predominantly used survey study methods 
(see Appendix 3). 
 
Black patients in the study included black British, black African, black Caribbean and 
black other groups whilst white patients included white British, white Irish and white 
other. Classification of ethnicity using the Office of National Statistics groups masked 
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the heterogeneity of the people in these categories and could have affected the results. 
For example prescribers may have used higher doses for the black Caribbean group but 
the effect was concealed by inclusion in a larger black patient group. 
 
Not all data on confounding factors was obtainable for all patients. The total number of 
black and white patients in this analysis was 972. Primary outcome-complete data 
accounted for 938 (96.5%) cases with missing data imputed for incomplete variables. 
The primary outcome-complete and complete cases results have been included so these 
two methods of analysis can be compared.  Overall there appeared to be few if any 
major differences between the data sets.       
 
Centres were recruited for this study by approaching mental health trusts containing the 
largest populations of black and minority ethnic group patients. These centres, because 
of their ethnically diverse patient population, may be in some way more or less likely to 
demonstrate prejudicial prescribing (using higher doses, numbers, older types, 
injectable routes of antipsychotics to an individual member of or ethnic group because 
of a negative attitude or belief about that group) in a multicultural environment which 
may improve or worsen racial tolerance. Furthermore psychiatry is a medical speciality 
known for it racial diversity (Goldacre et al., 2004) which may, or may not, affect 
prejudice. Nonetheless, a previous study (Connolly & Taylor, 2008) included one 
centre, Oxleas that had a predominantly white population and did not find differences in 
antipsychotic prescribing between centres. Centre was not included as a potential 
confounder in this study because variation in prescribing by centre was considered to be 
an outcome rather than a confounder. A separate analysis including centre as a 
confounder did not alter results (see Chapter 3).  
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Confidence intervals around some outcome measures were wider than anticipated. This 
was a result of larger than expected variances and because of the large number of 
confounding variables identified and accounted for in the analysis. Many of the 
variables included in the models had several levels. This added to the complexity of the 
models and possibly poor model fit. The results could have been affected by the 
inclusion of too many variables i.e. the overadjustment of outcomes. Overadjustment is 
defined as “Statistical adjustment by an excessive number of variables or parameters, 
uninformed by substantive knowledge (e.g. lacking coherence with biologic, clinical, 
epidemiological, or social knowledge). It can obscure a true effect or create an apparent 
effect when none exists.(Breslow, 1982)” Overadjustment may bias results towards the 
null hypothesis. Confounders were determined by examining previous research and 
seeking expert advice from professionals working in the field of ethnicity research. All 
confounders collected were included in the models as described – many more than in 
previous studies (see Appendix 2) – which may have had an impact on the results. 
Variables could have been limited more carefully to avoid possible overadjustment. 
Unadjusted results are available for each outcome (see Figures 5 to 9 and 12) with 
prescribed polypharmacy and use of an FGA more likely in black patients. Interestingly 
these results differ markedly from the adjusted outcomes. 
 
All of these limitations may have resulted in the negative findings. This study analysed 
data from black and white patients only as concerns about differences in prescribing by 
ethnicity have focussed mostly on the difference between these two groups. 
Furthermore these were the two largest ethnic groups in UK inpatient mental health 
services and in my sample. This study did not analyse the effect of each centre on the 
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outcomes. The next chapter will investigate differences in prescribing by individual 
centres and also total data including centre as a confounding variable.  
2.5 CONCLUSIONS 
There have long been concerns expressed by patients, carers (Norfolk Suffolk & 
Cambridgeshire Strategic Health Authority, 2003; South London and Maudsley NHS 
Trust, 2005) and the UK government (Department of Health, 2003) about differences in 
prescribing of antipsychotics by ethnicity. This study addresses these concerns and, 
notwithstanding the limitations described above, the adjusted findings suggest that 
across eight NHS trusts prescribing of antipsychotics for six major outcomes is not 
different for black and white patients. Unadjusted findings found prescribed 
polypharmacy and use of FGA were more likely in black patients.  The significant 
limitations of the study may have resulted in negative findings.
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CHAPTER 3 ANTIPSYCHOTIC PRESCRIBING BY ETHNICITY - CENTRE 
ANALYSIS 
3.1 INTRODUCTION 
Antipsychotic prescribing may be influenced by ethnicity. Specifically black patients, 
compared with white, are reported to be more likely to receive higher doses, older 
antipsychotic treatments and more than one antipsychotic. The studies reporting these 
differences have been predominantly from the US although earlier multicentre UK 
studies have, overall, not reported major differences in antipsychotic prescribing 
(Connolly et al., 2007; Connolly & Taylor, 2008). An in-depth review of antipsychotic 
prescribing by ethnicity is described in Chapter 1 with further details provided in 
Appendices 3 and 4. 
 
A previous UK study of antipsychotic prescribing in black and white inpatients in three 
London NHS trusts found that centre effects were a significant predictor of 
polypharmacy (Connolly & Taylor, 2008). One of the three centres had extremely high 
levels of polypharmacy for black compared with white patients (74% vs. 37% - other 
centres 13% vs. 17% and 16% vs. 10% respectively). This shows the importance of 
analysis by centre to determine if irregular prescribing by any centres is influencing the 
overall result. Such sub-analysis also provides individual centres with data to enable 
them to take the necessary steps to improve prescribing practice if required.  
 
Nationally, POMH-UK was created to help NHS trusts improve their prescribing in 
psychiatry. It has audited numerous areas of prescribing practice, for example 
antipsychotic high doses and polypharmacy, collecting data from over 3000 patients in 
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32 services in a baseline then a re-audit 1-year later. Unfortunately the re-audit found 
little change in these prescribing outcomes (Paton et al., 2008). POMH-UK publishes 
results and NHS trusts are benchmarked anonymously against each other in an effort to 
improve prescribing. It has also undertaken quality improvement programmes to help 
implement their work and encourage prescribers to change poor prescribing habits. 
These programmes have, overall, had modest success (Paton et al., 2008; Thompson et 
al., 2008) but some centres have made dramatic improvements with sustained and 
concerted efforts over many years (Mace & Taylor, 2015).  
 
The study in Chapter 1 did not analyse the effect of each centre on outcomes. Individual 
centres i.e. NHS mental health trusts may have different prescribing practices that 
require analysis. This chapter reports the individual centre results for each outcome 
from a multicentre cross-sectional survey of antipsychotic prescribing in black and 
white patients. It also reports primary outcome-complete total data analysis for black 
and white patients when centre was included as a variable. Centre effects (SLaM vs. 
non-SLaM) for all ethnicities and outcomes (including route of administration and 
clozapine use) are reported separately in Chapter 4. 
3.2 METHOD 
In summary, eight UK centres (six NHS trusts in London, one in Nottingham and one in 
Manchester) completed data collection during late 2008 and early 2009. These centres 
were included because they served the highest proportion of black and minority ethnic 
groups in the UK.  Ethnicity classification was categorised according to the Office for 
National Statistics groupings (see Chapter 2). The main outcomes of the study were 
dose, high dose, polypharmacy (prescribed or administered), type of antipsychotic and 
cost.  
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Over twenty potential confounders were identified from previous studies (see Appendix 
2) and expert opinion. The confounders were defined for the data collectors as in 
Appendix 10. Data were collected from casenotes and prescription charts by 
pharmacists or medical staff. Subjects included were all inpatients on acute adult wards 
prescribed a regular antipsychotic or having received an as required dose in the previous 
24 hours.  
 
The study compared the six outcomes previously described (in Chapter 2) between two 
groups (black and white patients) and linear and logistic regression analysis was used to 
adjust the resulting comparisons for the effect of confounding variables. Baseline 
demographic and clinical characteristics were analysed by ethnicity.  
 
Details of the method and statistical analysis have been fully described in Chapter 2. 
3.3 RESULTS 
Data were collected for 938 patients from eight centres of which 541 (57.7%) were white 
and 397 (42.3%) black. All centre results were anonymised and individual centres were 
notified of their number code. Demographic and clinical characteristics of these patients 
by ethnicity and centre are listed in Chapter 2. Not all confounder data were available for 
all subjects at the time of the survey as described in the previous chapter. Primary 
outcome (i.e. total dose) complete data were used with multiple imputations for missing 
data for both the individual centre analyses and total data analysis with centre for black 
and white patients. Each outcome model was adjusted for multiple confounders as 
described below (see Tables 21 to 26). Centre data for black and white ethnicity were 
analysed separately so the effect of individual centres could be assessed. For primary 
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outcome-complete total data analysis for black and white ethnicities centre was included 
as a confounder in this chapter. 
Note that all results compare black with white patients i.e. white is the reference category. 
A negative effect size/adjusted percentage difference or an odds ratio less than 1 means 
black patients are less likely than whites to have this outcome. 
 
3.3.1 INDIVIDUAL CENTRE ANALYSES 
Statistically significant results for the outcome of median dose were as follows. In 
centre 2 black patients were prescribed a 13% lower median dose of antipsychotic than 
whites (adjusted percentage difference = -13.08%, 95% confidence intervals  
-25.71, -0.45, p=0.04). Whilst in centre 7 black patients were prescribed an almost 81% 
higher median dose of antipsychotic than whites (adjusted percentage difference = 
80.87, 95% CI 50.51, 111.23, p <0.001).  
 
Statistically significant results for the outcome of median cost were as follows. In 
centres 6 and 7 black patients antipsychotic treatment cost more than whites (centre 6 
adjusted cost difference = £31.13, 95% CI 2.82, 59.43, p=0.03; centre 7 adjusted cost 
difference = £95.06, 95% CI 35.37, 154.76, p=0.003). 
 
Statistically significant results for outcome of high dose (> 100% BNF maximum dose) 
were as follows. No centres had a significant difference after adjustment for 
confounders. For the unadjusted results, centre 7 black patients were more likely than 
whites to receive a high dose (unadjusted OR = 3.87, 95% CI 1.24, 12.14, p=0.02). 
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Statistically significant results for polypharmacy prescribed were as follows. No centres 
had a significant difference after adjustment for confounders. For the unadjusted results, 
centre 7 black patients were more likely than whites to be prescribed more than one 
antipsychotic (unadjusted OR = 2.85, 95% CI 1.09, 7.45, p=0.03). 
 
Statistically significant results for administered polypharmacy were as follows. 
No centres had a significant difference after adjustment for confounders. For the 
unadjusted results, centre 7 black patients were more likely than whites to receive more 
than one antipsychotic (unadjusted OR 3.5, 95% CI 1.36, 9.02, p=0.01). 
 
Statistically significant results for type of antipsychotic were as follows. Centre 3 black 
patients were significantly more likely than whites to receive FGA (adjusted OR = 4.44, 
95% CI 1.22, 16.14, p=0.02). 
 































 (95% CI) 
p Outcome adjusted for 
following confounders 
1 199 -6.97 (-18.31, 
4.38) 
0.23 198 -7.67 (-18.23, 
2.89) 
0.15 Previous admissions; gender; 
duration of illness; length of 
treatment; previous treatment 
with current antipsychotic 




-13.08 (-25.71,  
-0.45) 
0.04 Previous treatment with current 
antipsychotic; route 






0.95 Smoking status; section status; 
weight 






0.13 Substance misuse; section status; 
employment; previous treatment 
with current antipsychotic; 
smoking status 






0.09 Weight; length of admission 
6 148 6.46 (-6.32, 
19.23) 
0.32 106 6.60 (-7.72, 
20.91) 
0.36 Previous treatment with current 
antipsychotic; length of 
admission 
7 94 35.17 (16.28, 
54.06) 
<0.001 34 80.87 (50.51, 
111.23) 
<0.001 Previous admissions; weight; 
length of admission 
8 89 10.75 (-15.47, 
36.96) 
0.42 Not possible to calculate adjusted effect size 
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Unadjusted effect size 
(95% CI) 




Adjusted effect size 
(95% CI) 
p Outcome adjusted for 
following confounders 
1 199 -9.30 (-32.48, 13.88) 0.43 198 -5.77 (-28.17, 16.63) 
 
0.61 Length of treatment; previous 
treatment with current 
antipsychotic; weight; 
anticholinergic use 
2 109 -9.68 (-37.66, 18.30) 0.49 102 -10.67 (-39.56, 18.22) 
 
0.47 Previous treatment with 
current antipsychotic 
3 98 4.14 (-33.52, 41.82) 0.83 93 2.90 (-30.76, 36.57) 
 
0.86 Length of admission; 
smoking status; weight; route; 
length of treatment 
4 80 17.24 (-41.25, 75.72) 0.56 78 -16.70 (-71.00, 37.60) 
 
0.54 Substance misuse; 
compliance history 
5 121 -17.69 (-55.42, 20.04) 0.36 114 -21.95 (-59.59, 15.69) 
 
0.25 Length of admission; length 
of treatment 
6 148 11.80 (-15.48, 39.09) 0.39 106 31.13 (2.82, 59.43) 
 
0.03 Length of admission; route; 
previous admissions; duration 
of illness; employment status; 
anticholinergic use 
7 94 59.81 (19.09, 100.54) 0.004 34 95.06 (35.37, 154.76) 0.003 Previous admissions; 
substance misuse 
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0.84 (0.36, 1.95) 0.68 192 
 
0.75 (0.30, 1.85) 0.53 Previous treatment with current 
antipsychotic; gender; previous 
admissions; smoking status; 
ethnicity of consultant 
2 109 
 
0. 21 (0.02, 1.91) 0.16 Not possible to calculate adjusted odds ratio 
3 98 
 
0.73 (0.20, 2.61) 0.63 43 
 
0.13 (0.02, 1.03) 0.05 Route; weight 
4 80 
 
1.67 (0.30, 9.27) 0.56 Not possible to calculate adjusted odds ratio 
5 121 
 
1.55 (0.46, 5.28) 0.48 93 1.51 (0.36, 6.37) 0.57 Weight  
6 148 
 
1.36 (0.40, 4.69) 0.62 43 
 
1.50 (0.32, 7.01) 0.61 None 
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3.87 (1.24, 12.14) 0.02  
Not possible to calculate adjusted odds ratio 
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199 1.56 (0.85, 2.87) 0.15 198 1.49 (0.80, 2.78) 0.21 Previous treatment with current 
antipsychotic; compliance 
history 
2 109 0.94 (0.44, 2.01) 0.88 101 0.72 (0.31, 1.69) 0.45 Anticholinergic use; gender 
3 98 1.06 (0.46, 2.46) 0.89 90 0.68 (0.22, 2.05) 0.49 Section status; age; smoking 
status; weight 
4 80 4.4 (1.12, 17.24) 0.03 78 4.11 (0.99, 17.01) 0.05 Substance misuse 
5 121 1.45 (0.67, 3.14) 0.34 108 1.34 (0.54, 3.34) 0.53 Previous treatment with current 
antipsychotic; weight; 
anticholinergic use 
6 148 2.38 (1.19, 4.76) 0.02 101 1.75 (0.70, 4.41) 0.23 Ethnicity of consultant; previous 
treatment with current 
antipsychotic; compliance 
history; anticholinergic use 
7 94 2.85 (1.09, 7.45) 0.03  


























P Outcome adjusted for 
following confounders 
1 199 1.18 (0.58, 2.39) 0.65 192 1.20 (0.57, 2.52) 0.63 Previous treatment with current 
antipsychotic; anticholinergic 
use; smoking status 
2 109 0.97 (0.36, 2.62) 0.96 96 1.31 (0.45, 3.82) 0.62 Route 
3 98 1.10 (0.45, 2.66) 0.84 90 0.43 (0.13, 1.38) 0.16 Previous treatment with current 
antipsychotic; age; route 
4 80 1.36 (0.37, 4.96) 0.64 73 2.70 (0.44, 16.36) 0.28 Length of treatment; previous 
admissions; gender; 
anticholinergic use 
5 121 1.87 (0.68, 5.17) 0.23 108 1.39 (0.40, 4.83) 0.61 Weight; anticholinergic use; 
previous treatment with current 
antipsychotic 
6 148 1.47 (0.62, 3.45) 0.38 101 1.06 (0.35, 3.23) 0.92 Language 
7 94 3.5 (1.36, 9.02) 0.01  































199 1.38 (0.69, 2.76) 0.37 172 0.81 (0.28, 2.34) 0.70 Route; anticholinergic use; 
duration of illness; section status 
2 109 1.07 (0.48, 2.39) 0.88 98 1.59 (0.52, 4.85) 0.42 Route; anticholinergic use; 
ethnicity of consultant; 
compliance history 
3 98 2.47 (0.92, 6.60) 0.07 90 4.44 (1.22, 16.14) 0.02 Route; previous admissions; 
section status 
4 80 1.5 (0.46, 4.86) 0.50 76 1.99 (0.39, 10.09) 0.41 Route; substance misuse; 
smoking status; duration of 
illness 
5 121 3.17 (1.25, 8.04) 0.02 113 2.06 (0.57, 7.40) 0.27 Anticholinergic use; route; 
previous treatment with current 
antipsychotic; language; 
substance misuse 
6 148 1.40 (0.63, 3.12) 0.41 88 0.18 (0.03, 1.01) 0.05 Route; length of treatment; 
previous admissions; weight 
7 94 0.77 (0.25, 2.38) 0.66 Not possible to calculate adjusted odds ratio 
8 89 0.97 (0.24, 3.88) 0.97 
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3.3.2 PRIMARY OUTCOME-COMPLETE DATA ANALYSIS WITH CENTRE 
 
TABLE 27 LINEAR REGRESSION MODEL FOR MEDIAN TOTAL PERCENTAGE 
MAXIMUM DOSE WITH CENTRE (PRIMARY OUTCOME-COMPLETE, N=938) 
 
Variable  Coefficient Standard 
Error 
p value 95% CI 
Ethnicity: black 2.34 2.71 0.39 -2.98, 7.67 
Length of admission (log) 4.78 0.97 <0.01 2.87, 6.68 
Centre 2 -6.71 4.03 0.10 -14.62, 1.19 
Centre 8 7.92 4.62 0.09 -1.15, 16.99 
Centre 7 7.42 4.48 0.10 -1.37, 16.20 
Gender: female -8.26 2.78 <0.01 -13.71, -2.80 
Previous admissions: 
more than 5 
3.40 1.51 0.03 0.42, 6.37 
Previous treatment with 
current antipsychotic: yes 
12.63 3.04 <0.01 6.62, 18.63 
Route: intramuscular -2.93 3.09 0.34 -9.00, 3.13 
Legal status: sectioned 6.22 2.90 0.03 0.53, 11.90 
Weight 1 0.19 0.34 0.58 -0.50, 0.87 
Weight 2 1.07 1.12 0.35 -1.18, 3.31 
Weight 3 -5.51 3.81 0.15 -13.11, 2.08 
 
Higher doses were associated with a longer length of admission (log), a greater number 
of previous admissions, previous treatment with current antipsychotic and being 
sectioned under the Mental Health Act. Lower doses were associated with female 
gender. Centre and ethnicity effects were not significantly associated with dose. The 
weight variable violated an assumption of linear regression that there must be a linear 
relationship between outcome and confounder. It was transformed and included in the 
model using restricted cubic splines (a third order polynomial equation) using four 









TABLE 28 LOGISTIC REGRESSION MODEL FOR HIGH DOSE WITH CENTRE 
(PRIMARY OUTCOME-COMPLETE, N=938) 
 




p value 95% CI 
Ethnicity: black 1.08 0.25 0.75 0.68, 1.70 
Centre 2 0.39 0.19 0.05 0.15, 1.01 
Centre 8 1.44 0.49 0.29 0.73, 2.82 
Centre 7 1.58 0.53 0.18 0.81, 3.07 
Diagnosis: not schizophrenia 0.55 0.19 0.09 0.28, 1.11 
Education: A level/up to age 18  0.53 0.17 0.05 0.28, 1.00 
Previous treatment with current 
antipsychotic: yes 
2.66 0.80 <0.01 1.46, 4.83 
Ethnicity of consultant: 
Chinese/other 
2.01 0.50 0.01 1.23, 3.29 
Legal status: sectioned 1.17 0.30 0.55 0.71, 1.92 
Weight (kg)* 1.01 0.01 0.03 1.01, 1.02 
*OR for 1kg weight change 
 
High doses were associated with having previously been treated with the current 
antipsychotic, having a consultant of Chinese/other ethnicity and a heavier weight.  
 
TABLE 29 LOGISTIC REGRESSION MODEL FOR POLYPHARMACY 
PRESCRIBED WITH CENTRE (PRIMARY OUTCOME-COMPLETE CASES, 
N=938)  
 







Ethnicity: black 1.35 0.21 0.05 1.00, 1.83 
Age (years)* 0.98 0.01 <0.01 0.97, 0.99 
Centre 2 2.40 0.56 <0.01 1.52, 3.78 
Centre 3 3.91 0.99 <0.01 2.38, 6.41 
Centre 5 1.39 0.32 0.15 0.89, 2.20 
Centre 8 2.06 0.53 <0.01 1.24, 3.42 
Centre 7 2.75 0.70 <0.01 1.66, 4.53 
Centre 4 2.46 0.65 <0.01 1.46, 4.14 
Previous treatment with current 
antipsychotic: yes 
1.79 0.27 <0.01 1.33, 2.41 
Ethnicity of consultant: black 1.24 0.27 0.34 0.80, 1.90 
Route: intramuscular 1.53 0.25 0.01 1.11, 2.11 
Legal status: sectioned 1.63 0.26 <0.01 1.19, 2.23 
Employment: student 0.40 0.20 0.07 0.15, 1.107 
*OR for change per increase in years,  
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Polypharmacy prescribed was associated with younger age (as each year increase in age 
reduced the odds of being prescribed polypharmacy by 2%), being a patient at centres 2, 
3, 4, 7 and 8, having previously been treated with current antipsychotic, intramuscular 
route of administration and being sectioned under the Mental Health Act. 
 
TABLE 30 LOGISTIC REGRESSION MODEL FOR POLYPHARMACY 









p value 95% CI 
Ethnicity: black 1.13 0.20 0.48 0.80, 1.60 
Age (years)* 0.98 0.01 <0.01 0.96, 0.99 
Centre 3 1.84 0.47 0.02 1.11, 3.04 
Centre 8 1.70 0.48 0.06 0.98, 2.95 
Centre 7 2.47 0.65 <0.01 1.47, 4.14 
Education: secondary 1.61 0.28 <0.01 1.14, 2.28 
Previous admissions: more than 5 1.31 0.14 0.02 1.05, 1.63 
Previous treatment with current 
antipsychotic: yes 
2.04 0.47 <0.01 1.29, 3.23 
Route: intramuscular 1.80 0.33 <0.01 1.26, 2.58 
Legal status: sectioned 1.31 0.26 0.16 0.89, 1.93 
*OR for change per increase in years 
Polypharmacy administered was associated with being a patient at centres 3 and 7, 
having been educated to secondary level, having a greater number of previous 
admissions, previously being treated with current antipsychotic and IM route of 
administration. Antipsychotic monotherapy was associated with younger age (each year 








TABLE 31 LOGISTIC REGRESSION MODEL FOR FIRST GENERATION TYPE 
OF ANTIPSYCHOTIC WITH CENTRE (PRIMARY OUTCOME-COMPLETE 
CASES, N=938) 
 




p value 95% CI 
Ethnicity: black 1.31 0.25 0.15 0.91, 1.91 
Anticholinergic use: no 0.23 0.05 <0.01 0.15, 0.35 
Centre 2 1.96 0.54 0.01 1.14, 3.36 
Centre 6 0.71 0.19 0.21 0.41, 1.21 
Centre 4 2.46 0.77 <0.01 1.33, 4.55 
Previous treatment with 
current antipsychotic: yes 
1.31 0.26 0.19 0.88, 1.95 
Ethnicity of consultant: black 0.53 0.17 0.04 0.28, 0.98 
Route: intramuscular 11.38 2.19 <0.01 7.80, 16.59 
Length of treatment (days) 1.03 0.02 0.07 0.99, 1.07 
 
FGA use was associated with being a patient at centres 2 and 4 and IM route of 
administration of an antipsychotic. Having a consultant of black ethnicity and not using 
an anticholinergic were associated with reduced odds of having a FGA.  
 
TABLE 32 LINEAR REGRESSION MODEL FOR MEDIAN COST WITH CENTRE 
(PRIMARY OUTCOME-COMPLETE N=938) 
 
Variable  Coefficient Standard 
Error 
p value 95% CI 
Ethnicity: black 3.01 5.88 0.61 -8.54, 14.56 
Length of admission (log) 9.51 2.15 <0.01 5.28, 13.74 
Anticholinergic use: no 25.91 7.82 <0.01 10.56, 41.27 
Centre 2 -25.24 8.93 <0.01 -42.76, -7.72 
Previous admissions: more 
than 5 
6.41 3.32 0.05 -0.11, 12.93 
Previous treatment with 
current antipsychotic: yes 
17.05 6.68 <0.01 3.90, 30.21 
Weight 1 0.06 0.72 0.93 -1.37, 1.49 
Weight 2 2.89 2.31 0.21 -1.66, 7.45 
Weight 3 -13.95 7.87 0.08 -29.43, 1.53 
 
Higher costs of antipsychotic treatment were associated with a longer length of 
admission, not using anticholinergic medication and previously being treated with 
current antipsychotic. Being a patient at centre 2 was associated with lower costs of 
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antipsychotic treatment. As with the dose outcome, some variables violated an 
assumption of linear regression that there must be a linear relationship between outcome 
and confounder. These were transformed and included in the model using the log scale 
for the length of admission in days and restricted cubic splines (a third order polynomial 
equation) using four knots (where polynomial sections join) equally spaced for the 
weight variable. 
3.4 DISCUSSION 
3.4.1 MAIN FINDINGS 
There were several statistically significant differences between individual centres in 
prescribing for black and white patients when individual centre data were analysed 
separately. Specifically black patients were more likely than whites to receive higher 
median doses (centre 7), high doses (centre 7, unadjusted outcome), to be prescribed 
polypharmacy (centre 7, unadjusted outcome), to be administered polypharmacy (centre 
7, unadjusted outcome) and to be prescribed a FGA (centre 3). Conversely at some 
centres black patients, compared with whites, received lower median doses (centre 2) 
and higher cost drug treatment (centres 6 and 7). Centre number 7 had worse 
prescribing outcomes for black patients compared with whites for four out of the six 
outcomes. This is a concern as these results may suggest racist prescribing in this centre 
– an effect that was largely masked when centre results were combined. Still it is 
important to note that for several of these outcomes it was not possible to adjust results 
for potential confounders because of small sample sizes. Centre 7 had the smallest 
sample size and was one of the centres with the largest proportion of missing data.  
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Each centre was informed of their results, highlighting differences, through a 
presentation and a written report. They were encouraged to investigate reasons for 
differences and to take remedial action where necessary. 
 
As it was not possible to adjust all individual centres outcomes for confounders because 
of sample size constraints, it was important to analyse total black and white data 
including centre as a confounder. Primary outcome-complete data were analysed in 
detail in Chapter 2 without centre effects but when centre was included it was a 
significant predictor of several outcomes. In this analysis patients were more likely to 
be prescribed more than one antipsychotic in centres 2,3,4,7 and 8 and administered 
more than one antipsychotic in centres 3 and 7. Being prescribed more than one 
antipsychotic occurred in more centres than being administered more than one 
antipsychotic, in all likelihood because of PRN prescribing for behavioural disturbance 
(Paton et al., 2008). Those patients in centres 2 and 4 were more likely to receive a 
FGA. Restrictive formularies and funding, prescribing cultures or differing patient 
populations are potential causes. Centre 2 had lower costs of antipsychotic treatment 
possibly been because of greater use of cheaper FGA. For further discussion of the other 
variables associated with outcomes see section 2.4.3 and 4.4.1. 
 
3.4.2 COMPARISON WITH OTHER STUDIES 
Previous (mainly US) studies have found differences in antipsychotic prescribing 
between black and white patients (see Appendices 3 and 4). UK studies have, overall, 
not found such differences in inpatients (Connolly et al., 2007; Connolly & Taylor, 
2008) but have done so in a large study of community patients {Das-Munshi, 2018 
#1105. Indeed analysis of patients recruited in the study revealed no important 
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statistically significant differences in prescribing of antipsychotics between black and 
white patients after adjustment for confounding variables (see Chapter 2). Nevertheless 
individual centre differences can be masked in a combined data analysis as shown by 
the results in this chapter. Indeed a previous study found that polypharmacy rates were 
driven by one centre’s data (Connolly & Taylor, 2008). National differences in 
prescribing by centre are highlighted by POMH-UK audits but NHS trusts are not 
compelled to be members of this organisation and significant costs and workloads are 
involved. Benchmarking data against other NHS trusts performance has resulted in 
those with poorer results making concerted efforts to change the culture and quality of 
prescribing, for example a reduction in high dose antipsychotic use from 58% to 10% 
and polypharmacy from 57% to 16% (Mace & Taylor, 2015). 
 
Comparison of this analysis (primary outcome-complete, black and white patients with 
centre variable) with that in Chapter 2 (primary outcome-complete, black and white 
patients without centre variable) found variables associated with the outcomes were, 
overall, broadly similar. Furthermore in this analysis individual centres were 
significantly associated with several outcomes. Lower costs of antipsychotic treatment 
at centre 2 may have been related to their higher use of FGAs. Conversely higher costs 
were not associated with centres 3 and 7 even though polypharmacy administered was 
significantly more likely in these centres. Centre was a common association with 
polypharmacy prescribed - more likely in five centres (see Chapter 4 for further 
analyses). Unsurprisingly centres where polypharmacy prescribed was more likely had a 
greater risk of polypharmacy administered. Likewise higher use of FGAs through PRN 
prescribing may have contributed to centre 4’s greater risk of polypharmacy prescribed. 
Reasons for these differences required follow-up by the centre involved. 
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3.4.3 LIMITATIONS 
The study was not powered to detect differences between black and white patients in 
individual centres. Where differences were not shown it should not be assumed that 
there were none as confidence intervals were wide for all of the outcomes so limiting 
the accuracy of the results. Small sample sizes and missing confounder data meant that 
it was not possible to adjust all outcomes for all centres. 
 
Multilevel modelling would have been a useful statistical technique to use on this data 
as the cases are nested at each centre. The analysis in section 3.3.2 with centre as a 
variable provides a preliminary analysis. Several centres had significant effects on the 
outcomes indicating clustering of effect. 
 
Many of the variables included in the models had several levels. This added to the 
complexity of the models and possibly accounted for poor model fit. Inclusion of all 
variables collected in the study may have resulted in overadjustment of outcomes and 
bias towards the null hypothesis (see Section 2.4.6 for more details). Unadjusted results 
were available for the individual centre analyses and, where outcomes could be 
adjusted, some results differed. Specifically black patients were more likely to 
experience prescribed polypharmacy (centre 4 and centre 6) and FGA use (centre 5) 
when unadjusted (but not adjusted) data outcomes were examined. For some outcomes 
only unadjusted data were available; in centre 7 black patients were more likely than 
white to be prescribed high doses, administered and prescribed polypharmacy and have 
a higher cost of antipsychotic treatment. Conversely some insignificant unadjusted 
outcomes were significant when adjusted – in centre 2 median dose was higher for 
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black patients compared with white and for centre 3 FGA use greater for black 
compared with white patients.  
 
Unfortunately this study was not funded to allow follow-up investigation with each 
centre to determine reasons for differences in prescribing. This would be a valuable 
future research project. 
 
As in Chapter 2 classification of ethnicity using the Office of National Statistics groups 
masked the heterogeneity of the people in these categories and could have affected the 
results. Thus far the studies in this thesis have investigated the prescribing of 
antipsychotics in black and white patients only. Although Asian, mixed, Chinese/other 
patients are a smaller proportion of the UK inpatient mental health population, 
differences in the care of these groups has been reported (Care Quality Commission, 
2010) and analysis of prescribing of antipsychotics for these populations is required. 
The next chapter analyses antipsychotic prescribing data from patients of all ethnicities 
to determine if there are any differences in outcomes. 
3.5 CONCLUSIONS 
It is difficult to reach firm conclusions on the centre analysis data despite significant 
results for some centres in both adjusted and unadjusted analyses. This is because of the 
limitations described earlier in Section 3.4.3. Even after accounting for these 
shortcomings, it is clear that for some centres, particularly centre 7, major differences in 
antipsychotic prescribing were recorded between black and white patients. 
Determination of the reasons for these disparities, however complex, requires further 
investigation and remedial action from the trusts identified in this report. 
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CHAPTER 4 PREDICTORS OF PRESCRIBING OUTCOMES AND ETHNICITY 
4.1 INTRODUCTION 
Poor prescribing of antipsychotics is common both nationally and worldwide and is not 
restricted to those from minority ethnic groups (Barnes & Paton, 2011). The prescribing 
measures most often employed are dose, high dose (either more than 100% of the BNF 
maximum percentage dose (i.e. dose divided by maximum licensed dose multiplied by 
100) or more than 1g of CPZe) and combinations of antipsychotics (Harrington et al., 
2002; Taylor et al., 2002).  High doses often result from antipsychotic combinations 
(where the percentage maximum of each drug added together equals more than 100%) 
whether used inadvertently because of PRN use or deliberately by use of two or more 
regular antipsychotics.  
 
Combining antipsychotic is, in most instances, not logical. This is because 
antipsychotics, unlike other groups of medicines for HIV or tuberculosis, have broadly 
similar mechanisms of action (Kapur & Seeman, 2001). Irrational and harmful 
antipsychotic combinations are numerous and the potential consequences are described 
in Table 33. The commonest combinations involve depots with oral antipsychotics, 
quetiapine with other antipsychotics and FGAs as PRNs (Taylor et al., 2015). 
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Depot and oral Defeats the purpose of ensuring compliance with an 
injection. 
Increased non-adherence (Fenton et al., 1997). 
FGA and SGA  Financially costly. 
Exposes patients to metabolic, cardiac and movement side 
effects of both types of antipsychotic (Carnahan et al., 2006; 
Correll et al., 2007; Haddad, 2005; Haddad & Wieck, 2004; 
Peveler et al., 2008). 
Increased mortality (Joukamaa et al., 2006; Waddington et 
al., 1998). 
Two FGAs Increased risk of additive neurocognitive and cardiac effects 
(Carnahan et al., 2006; Elie et al., 2010). 
Greater mortality (Joukamaa et al., 2006). 
Regular and PRN 
antipsychotic 
Routinely used for inpatients for behavioural disturbance 
(National Institute for Health and Care Excellence, 2015). 
Lack of regular review of need may result in inadvertent 
high dose prescribing (Paton et al., 2008). 
 
There appear to be clear differences in high dose antipsychotic prescribing and use of 
antipsychotic combinations for hospital inpatients compared with community patients. 
Lower rates of combinations are reported for those no longer in hospital (15% vs. 
approximately 40% in community (Patel et al., 2014; Paton et al., 2008)). This reflects 
differing patient characteristics (e.g. illness severity and chronicity, treatment resistance, 
diagnosis) in each treatment setting and one assumes the effects of routine PRN 
prescribing of antipsychotics for inpatients. 
 
High dose antipsychotic prescribing is an indicator of poor prescribing quality and 
prescribing of combinations of antipsychotics is a major predictor of high doses (Paton 
et al., 2008). Again as with combinations of antipsychotics, high doses occur more 
frequently in inpatients (approximately a third of patients) than in community patients 
(in approximately a tenth) (Patel et al., 2014; Paton et al., 2008), probably because of 
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PRN prescribing.  Studies of antipsychotic dose response have found that optimally 
effective doses are often found in doses at the lower end of the range e.g. risperidone 
4mg (Ezewuzie & Taylor, 2006), aripiprazole 10-15mg (Sparshatt et al., 2010) and, 
given that antipsychotics have similar mechanisms of action, continuing to increase 
dopamine blockade does not have a beneficial effect for most patients.  
 
Although there are some studies reporting the efficacy of high doses, many of these 
studies are dated, poorly designed and use mega-doses of antipsychotics e.g. 10g 
chlorpromazine equivalent doses (Taylor et al., 2015). Using high doses of SGAs such 
as quetiapine or olanzapine may yield modest benefits for some patients with treatment-
resistant illness but data are conflicting (Boggs et al., 2008; Honer et al., 2012; Meltzer 
et al., 2008). Interestingly the seminal study of clozapine use in treatment-resistant 
schizophrenia compared clozapine with high dose chlorpromazine (doses up to 
1800mg/day) treatment and found response rates of 30% and 4% respectively (Kane et 
al., 1988). Use of clozapine is, for most patients, a more successful treatment. 
 
So why do prescribers continue to use antipsychotics in this way? There are a number of 
reasons why prescribing more than one antipsychotic may occur. It may be the result of 
a partial response to the first treatment (reflecting the inefficacy and lack of truly new 
pharmacological treatments for schizophrenia) (Harrington et al., 2002) or the 
prescriber may be using two antipsychotics together to avoid high doses of a single 
agent (but addition of BNF percentage maximum doses of each agent often results in 
high dose) or a PRN antipsychotic prescribing strategy for behavioural disturbance 
(Paton et al., 2008). A survey of US psychiatrists found a third would add a second 
antipsychotic if a patient did not respond to the first (Kreyenbuhl et al., 2007a) whilst 
 150 
two thirds of psychiatrists in Denmark would rather prescribe two antipsychotics than 
clozapine (Nielsen et al., 2010). Prescribing combinations of antipsychotics is clearly 
entrenched practice in some countries but psychiatrists are aware such practices are 
ineffective (Kreyenbuhl et al., 2007a). 
 
There are situations where prescribing antipsychotics in combination is necessary or  
advantageous. These include switching between antipsychotics (although this can be a 
situation where patients become erroneously ‘stuck’ on two agents if the first is not 
withdrawn as planned (Taylor, 1997)); augmentation of clozapine to improve efficacy 
(unfortunately only small improvements have been found (Taylor & Smith, 2009)); 
managing side effects of an effective antipsychotic (e.g. aripiprazole augmentation to 
reduce prolactin elevation or improve metabolic symptoms (Fleischhacker et al., 2010; 
Henderson et al., 2009; Shim et al., 2007)); management of behavioural disturbance 
(can be minimised with the use of single dose or ‘stat’ prescription rather than unlimited 
PRN use (Taylor et al., 2015)). 
 
Changing the culture and ingrained habits of prescribing is difficult. In psychiatry poor 
prescribing has not been easy to address even when sustained and methodical efforts are 
made (Constantine et al., 2010a; Paton et al., 2008; Thompson et al., 2008). Change is 
possible, as other organisations have shown, through the use of sustained 
multidisciplinary quality improvement programmes (Mace & Taylor, 2015). 
 
Thus far the studies in Chapters 2 and 3 have investigated the prescribing of 
antipsychotics in black and white patients only. In this analysis patients from all 
ethnicities (white, black, Asian, mixed, Chinese/other groups) were included to 
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determine if ethnicity, and other factors, predicted any of the prescribing outcomes. 
Although these groups make up a smaller proportion of the UK inpatient mental health 
population, differences in care has been reported (Care Quality Commission, 2010) 
making analysis of prescribing of antipsychotics for these populations necessary. 
Prescribing outcomes included dose, high dose and polypharmacy (both prescribed and 
administered to differentiate between regular and PRN use) as discussed above but also 
type of antipsychotic, clozapine use, route of administration and cost. This analysis 
allowed use of all of the data to determine if ethnicity, not just black and white, was a 
factor in prescribing of antipsychotics. It also allowed identification of whether certain 
patient factors associated with poorer prescribing could be targeted for improvements. 
4.2 METHOD 
This study was conducted in six mental health trusts in London, one in Nottingham and 
one in Manchester and analyses data from previous research. The details of the method 
are described extensively in Chapter 2.  
 
In summary, data were collected for all adult inpatients on acute psychiatric wards in 
the eight UK trusts taking part in the study. Subjects were of all ethnicities i.e. black, 
white, Asian, mixed or other (as categorised by the most recent Office for National 
Statistics Census 2001 at the time of data collection) and were prescribed and taking 
one or more regular antipsychotics. Outcomes in the original study were total dose, high 
dose (more than 100% of BNF percentage maximum dose), type of antipsychotic (1st or 
2nd generation), polypharmacy (both prescribed and administered) and cost. This 
analysis examines predictors of all these outcomes listed and, as well as these, included 
route of administration and clozapine use. These additional outcomes were included 
because reviewers of the previous study suggested them for inclusion as they have 
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previously been reported to be influenced by ethnicity (Kuno & Rothbard, 2002; Lloyd 
& Moodley, 1992; Whiskey et al., 2011). Data for these additional outcomes had 
already been collected and so could be extracted from the original dataset. 
 
Medical and pharmacy staff at each trust performed the data collection and numerous 
confounding factors were gathered from case notes: age, legal status, substance misuse, 
diagnosis, duration of illness, education, employment status, forensic history, gender, 
compliance history, language, length of current admission, number of previous 
admissions, patient ethnicity, previous antipsychotic treatments, previous treatment with 
current antipsychotic, smoking status, weight. Other factors were collected from 
prescription charts including anticholinergic prescription, clozapine use, dose, length of 
treatment with current antipsychotic, polypharmacy prescribed, polypharmacy 
administered, type of antipsychotic, route of administration. How these confounders 
were defined for data collectors is described in Appendix 10.  
 
4.2.1 SUMMARY OF STATISTICAL ANALYSIS 
Multivariate linear regression was completed for dose and cost to determine the 
relationship between the variables collected (as described above) and continuous 
outcomes. Dummy variables were created for non-binary categorical classifications 
(only patient ethnicity had 3 categories – white, black, other (Asian, mixed, Chinese, 
other)) so they could be included in the multiple regression of continuous and 
categorical variables. For the remaining six categorical outcomes i.e. clozapine use (or 
not); high dose (or not); polypharmacy prescribed (or not); polypharmacy administered 
(or not); type of antipsychotic (FGA or SGA); route of administration (IM or oral) 
multivariate binary logistic regression was used. All outcome variables were binary and 
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the reference (or indicator) category was as follows; not clozapine, no high dose, no 
polypharmacy prescribed, no polypharmacy administered, FGA, IM route. Coding is as 
listed in the regression models. 
 
The number of variables that can be included in a regression model depend on the 
amount of data collected. If too many variables are included then the model produced is 
unreliable. It is worth noting that variable numbers per cases of data rules simplify the 
issue as it is the magnitude of effect and the power required to detect this effect that are 
important. Nonetheless there are minimum cases per variable methods available. These 
include the often quoted 10-15 cases per predictor in a regression model (Field, 2013). 
Other experts (Green, 1991) recommend using overall fit (50 + (8 x predictor number)) 
and contribution of predictors (104 + predictor number). All three methods of 
calculation of sample size for number of variables were used and the largest case 
number chosen.  
 
A ‘power’ calculation was performed before starting the study to determine sample size 
and avoid a false negative/type II error. A sample size of 788 was calculated to be 
required to have an 80% chance of detecting a 5 percentage point (55% vs. 50%) 
difference for the main outcome (percentage maximum dose) between black and white 
patients (assuming a standard deviation of 25). Sample size was not calculated for the 
outcome of cost. 
 
Previous research studies measuring associations between antipsychotic prescribing and 
ethnicity were examined and tabulated to determine which variables were important to 
include in the model i.e. which variables predicted or adjusted outcomes (see Appendix 
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2). Then each variable was entered into a simple univariate regression model to 
determine the strength of the relationship between predictor and outcome. All variables 
with a significance of p<0.05 were then included in a multivariate regression model 
using a backward method (likelihood ratio (LR) for logistic method, entry p<0.05, 
removal p<01) with a complete cases dataset. Variables derived from the outcomes 
were not included in the model to avoid high correlation and non-independence. Where 
patient ethnicity was not significantly associated with outcome it was still included in 
the model as it was the predictor of interest in the study. Finally significant variables 
from this method were included in each model using the enter method. Non-significant 
variables were removed singly in order of least significance until a final parsimonious 
model was determined.  
 
Data were checked for outliers using descriptive statistics, casewise diagnostics and 
graphical boxplot representation. Outliers were also checked for accuracy and included 
if clinically important. Two-way interactions between variables included in the model 
were tested for association. Interactions of significance were then added to the final 
model using the forced entry method with the higher order variables. Each interaction 
was examined for statistical significance at the 5% level.  
 
Linear regression assumptions were tested graphically for linear relationships between 
continuous variables and outcomes, normally distributed errors and homoscedasticity 
(i.e. residuals having similar variance). Then multicollinearity (i.e. no perfect linear 
relationship between variables) was checked for by examining correlations between 
variables and collinearity diagnostics i.e. VIF, tolerance and eigenvalues. The outcome 
values came from separate entities so were independent but high dose and cost were not 
included as variables in the dose model as not independent. Likewise high dose and 
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total dose were not included in the cost model for the same reason. Finally 
independence of errors (i.e. residuals should be uncorrelated) was tested using the 
Durbin-Watson test for serial correlations between errors. 
 
Logistic regression assumptions were tested as follows:  
Linearity of logit (i.e. each variable must be linearly related to the natural log of 
outcomes). This was tested by calculation of the quartiles for continuous predictors to 
make a categorical variable, then fitting a logistic regression model replacing the 
continuous variable with the 4-point categorical one, plotting estimated coefficients vs. 
midpoints of the groups and connecting the points. Finally the plot was visually 
inspected to check if linear and passed assumption. If not linear then the variable was 
transformed. (Hosmer & Lemeshow, 2000).  
 
Multicollinearity (i.e. predictors should not be too highly correlated) was checked with 
tolerance, VIF, eigenvalues, condition indices and variance proportions. IBM SPSS 
does not produce collinearity diagnostics for logistic regression so these were obtained 
by running a linear regression of categorical outcomes and the same predictors used in 
the logistic regression above. The condition index is the square root of the ratio of the 
largest eigenvalue to the eigenvalue of interest. There is no limit as to how large a 
condition index needs to be to indicate a problem but they should be broadly similar. 
Variance proportions are the proportion of the variance of each predictors regression 
coefficient attributed to each eigenvalue. Predictors that have high proportions on the 
same small eigenvalue (conversely the highest eigenvalue number) indicate that the 
variances of their regression coefficients are dependent. 
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Independence of errors (i.e. cases of data should not be related). Violating this 
assumption causes overdispersion (the observed variance is larger than expected from 
the logistic regression model). This results in limited standard errors and narrower 
confidence intervals for the test statistics of predictors in the model and increases the 
risk of type I (false positive) errors.  
 
Model fit (i.e. how well model fits the data and predicts outcome) for linear regression 
was evaluated with R2 (i.e. multiple correlation coefficient squared) and for logistic 
regression was assessed by calculating several measures. These were the omnibus test 
of model coefficients i.e. the difference between the -2 log-likelihood values of the 
basic constant only model and the model with predictors included. Also Cox and Snell’s 
R2 and Nagelkerkes R2 which give an indication of the measure of explained variation 
of the model. Both were calculated as Nagelkerke’s is a more reliable measure than Cox 
and Snell’s.  Then the Hosmer and Lemeshow test comparing observed and expected 
events in each group using chi-squared was completed. Finally a classification table and 
plot (histogram of the predicted probabilities) were produced for each model.  
 
Residuals were examined so that cases that fit the model poorly and those exerting 
undue influence could be identified. Poorly fitting cases were identified using 
Studentized (unstandardised residual divided by an estimate of its standard deviation) 
and standardised residuals. Studentized residuals are more precise than standardized 
residuals and the number of cases more than 2.5 should number less than 1% to ensure 
good representation of the data. For standardised residuals (residuals expressed in 
standard deviation units), cases more than 2 should number less than 5% for the same 
reason.  Those cases exerting undue influence in the model were then examined using 
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Cook’s distance statistic (i.e. measure of influence of a case on the model, should be 
less than 1); leverage statistics (i.e. influence of observed value of outcome over 
predicted value, range from 0 to 1, calculated as no of predictors in model + 1/divided 
by sample size) - three times the average leverage value is a suggested cut-off for 
examining cases with excess influence; absolute DFBeta (measures the influence of a 
case on the coefficients of the regression model), should be less than 1.  
 
Several sensitivity analyses were conducted for all models. These were for missing data, 
variables chosen for inclusion in model, outlier inclusion and exclusion and interaction 
inclusion and exclusion.  
4.3 RESULTS 
4.3.1 STUDY POPULATION 
Demographic and patient variable details for the total sample are described in Tables 34 
and 35. Data were collected for a total of 1198 patients. Overall 332 (27.2%) patients 
had at least one unrecorded demographic detail. There were 866 (72.3%) complete 
cases used in this analysis. 
 
Sample sizes were calculated as follows (including dummy variables), for dose between 
123 to 285, for cost 119 and 225, for clozapine use116 to 180, for high dose 116 to 180, 
for polypharmacy prescribed 120 to 240, for polypharmacy administered 118 and 210, 
for type of antipsychotic 120 to 240 and for route of administration 120 to 240. The 
complete case sample was 978 for dose, 1032 for cost, 1023 for clozapine use, 909 high 
dose, 1071 polypharmacy prescribed, 1081 polypharmacy administered, 996 type of 
antipsychotic, 1070 route of administration and so the data set was larger than the 
minimum number of cases needed and enough to include all covariates. 
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Most patients were from non-SLaM centres, male, of non-white ethnicity, had English 
as a first language, had completed secondary school education, were not employed, 
smokers, not misusing substances, were diagnosed with schizophrenia, had no forensic 
history, a white consultant psychiatrist, were detained in hospital, with two or more 
previous admissions and a history of medication non-compliance. They were taking 
oral, SGA monotherapy (but not clozapine), no anticholinergic medication, had taken 




















TABLE 34 DEMOGRAPHIC AND CLINICAL DETAILS  
 
Variable n (%) Missing (%) 
Centre   
SLaM 228 (19) 
0 (0) Not SLaM 970 (81) 
Gender 
Female 427 (35.6) 
0 (0) Male 771(64.4) 
Patient ethnicity 
White 562 (46.9) 
17 (1.4) 
Black 410 (34.2) 
Other (Asian, mixed, 
Chinese/other) 209 (17.4) 
Employment 
Not employed 1127 (94.1) 
22 (1.8) Employed 49 (4.1) 
Education 
Secondary 618 (51.6) 
105 (8.8) Other 475 (39.6) 
Language 
Not English 168 (14) 
34 (2.8) English 996 (83.1) 
Smoking status 
Non-smoker 325 (27.1) 
55 (4.6) Smoker 818 (68.3) 
Diagnosis 
Not schizophrenia 329 (27.5) 
76 (6.3) Schizophrenia 793 (66.2) 
Ethnicity of consultant 
White 768 (64.1) 
45 (3.8) Not white 385 (32.1) 
Previous treatment with 
current antipsychotic 
No 382 (31.9) 
138 (11.5) Yes 678 (56.6) 
Legal status 
Sectioned 824 (68.8) 
6 (0.5) Informal 368 (30.7) 
Forensic history 
No 636 (53.1) 
87 (7.3) Yes 475 (39.6) 
Previous number of 
antipsychotic treatments 
0 or 1 468 (39.1) 
178 (14.9) 2 or more 552 (46.1) 
Previous admissions 
0 or 1 254 (21.2) 
83 (6.9) 2 or more 861 (71.9) 
History of medication 
non-compliance 
No 227 (18.9) 
77 (6.4) Yes 894 (74.6) 
Route of administration 
Intramuscular 280 (23.4) 
0 (0) Oral 918 (76.6) 
Clozapine use 
No 1074 (89.6) 
0 (0) Yes 124 (10.4) 
Type of antipsychotic 
FGA 284 (23.7) 
0 (0) SGA 914 (76.3) 
Polypharmacy 
prescribed 
No 640 (53.4) 
1 (0.1) Yes 557 (46.5) 
Polypharmacy 
administered 
No 911 (76) 
29 (2.4) Yes 258 (21.5) 
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Variable  n (%) Missing (%) 
Anticholinergic use 
No 963 (80.4) 
41 (3.4) Yes 194 (16.2) 
Substance Misuse 
No 628 (52.4) 
57 (4.8) Yes 513 (42.8) 
 
TABLE 35 CONTINUOUS DEMOGRAPHIC AND CLINICAL VARIABLES 
 
Variable Median Missing (%) 
Age (years; range) 38 (18-76) 2 (0.2) 
Weight (kg; range) 77.8 (33-175.7) 156 (13) 
Length of hospital admission (days; 
range) 56 (1-4210) 31 (2.6) 
Duration of illness (days; range) 3285 (1-18250) 131 (10.9) 
Duration of current antipsychotic 
therapy (days; range) 30 (1-7300) 146 (12.2) 
Total antipsychotic dose (% 
maximum; range) 55.5 (2.5-272.5) 41 (3.4) 
Cost of antipsychotic treatment (£ for 
28 days; range) 87.82 (1.40-632.26) 40 (3.3) 
 
4.3.2 TOTAL DOSE AND COST OUTCOMES 
The analysis used complete cases and the process of choice of variables for each model 
is described in the section 4.2.1. Missing data case numbers for variables included in the 
development of the models represented more than 5% of the study population (for dose 
- complete cases 978/1198 total data cases, 81.6% of the total data; for cost - complete 
cases 1032 /1198 total data, 86.1% of total sample). No effect of missing data on total 
dose or cost was found in a sensitivity analysis.  
4.3.2.1 VARIABLE CHOICE 
The variables significantly associated (p<0.05) with log total dose and log cost are listed 
in Table 36. Categorical variable categories were collapsed to enable model fit. Patient 
ethnicity was not significantly associated with dose or cost but was included in the 
model as it is the outcome of interest. The outcome values came from separate entities 
so were independent but high dose and cost were not included as variables in the dose 
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model as not independent. Likewise high dose and total dose were not included in the 
cost model for the same reason. 
 
TABLE 36 VARIABLES ASSOCIATED WITH LOG TOTAL DOSE AND LOG 
COST OUTCOMES  
 
Outcome Variable p 
 
Log total dose 
Gender 0.001 
Smoking status  0.01 
Diagnosis <0.001 
Legal status 0.001 
Forensic history 0.03 
Number of previous antipsychotics 0.019 
Number of previous admissions <0.001 
Compliance history  <0.001 
Route of administration 0.001 
Anticholinergic use  <0.001 
Substance misuse 0.006 
Type of antipsychotic <0.001 
Clozapine use  0.001 
Polypharmacy prescribed <0.001 
Duration of illness (log) 0.013 
Weight (log) <0.001 
Length of admission (log) <0.001 
Patient ethnicity (including dummy 
variables for black and other ethnicity) 





Ethnicity of consultant 0.018 
Legal status 0.035 
Previous number of antipsychotics 0.034 
Previous number of admissions <0.001 
Compliance history <0.001 
Route of administration 0.011 
Anticholinergic use 0.001 
Type of antipsychotic <0.001 
Clozapine use <0.001 
Polypharmacy prescribed <0.001 
Weight (log) <0.001 
Length of admission (log) 0.003 
Patient ethnicity (including dummy 






4.3.2.2 OUTLIERS  
Casewise diagnostics for log total dose outcome found fewer than 5% of cases had 
standardised residuals of 2 or more (43/978 in model), fewer than 1% of cases had 
standardised residual of 3 or more in the model (8/978 in model), no Cook’s distance 
statistic was more than 1 and 99.8% of cases were fewer than the average leverage 
value. For log cost outcome fewer than 5% of cases had standardised residuals of 2 or 
more (46/1032 in model), fewer than 1% of cases with standardised residual of 3 or 
more (7/1032 in model), no Cook’s distance statistic more than 1 and 98.8% of cases 
fewer than the average leverage value. Outliers were included in the dose and cost 
models as both models predictive capacity was only marginally improved when 
removed. 
4.3.2.3 INTERACTION EFFECTS 
Inclusion of interactions removed higher order variables from the model and had little 
impact on predictive power so were not included. 
4.3.2.4 LINEAR REGRESSION ASSUMPTIONS 
i. A linear relationship between variables and dose and cost outcomes was made 
possible by a log transformation of some continuous predictors i.e. weight, 
length of admission, duration of illness.  
ii. Errors (i.e. residuals) were normally distributed and tested graphically with a P-
P plot and histogram for log total dose and log cost. P-P (observed probability 
vs. expected probability) plots produced a relatively straight line. Histograms 
were normally distributed. 
iii. Log transformation of total dose and cost outcomes ensured residuals were 
homoscedastic. Scatterplot graphs of ZRESID (standardised residuals) against 
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ZPRED (standardised predicted values of outcome based on the model) showed 
a random array evenly dispersed around zero - they were not funnelled or 
curved. 
iv. No multicollinearity. Pearson correlation, highest value 0.332 for dose and 
0.633 for cost, none more than +/- 0.9. The VIF highest value 1.192 for dose 
and 1.410 for cost, none more than 10. Tolerance (1/VIF) lowest value is 0.839 
for dose and 0.709 for cost, neither less than 0.2. Predictors have variance 
loading on different eigenvalue dimensions.  
v. Errors were independent and uncorrelated as the Durbin-Watson test for dose 
model was 1.901 and cost 1.964 (not less than 1 or more than 3). 
4.3.2.5 CAUSES OF ASSOCIATIONS WITH LOG TOTAL DOSE 
Associations with higher log total dose (see Table 37) were; larger weight, greater 
number of previous admissions, longer length of admission, non-compliance with 
medication and use of a SGA. Taking clozapine was associated with a lower log total 
dose than not taking clozapine.  
4.3.2.6 CAUSES OF ASSOCIATIONS WITH LOG COST 
Associations with higher log cost (see Table 38) were; greater number of previous 
admissions, longer length of admission, non-compliance with medication, intramuscular 
route of administration, use of a SGA and greater use of prescribed polypharmacy.  
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4.3.2.7 LOG TOTAL DOSE AND LOG COST MODELS 
 
TABLE 37 LINEAR REGRESSION MODEL LOG TOTAL DOSE OUTCOME (ALL ETHNICITIES) 
 
Variables 
   
 
p-value 










Constant 0.95 0.41 0.021 0.15 1.76 
Weight (log) 0.45 0.09 0.001 0.26 0.63 
Previous admissions; 2 or more 0.30 0.06 0.001 0.19 0.42 
Length of admission (log) 0.10 0.02 0.001 0.06 0.13 
Compliance history; non-compliant 0.19 0.06 0.001 0.08 0.30 
Clozapine use; yes -0.35 0.08 0.001 -0.50 -0.20 
Type of antipsychotic; 2nd generation 0.44 0.05 0.001 0.34 0.55 
n=978, R2 0.153 
 






TABLE 38 LINEAR REGRESSION MODEL LOG COST OUTCOME (ALL ETHNICITIES) 
 











Constant 2.41 0.11 0.001 2.20 2.62 
Previous admissions; 2 or more 0.26 0.06 0.001 0.15 0.37 
Length of admission (log) 0.09 0.02 0.001 0.06 0.13 
Compliance history; non-compliant 0.17 0.06 0.005 0.05 0.28 
Route; oral -0.67 0.06 0.001 -0.80 -0.55 
Type of antipsychotic; 2nd generation 2 0.06 0.001 1.88 2.12 
Polypharmacy prescribed; yes 0.39 0.05 0.001 0.33 0.48 
n=1032, R2 0.553 
 
 
Model can predict 55.3% (R2 = 0. 553) of the variability of cost. Dependent variable is cost (log). 
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4.3.3 CLOZAPINE USE, HIGH DOSE, POLYPHARMACY PRESCRIBED, POLYPHARMACY 
ADMINISTERED, TYPE OF ANTIPSYCHOTIC AND ROUTE OF ADMINISTRATION 
OUTCOMES 
The analysis used complete cases and the process of choice of variables for each model 
is described in section 4.2.1. Missing data case numbers (for variables included in 
model) are more than 5% of the study population (for clozapine use complete cases 
1023 /1198 total data cases; 909/1098 for high dose; 1071/1198 for polypharmacy 
prescribed; 1081/1198 for polypharmacy administered; 996 /1198 for type of 
antipsychotic and 1070/1198 for route of administration). No significant effect of 
missing data on clozapine use, high dose, polypharmacy prescribed, polypharmacy 
administered, type of antipsychotic or route of administration was found in this analysis.  
4.3.3.1 VARIABLE CHOICE 
The predictors significantly (p<0.05) associated with each outcome are listed in Table 
39. Variables not included in model for clozapine use were type and route of 
antipsychotic; for high dose - total dose, cost, weight and length of admission (the latter 
two removed as violated assumption of linearity of logit); for polypharmacy prescribed 
– polypharmacy administered, cost and high dose; for polypharmacy administered - 
polypharmacy prescribed, cost and high dose; for type of antipsychotic - polypharmacy 
prescribed, clozapine use, cost and high dose; for route of administration - 
polypharmacy prescribed, clozapine use and cost. 
 
For the outcome of clozapine use, three preliminary models were constructed. The first 
included all significant variables and initially the model fitted the data but after outliers 
were removed this was not the case. Removal of employment status from this first 
model because of large standard errors also did not allow a model to be fitted to the 
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data. In the second model centre, employment status, diagnosis and number of previous 
antipsychotics predictors were removed again because of large standard errors. A model 
was initially fitted but when outliers removed could not be fitted to the data. In a third 
model variables were removed as in models 1 and 2 but now also patient ethnicity and 
number of previous admissions because of large standard errors. This model fitted the 
data both with and without outliers but was a poor quality model with no significant 
predictors.  
 
For high dose outcome the following attempts were made to fit a model. Model one 
included significant predictors listed in Table 39 but when outliers removed would not 
fit to the data. A second model used variables that, in expert opinion, would be expected 


























TABLE 39 VARIABLES ASSOCIATED WITH CLOZAPINE USE, HIGH DOSE, 
POLYPHARMACY PRESCRIBED, POLYPHARMACY ADMINISTERED, TYPE 
OF ANTIPSYCHOTIC AND ROUTE OF ANTIPSYCHOTIC OUTCOMES  
 




Employment status 0.016 
Diagnosis <0.001 
Number of previous antipsychotics <0.001 
Number of previous admissions 0.003 
Duration of illness 0.01 
Weight 0.014 
Length of admission 0.001 
Length of treatment 0.017 
Patient ethnicity 0.287 
 
High dose 
Diagnosis  0.003 
Previous treatment with current antipsychotic <0.001 
Forensic history 0.005 
Number of previous antipsychotics 0.002 
Number of previous admissions 0.001 
Compliance status 0.001 
Polypharmacy prescribed <0.001 
Polypharmacy administered <0.001 








Smoking status 0.002 
Diagnosis 0.005 
Legal status <0.001 
Forensic history <0.001 
Number of previous admissions 0.019 
Compliance history 0.002 
Route of administration 0.001 
Anticholinergic use 0.003 
Substance misuse <0.001 
Total dose <0.001 
Age 0.012 
Weight <0.001 
Patient ethnicity  0.042 
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Legal status 0.005 
Forensic history 0.004 
Number of previous antipsychotics 0.014 
Number of previous admissions <0.001 
Compliance history <0.001 
Route of administration  <0.001 
Anticholinergic use <0.001 
Total dose <0.001 
Type of antipsychotic 0.008 
Weight <0.001 
Patient ethnicity 0.234 
 
Type of antipsychotic 
Smoking status 0.033 
Diagnosis 0.01 
Ethnicity of consultant 0.039 
Legal status 0.01 
Forensic history <0.001 
Number of previous antipsychotics <0.001 
Number of previous admissions <0.001 
Compliance history <0.001 
Route of administration <0.001 
Anticholinergic use <0.001 
Total dose <0.001 
Polypharmacy administered 0.008 
Weight 0.019 
Duration of illness <0.001 
Patient ethnicity 0.033 
 
Route of administration 
Diagnosis <0.001 
Legal status <0.001 
Forensic history <0.001 
Number of previous antipsychotics 0.001 
Number of previous admissions <0.001 
Compliance history <0.001 
Anticholinergic use <0.001 
Total dose 0.012 
Polypharmacy administered <0.001 
Age 0.029 
Duration of illness <0.001 
Weight 0.013 
Length of admission <0.001 




4.3.3.2 ASSESSMENT OF MODEL FIT 
The full results of assessment of model fit are in Table 40. The omnibus tests of model 
coefficients (i.e. the log-likelihood) of models with predictors were very large 
(indicating poorly fitting statistical models) for all outcomes and were mostly only 
slightly, but statistically significantly (p<0.001 for each model) better than with the 
constant alone. 
 
The Hosmer and Lemeshow test results were statistically insignificant for most of the 
outcomes meaning there were no significant difference between observed and expected 
values and the models fit data reasonably well. The exception was for polypharmacy 
administered outcome which did not fit data well. 
 
 
Classification table results show that the models for most outcomes were slightly better 
at predicting the results than when the constant only was included. 
 
The classification histogram plots of predicted probabilities were incorrect for 
polypharmacy prescribed outcome. This is because for polypharmacy prescribed many 
of the cases with a predicted probability of ‘yes prescribed polypharmacy’ were 
clustered in the ‘no’ part of the histogram and vice versa. Results were better for the 
other outcomes; polypharmacy administered’ were broadly correct as the predicted 
probability for ‘no polypharmacy administered’ outcome was clustered in the ‘no’ part 
of the histogram however some of the ‘yes polypharmacy administered’ were in the ‘no’ 
probability portion of the graph; type of antipsychotic was broadly correct as the 
predicted probabilities for both outcomes are clustered at each end of the histogram in 
the correct places; route was broadly correct as the predicted probability for oral route 
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outcome was clustered on the oral side of the histogram but IM route was spread on 



















Methods of assessment of model fit 
 

























1306.14 1476.69 0.147 0.197 0.349 66.5% 54.2% 
Polypharmacy 
administered 
833.63 1116.43 0.230 0.357 0.001 84.7% 78.8% 
Type of 
antipsychotic 
798.94 1135.29 0.287 0.421 0.083 82.7% 74.3% 
Route of 
administration 







Outliers (more than 2 standardised residuals from regression line) for polypharmacy 
prescribed (n=1), polypharmacy administered (n=44), type of antipsychotic (n=38), 
route of administration (n=37) were excluded from the model, the analyses rerun and 
models refit. Exclusion produced a model that fit the data slightly better for 
polypharmacy prescribed, polypharmacy administered, type of antipsychotic and route 
of administration. The polypharmacy administered outlier free model had the same 
variables as the model with outliers included but also centre, route and anticholinergic 
use. Whilst for type of antipsychotic the outlier free model fit the data with the same 
significant predictors but also included number of previous admissions. Outliers were 
still included for all five models as they were part of the natural variation of the data and 
exclusion improved model accuracy only marginally.  
4.3.3.4 INTERACTION EFFECTS 
No interactions were significantly associated with polypharmacy prescribed, 
polypharmacy administered and route of administration so were not included in the final 
model. Two interactions were significantly associated with type of antipsychotic i.e. 
polypharmacy administered and anticholinergic use, total dose and anticholinergic use. 
When these interactions were included in the model they caused the removal of 
anticholinergic use (a higher order variable) so were not included in the final model. 
4.3.3.5 LOGISTIC REGRESSION ASSUMPTIONS 
i. Linearity of logit 
There are two continuous variables in the models polypharmacy prescribed and 
route of administration (age and total dose); one continuous variable in the 
polypharmacy administered and type of antipsychotic models (total dose). Using 
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the Hosmer and Lemeshow method (Hosmer & Lemeshow, 2000), the graphs for 
total dose and age were linear. 
 
ii. Multicollinearity 
Pearson’s correlation checked, none more than +/- 0.9; 
variance inflation factor (VIF) values, none more than 10; 
 tolerance (1/VIF) values, none below 0.1 for all models. 
 
Eigenvalues were similar overall for almost all for polypharmacy prescribed (except 
eigenvalue on dimension 1 of 5.231, other values less than 1), polypharmacy 
administered (except eigenvalue value 3.451 on dimension 1), type of antipsychotic 
(except eigenvalue 3.765 on dimension 1 and route of administration (except 
eigenvalue 5.387 on dimension 1) 
 
Condition indices were broadly similar except for polypharmacy prescribed model 
on dimension 7 condition index is 16.629 other values were less than 9; route of 
administration model on dimension 7 of 12.379; polypharmacy administered and 
type of antipsychotic models were broadly similar. 
 
The polypharmacy administered, type of antipsychotic and route of administration 
models variance proportions were evenly spread over the smallest eigenvalues. The 
polypharmacy prescribed models variance proportions were evenly spread over the 
smallest eigenvalues apart from centre which had a relatively high variance 




4.3.3.6 RESIDUAL ANALYSIS 
Studentized residual, number of cases more than 2.5 for polypharmacy prescribed 
1/1071, 0.1% of sample; polypharmacy administered 44/1081, 4.1%; type of 
antipsychotic 38/996, 3.8%; route of antipsychotic 37/1070, 3.5%. 
 
Standardised residuals number of cases over 2 for polypharmacy prescribed 1/1071, 
0.1% of cases; polypharmacy administered 83/1081, 7.7%; type of antipsychotic zero 
cases; route of administration 89/1070, 8.3%. 
 
No Cook’s distance statistic was more than 1 for polypharmacy prescribed, 
polypharmacy administered, type of antipsychotic or route of antipsychotic models.  
Leverage values were, for polypharmacy prescribed model 99.6%; polypharmacy 
administered 91.5%; type of antipsychotic 99.3%; route of administration 99.4%.  
 
Absolute DFBeta were less than 1 for all cases for polypharmacy prescribed, 
polypharmacy administered, type of antipsychotic, route of administration. 
4.3.3.7 CAUSES OF ASSOCIATIONS WITH CLOZAPINE USE 
No significant predictors of taking clozapine were identified from analysis of this 
dataset. 
4.3.3.8 CAUSES OF ASSOCIATIONS WITH HIGH DOSE 
No significant predictors of high dose were identified from analysis of this dataset. It 




4.3.3.9 CAUSES OF ASSOCIATIONS WITH POLYPHARMACY PRESCRIBED 
Associations with being prescribed more than one antipsychotic (see Table 41) were; 
non-South London and Maudsley NHS trust centre (SLaM), the subject having a 
forensic history and a higher total dose. Younger age, not being detained under a Mental 
Health Act section and oral route were predictors of prescribed antipsychotic 
monotherapy. 
4.3.3.10 CAUSES OF ASSOCIATIONS WITH POLYPHARMACY ADMINISTERED  
Associations with being administered more than one antipsychotic (see Table 42) were; 
greater number of previous admissions and a higher total dose. SGA use predicted being 
administered monotherapy.  
4.3.3.11 CAUSES OF ASSOCIATIONS WITH TYPE OF ANTIPSYCHOTIC  
Associations with SGA use (see Table 43) were; oral route, higher total dose, being 
administered only one antipsychotic, having had fewer previous antipsychotics and no 
anticholinergic use. 
4.3.3.12 CAUSES OF ASSOCIATIONS WITH ROUTE OF ADMINISTRATION 
Associations with oral route (see Table 44) were; not being sectioned under the Mental 
Health Act, SGA use, younger age, non-schizophrenia diagnosis, fewer previous 
admissions and a lower total dose.
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4.3.3.13 POLYPHARMACY PRESCRIBED, POLYPHARMACY ADMINISTERED, TYPE OF ANTIPSYCHOTIC AND ROUTE OF 
ADMINISTRATION MODELS 







95% CI for Odds Ratio 
Lower Upper 
Constant -0.87 0.33 0.008 0.42 N/A N/A 
Centre; non-SLaM 0.80 0.17 0.001 2.23 1.60 3.11 
Age -0.02 0.01 0.001 0.98 0.97 0.99 
Forensic history; yes 0.34 0.14 0.015 1.40 1.07 1.84 
Section status; not sectioned -0.42 0.15 0.005 0.66 0.49 0.88 
Route of administration; oral -0.40 0.16 0.012 0.67 0.49 0.92 
Total dose 0.02 0.002 0.001 1.02 1.01 1.02 
n= 1071, -2 log-likelihood = 1306.144 ,CI = confidence intervals, N/A = not applicable.  
 
 







95% CI of Odds Ratio 
Lower Upper 
Constant -3.68 0.32 0.001 0.03 N/A N/A 
Previous admissions; 2 or more 0.59 0.26 0.02 1.78 1.09 2.98 
Type of antipsychotic; 2nd 
generation -1.07 0.20 0.001 0.34 0.23 0.51 
Total dose 0.04 0.01 0.001 1.03 1.03 1.04 
n = 1081, -2 log-likelihood = 833.632, CI = confidence interval. N/A = not applicable.  
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95% CI for Odds Ratio 
Lower Upper 
Constant -1.27 0.26 0.001 0.28 N/A N/A 
Route; oral 2.64 0.20 0.001 14.08 9.51 20.83 
Polypharmacy administered; yes -0.89 0.24 0.001 0.41 0.26 0.66 
Previous number of antipsychotics; 2 or more -0.55 0.18 0.003 0.58 0.40 0.83 
Anticholinergic use; yes -1.42 0.23 0.001 0.24 0.16 0.38 
Total dose 0.02 0.003 0.001 1.02 1.02 1.03 
n= 996, -2 log-likelihood = 798.936,  CI = confidence interval, N/A = not applicable 
 
 







95% CI for Odds Ratio 
Lower Upper 
Constant 1.80 0.41 0.001 6.06 N/A N/A 
Age -0.02 0.01 0.022 0.98 0.97 0.99 
Diagnosis; schizophrenia -0.99 0.22 0.001 0.37 0.24 0.57 
Section status; not sectioned 0.64 0.21 0.002 1.90 1.26 2.86 
Previous admissions; 2 or more -0.75 0.26 0.004 0.47 0.28 0.79 
Type of antipsychotic; 2nd generation 2.57 0.19 0.001 13.09 9.08 18.86 
Total dose -0.007 0.002 0.001 0.99 0.98 0.99 
n= 1070, -2 log-likelihood = 862.526, CI = confidence interval, N/A = not applicable 
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4.4 DISCUSSION  
4.4.1 MAIN FINDINGS 
The most important finding was that ethnicity was not associated with any of the 
study’s multiple outcomes but the significant limitations of the study may have resulted 
in negative findings. The number of outcomes was extended from previous analyses and 
included clozapine use and route of administration thus providing a more 
comprehensive assessment of the effect of ethnicity on prescribing of antipsychotics.  
 
Given that ethnicity was not associated with any of the outcomes, it is worth examining 
the other factors that did affect antipsychotic prescribing. Dose equivalence of 
antipsychotics can be expressed in many ways. The most commonly used methods are 
chlorpromazine equivalents, defined daily dose and percentage maximum dose. 
Historically the CPZe method is used. Chlorpromazine is a low potency, FGA with a 
large dose range (25 to 1000mg) (British Medical Journal Group and Pharmaceutical 
Press, 2014). Doses of other FGAs were converted to chlorpromazine doses to allow 
comparison. The conversion ratios were based on dopamine receptor occupancy rates in 
vitro, often had hugely different quoted equivalences and relied for legitimacy through 
repetition in the published literature (Yorston & Pinney, 2000). High doses are 
described as being more than 1g CPZe (British Medical Journal Group and 
Pharmaceutical Press, 2014) but some authors suggest they may be as low as 600mg 
CPZe (Buchanan et al., 2010). DDD is the average daily maintenance dose per day of a 
medication when used for its main indication in adults. It is calculated by dividing the 
prescribed daily dose by the defined daily dose. DDD is defined by the WHO and is 
based on systematic review of the literature but does not take into account differences in 
starting doses of antipsychotics, is costly to access and can result in erratic 
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recommendations (Gardner et al., 2010).  The percentage maximum dose method 
calculates each dose as a proportion of the BNF maximum dose. It is a useful practical 
measure as it is directly related to the legalities of prescribing and clinical practice. 
Comparison of these methods has yielded inconsistent results. Some authors report 
discrepancies between methods (Patel et al., 2013; Rijcken et al., 2003) whilst others 
describe coherence (Nose et al., 2008). It is unsurprising that, given these differences, 
expert consensus opinions are also sometimes used (Gardner et al., 2010). Choice of an 
antipsychotic dose equivalence method requires justification depending on the study 
being undertaken (see Chapter 2). 
 
Higher total doses were prescribed to patients of larger weight, those not compliant with 
medication, on SGAs, with a longer length of admission and a greater number of 
previous admissions. Let us look at each of these in turn. The metabolic effects of 
antipsychotics, particularly those from the 2nd generation (Rummel-Kluge et al., 2010), 
are well known and may account for why larger weight was associated with higher total 
doses. In addition larger patients may affect prescriber’s perception of the magnitude of 
dose needed and so also be associated with higher doses. Non-compliance is often 
undetected by prescribers and may result in them increasing doses of antipsychotics 
through perceived lack of effect of a treatment. Moreover not taking antipsychotic 
treatment greatly increases the risk of relapse which often leads to the prescribing of 
relatively higher acute doses (Harrington et al., 2002; Wyatt, 1991).  
 
The association of SGA use with higher doses was surprising. This is because doses of 
newer antipsychotics are well studied and clearly described, making it more difficult for 
prescribers to inadvertently prescribe larger doses. The estimates of minimum effective 
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doses and dose ranges of older FGAs have reduced over recent years. This is because 
neuroimaging studies have shown that much lower levels of dopamine blockade are 
needed for efficacy of antipsychotics than was previous recognised (Kapur et al., 2000). 
Haloperidol provides a good example when compared with olanzapine. The maximum 
dose of haloperidol at the time of data collection was 30mg/day (now 20mg/day and 
previously 200mg/day (British Medical Association and Royal Pharmaceutical Society 
of Great Britain, 2008)) whilst the effective dose of olanzapine is probably 10-15mg 
(Davis & Chen, 2004) and maximum is 20mg. Thus proportionally an effective dose of 
haloperidol of 5mg was 16% of the maximum dose at the time of the data collection 
whilst olanzapine was 50-75%.  
 
Chronicity of illness is represented by predictors of a longer length of admission and a 
greater number of previous admissions - factors that describe relapse and thus increased 
doses (Leucht et al., 2013). Finally clozapine use predicted a lower total dose possibly 
because of a lower risk of polypharmacy and better efficacy (Kane et al., 1988) and 
risks associated with combinations with clozapine. Unfortunately it was not possible to 
fit the data into a good quality model for clozapine use to test this theory and clozapine 
use was not a predictor of polypharmacy prescribed or polypharmacy administered 
outcomes. 
 
Higher costs of antipsychotic treatment were associated with a greater number of 
previous admissions (as doses are increased when people are admitted (Taylor et al., 
2015)), a longer length of admission, prescribed polypharmacy and a history of non-
compliance – all factors indicating a more severe and enduring illness, higher doses and 
thus greater costs. The oral route of administration was associated with lower costs 
 182 
probably owing to higher costs of depot treatments. SGA are more expensive than FGA 
so it was unsurprising that SGA were associated with higher costs. 
 
Antipsychotic polypharmacy was associated with higher total doses, greater number of 
previous admissions, having a forensic history and non-SLaM centre. Antipsychotic 
monotherapy was predicted by younger age, not being detained under a Mental Health 
Act section, oral route of administration and use of a SGA. As discussed in the 
introduction to this chapter antipsychotic polypharmacy often results in higher doses 
(Harrington et al., 2002) and unfortunately both are commonly prescribed in the UK 
(Paton et al., 2008). As with higher doses a greater number of previous admissions was 
associated with polypharmacy, given multiple admissions are likely to indicate a more 
severe and chronic illness. Those patients with a forensic history may be more at risk of 
antipsychotic combinations, high dose use and use of multiple routes (Barnes et al., 
2009; Lelliott, 2002). This is possibly because of lack of efficacy of a single agent 
(especially if this is a depot) and prescribers concern about patients’ risk histories 
(Grech & Taylor, 2012; Stubbs et al., 2006). The effects of centre on polypharmacy 
were interesting as non-SLaM NHS trusts were more likely to prescribe in this way. A 
previous study had also found a non-SLaM centre effect of polypharmacy – a result of 
particularly high polypharmacy rates in one centre (Connolly & Taylor, 2008). It is 
worth noting that centre only had an effect on polypharmacy prescribed not 
polypharmacy administered. The effect of non-SLaM centre may have been because of 
concerted efforts to improve polypharmacy prescribing in SLaM through a quality 
improvement programme. This paid particular attention to eliminating routine 
prescription of PRN antipsychotics for behavioural management (Mace & Taylor, 
2015). 
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Not being detained and being of younger age were associated with antipsychotic 
monotherapy. Both of these predictors, as with length of admission and number of 
previous admissions, suggest a less severe illness presentation and so a lower likelihood 
of antipsychotic polypharmacy use. Prescribers often use antipsychotic polypharmacy 
when faced with a severely unwell patient who is not responding to a single agent. They 
are under pressure to find an effective treatment and polypharmacy can be an 
inadvertent consequence rather than a rational evidence-based decision. Interestingly 
this result differs from the black and white data analysis in Chapter 2 where a younger 
age was associated with increased risk of antipsychotic polypharmacy. The addition of 
another ethnic group, of relatively small numbers compared with the black and white 
groups, is a factor in the conflicting results. There have been concerns that young, black 
patients are perceived stereotypically as more violent than other ethnic groups possibly 
accounting for the differing results (Prins 1993). Unusually SGA use was also 
associated with antipsychotic monotherapy, not reflecting other researchers findings 
(Paton et al., 2008). 
 
SGA use was associated with patients on oral medication (and vice versa as discussed 
below), antipsychotic monotherapy, having had fewer previous antipsychotics and not 
taking anticholinergic medication. Unexpectedly, higher doses were also associated 
with SGA (and again vice versa). As discussed earlier this may be because of: clearer 
dose ranges for the newer compared with older drugs; use of percentage maximum dose 
to express total dose; large differences between minimum and maximum doses for first 
and SGAs and poorer tolerability of older agents at higher doses. The finding of 
associations that occurred both when a predictor was used as an outcome and a 
covariate was methodologically reassuring i.e. SGA use and higher doses/oral route. 
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Lower use of anticholinergic medication to treat extra-pyramidal side effects would be 
expected when using SGAs as they are less likely to be cause movement side effects at 
standard doses than FGAs. 
 
Use of the oral route of administration was associated with younger age, not having a 
diagnosis of schizophrenia, informal section status, fewer previous admissions, SGA 
use and a lower dose. As with the other outcomes younger age, informal section status 
and fewer previous admissions suggest a less severe and earlier stage of illness and thus 
a lower likelihood of non-adherence and use of depot antipsychotics (Cañas et al., 2013; 
Novick et al., 2010). Depot antipsychotics are reserved for long-standing cases of illness 
usually after oral treatments have been unsuccessful (Barnes et al., 2009; Xiang et al., 
2006). At the time of data collection, depot antipsychotics were, with the exception of 
risperidone long-acting injection, available only as FGAs and so newer agents would be 
expected to be the associated with the oral route of administration. Oral antipsychotics 
were also associated with low doses. This may also be because depot antipsychotics, 
being mostly of the first generation type, have not had doses reduced as understanding 
of the mechanism of action of antipsychotics has developed. Flupentixol decanoate 
depot is a good example – the maximum dose in the UK is 400mg weekly (equivalent to 
approximately 8000mg of chlorpromazine equivalents (dose equivalents more than 
1000mg are classed as high dose)) whereas typical clinical doses are around 30mg 
weekly (Taylor et al., 2015) . Patients without schizophrenia were also associated with 
the oral route. This association is likely to be because of the use of SGAs (available 




4.4.2 COMPARISON WITH PREVIOUS STUDIES 
Ethnicity was not a predictor of any of the eight outcomes but the significant limitations 
of the study may have resulted in negative findings. This result is similar to that found 
previously in analysis of this data and other smaller UK studies of inpatients. An 
extensive literature search of studies examining antipsychotic prescribing and ethnicity 
can be found in Chapter 1. Most of these studies were conducted in the US and are large 
database surveys so differ from this study and its predecessors. There is a large, cross-
sectional UK study of antipsychotic use by ethnicity in a sample of community patients 
(Das-Munshi et al., 2018). As well as being from a different population to this study, 
the Das-Munshi paper analysed data for the five individual ethnic groups specified by 
the Office of National Statistics i.e. white, black, Asian, mixed, Chinese/other. It found 
that black patients, compared with white, were more likely to be prescribed depot 
antipsychotics and were less likely to be prescribed clozapine. Mixed patients were 
more likely than white to receive high dose antipsychotic treatment. The study was 
large enough (over ten thousand patients at 64 centres) to allow analysis in this way 
whereas this study, in order to fit models to the data, required the collapse of ethnic 
groups into white, black, other (Asian, mixed, Chinese/other). This distinction, as well 
as the differing populations are possible reasons for the differing results, 
notwithstanding the limitations of this study. 
 
Previous studies have found predictors of antipsychotic polypharmacy to be 
anticholinergic use, male gender, poor symptom control and longer lengths of 
admission to hospital (Barnes & Paton, 2011). The demographic data, for example 
diagnosis, collected in the current study were similar to that used in other studies of 
antipsychotic prescribing practice in the UK (Barnes et al., 2009; Paton et al., 2008) so 
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results, being taken from a national sample of eight centres, can be described as broadly 
generalisable to the wider UK population. 
 
Can antipsychotic prescribing be improved for all ethnicities? As described earlier 
quality improvement programmes can have major effects in some centres (Mace & 
Taylor, 2015) but the overall magnitude of change achieved is limited. Antipsychotic 
prescribing patterns are audited regularly and compared across UK NHS trusts (Paton et 
al., 2008). Those clinicians whose prescribing falls outside expected standards have to 
account for any differences and are expected to make improvements. So why do 
prescribers continue to use antipsychotics in an apparently ineffective and hazardous 
way? The main reason for poor prescribing is the lack of efficacy of many 
antipsychotics particularly when used in those with treatment-resistant illness. 
Clozapine is the most efficacious antipsychotic but it is underused for several reasons; 
patients refusal because of the need for regular full blood count monitoring owing to 
clozapine’s haematological adverse effects; prescriber reluctance because of other 
severe side effects e.g. myocarditis, cardiomyopathy, pneumonia; prescribers’ 
perception that patients on clozapine are less satisfied by this treatment; prescribers’ 
preference for using combinations of antipsychotics; prescriber inexperience of using 
clozapine; concerns about clozapine’s overall tolerability; patients’ medical 
complications contra-indicating or cautioning clozapine use and prescribers worries 
about erratic compliance requiring re-titration (Gee et al., 2014; Nielsen et al., 2010; 
Taylor et al., 2000).  The usual recommendation is that clozapine should be started after 
the failure (in response to or tolerability of) of two different antipsychotics. Delays in 
initiation are, on average, four years (Howes et al., 2012). Nonetheless providing 
support and expertise to prescribers when starting or re-challenging clozapine are 
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effective in improving prescribing rates (Gee et al., 2014; Meyer et al., 2015). 
Alongside this, development of specialist services to initiate and continue clozapine can 
also ensure earlier use. Management of clozapine’s many side effects, even the serious 
haematological ones, is also possible enabl1ing patients to remain on treatment (Meyer 
et al., 2015; Taylor et al., 2015) and reduce their length of stay in hospital (Gee et al., 
2016). 
 
4.4.3 LIMITATIONS  
Cases with complete data were used for analysis because of the large sample size. 
Simple single imputation methods (e.g. mean, last observation carried forward) may 
cause biased results because of small standard errors and do not account for the 
uncertainty of missing values. Even using multiple imputations can produce misleading 
results e.g. the QRISK study found no relationship between cholesterol and 
cardiovascular risk until completion of a complete case analysis (Sterne et al., 2009) and 
there is little research into calculating multiple imputations for binary or categorical 
data. Nonetheless errors can be avoided if results are carefully checked and appropriate 
imputation methods are used.  
 
Using complete cases for analysis may not always be biased if the missing data occur 
only in an outcome variable that is measured once in each individual, if all variables 
associated with missing outcome data can be included as covariates and if missing data 
in predictor variables are unrelated to outcome. This applied to the data used in this 
analysis if variables were not included that were derived from the outcomes. 
Notwithstanding this, complete case analysis can be biased unless data are MCAR. The 
data were MAR not MCAR because missing data were distributed in one or more 
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subsamples (i.e. centres with poorer complete data collection e.g. North East London, 
Manchester).  Data were analysed previously as MAR to allow multiple imputations 
(see Chapter 2) and the six variables with the most missing data (accounting for almost 
70% of total missing data) were education, weight, duration of illness, length of 
treatment with current antipsychotic, previous treatment with current antipsychotic, and 
number of previous antipsychotic treatments. For the final linear models, of these 
variables only weight was a significant predictor of dose and none of these variables 
were significant predictors of cost.  For the logistic final models, of these variables only 
number of previous antipsychotic treatments was a significant predictor of type of 
antipsychotic in the final model and none were significant predictors of polypharmacy 
prescribed, polypharmacy administered and route of administration. 
 
As in previous analyses the regression models had poor predictive power and the extent 
of the effects were mostly small. Numerous variables were collected that could have 
affected the outcomes, using both previous research and clinical experience to collate 
the covariates, but this added to the complexity of the models. Indeed for two outcomes, 
clozapine use and high dose, it was not possible to fit a model. Other researchers did not 
adjust their models for such a large number of confounders (see Appendix 2). The poor 
explanatory power of the models suggests that there are unknown or uncollected 
variables influencing the outcomes. The categorical variables in the models had their 
number of levels collapsed to reduce data complexity and allow model fit.  This may 
have affected the results by simplifying confounders associated with outcomes. 
It is also possible that the models’ predictive capacity could be affected by the inclusion 
of too many variables i.e. overadjustment of outcomes as discussed in Sections 2.4.6 
and 3.4.3. As multiple confounders were included in the models for all ethnicities data – 
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many more than in previous studies (see Appendix 2) but fewer than in the black and 
white patient analyses – this could have affected the results. 
 
There were some variables that were not collected that other researchers found were 
251associated with antipsychotic use and ethnicity - data on patients' mental state (Shi, 
2007; Van Dorn et al., 2005) and reasons for antipsychotic choice. Data on patients’ 
mental state (a CGI-S score) was collected in previous research (Connolly & Taylor, 
2008). But given the cross-sectional nature of the study, this score was collected on the 
day of data collection not at the time of prescribing of the antipsychotic so was of 
limited usefulness as what is important is the severity of illness before the treatment 
becomes effective. This analysis used complete cases whereas previous analyses had 
used multiple imputations to replace missing data. This may have affected the models’ 
reliability however those from the previous analysis also explained only limited 
variability. 
 
As in Chapters 2 and 3, classification of ethnicity using the Office of National Statistics 
grouping masked the heterogeneity of the people in these categories and could have 
affected the results. Furthermore this analysis collapsed the ethnicity groups, for 
statistical reasons, from five (white, black, Asian, mixed, Chinese/other) to three (white, 
black, other) further eroding group heterogeneity and very possibly the results. 
 
All variables collected in the study were not included in the regression models for all 
outcomes in this analysis (as they were for the black and white patient analysis in 
Chapters 2 and 3). Only those variables associated with each outcome were included as 
listed in Tables 36 and 39. This may have affected which variables were associated with 
each outcome, for example age was associated with prescribed polypharmacy and route 
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of administration but not administered polypharmacy as in previous analyses in Chapter 
2. 
 
This study did not find differences in the prescribing of antipsychotics by ethnicity in a 
sample including patients of all ethnicities, but there were significant limitations as 
detailed above. Given the shortcomings of this and the studies in Chapters 2 and 3 plus 
the feedback from prescribers about earlier studies of antipsychotics and ethnicity, an 
investigation of theoretical prescribing intention for black or white patients allowed 
further investigation, using a different research design, of the prescribing of 
antipsychotics by ethnicity. 
4.5 CONCLUSIONS 
Ethnicity did not affect prescribing of antipsychotics for any of the outcomes examined 
when adjusted for confounders but the significant limitations of the study may have 
resulted in negative findings. Higher doses and combinations of antipsychotics were 
used for patients who were detained under the Mental Health Act, had longer lengths of 
admission, more previous admissions, of larger weight, not taking clozapine, using a 
depot antipsychotic and being assessed as poorly compliant. 
 
Using the percentage maximum dose method of expressing dose may have allowed 
older agents to appear more favourably. As reported in other studies polypharmacy and 
high doses are linked. Newer SGAs were not associated with anticholinergic medicine 
use because of their lower risk of EPSE and were used for patients who had been treated 
with fewer previous antipsychotics. Oral medicines were used for patients who were 
younger, not detained, did not have schizophrenia, had had fewer previous admissions, 
on a SGA and taking a lower dose.  
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CHAPTER 5 DOES ETHNICITY AFFECT PRESCRIBING FOR ACUTE PSYCHOSIS? 
EVALUATION BY CASE VIGNETTE 
5.1 INTRODUCTION  
People from ethnic minorities, particularly black patients, are disproportionately 
represented in mental health services (Care Quality Commission, 2010), more likely to 
be admitted to hospital and sectioned under the Mental Health Act than white patients 
(Care Quality Commission, 2010; Morgan et al., 2006). There have also been a number 
of high-profile deaths of black patients in psychiatric services (Norfolk Suffolk & 
Cambridgeshire Strategic Health Authority, 2003; Prins, 1993) that have given rise to 
charges of institutional racism in UK mental health services (McKenzie & Bhui, 2007). 
The concern is that this racism is manifested in different prescribing practices for black 
people. 
 
Indeed prescribing of antipsychotics differs by ethnicity in some countries, especially 
the US. Studies show black patients are more likely to receive higher doses, FGAs and 
greater numbers of antipsychotics than white patients (Diaz & De Leon, 2002; 
Kreyenbuhl et al., 2003; Taylor, 2004).  
 
Studies from the UK have not shown major differences in antipsychotic prescribing 
between black and white patients (Connolly et al., 2007; Connolly & Taylor, 2008). 
These studies have examined outcomes including dose, type of antipsychotic, number of 
antipsychotics prescribed, route of administration, clozapine use and costs of 
antipsychotics in large, multicentre studies. Different health care systems, decline in and 
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awareness of racism and a multi-ethnic mental health workforce may account for these 
differences (Goldacre et al., 2004). 
 
After publication of the study examining antipsychotic prescribing in black and white 
patients, the results were presented and discussed with health care professionals. The 
informal feedback received from ethnic minority prescribers, rather than welcoming the 
results, was that the findings of previous studies were flawed. Individual prescribers 
stated that they purposefully used higher doses for black patients as these patients were 
more severely unwell on admission than white patients often because of delays in 
accessing mental health services. Illness severity was not collected as a measure in the 
study described in Chapter 2 as had been done in an earlier investigation (Connolly & 
Taylor, 2008). Moreover the AESOP study examined duration of untreated psychosis 
by ethnicity – a proxy measure of illness severity. It did not find that black patients 
compared with white had a longer duration of untreated psychosis (Morgan et al., 
2006). .  
 
Given the nature of this informal feedback and the limitations of previous studies, the 
legitimacy of these reports could be tested, using a different research design to studies 
in Chapters 2, 3 and 4, through a theoretical study examining attitudes of prescribers to 
prescribing by ethnicity. This was carried out by developing a patient case vignette 
capturing the different ethnicities and then requesting prescribers to choose 






A case vignette (see Appendix 16), prescriber demographic data form (Appendix 17) 
and study explanatory letter (Appendix 18) were sent to all medical prescribers in the 
South London and Maudsley NHS trust. The case study was produced using several 
methods - examining vignettes from previous studies (Clark & Rowe, 2006; Lewis & 
Appleby, 1988; Lewis et al., 1990), contacting authors of previous studies where the 
case was not published as part of the paper (Minnis et al., 2001), personal experience of 
common clinical scenarios and consulting with colleagues as to the validity and 
suitability of the case. Half of the prescribers for each grade of staff (foundation year 
(FY1-2), core trainee (CT1-2), speciality registrar (StR 1-6) and consultant) were 
emailed the case study where the ethnicity of the patient was white and the other half 
where the ethnicity was black. This was the sole difference between the vignettes. 
Replies could be made by email or anonymously in the post. Those who did not respond 
were sent a final reminder email 2 weeks later.  
 
The case study asked only two questions; which antipsychotic(s) would you prescribe 
for this patient and what dose(s) would you use? The explanatory letter asked 
prescribers to complete a survey of antipsychotic prescribing and stated that the reasons 
for the study could not be revealed as this would nullify the results. The case study was 
tested before distribution to ensure suitability and that it could be easily completed and 
understood.  
 
5.2.1 ETHICAL COMMITTEE APPROVAL 
The Health Research Authority’s guidance (Health Research Authority, 2014) on 
defining research was used to determine if the study was research, clinical audit or a 
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service evaluation. This study was defined as ‘not research’ (Appendix 19) and as such 
approval was obtained from the South London and Maudsley NHS trust Drugs and 
Therapeutics committee. 
 
5.2.2 STATISTICAL ANALYSIS 
The outcomes analysed were: total percentage maximum dose (calculated as dose 
divided by maximum BNF dose (British Medical Journal Group and Pharmaceutical 
Press, 2014), multiplied by 100); percentage maximum dose for 1st, 2nd, 3rd 
antipsychotic choice; high dose (more than 100% of BNF maximum dose); type of 
antipsychotic (FGA or SGA); route of administration (oral or IM) and antipsychotic 
polypharmacy (being prescribed more than one antipsychotic concurrently). Prescribers’ 
demographic data were summarised using descriptive statistics and then inferential 
statistics were used for each outcome by case ethnicity. Relationships between 
outcomes and prescriber demographic data were explored using t-tests and ANOVA for 
continuous and chi-squared for categorical outcomes. Some continuous variables were 
not normally distributed and so were transformed and in one case (age of prescriber), 
put into discrete categories to allow statistical interpretation. All analyses were 
performed using IBM SPSS software. 
5.3 RESULTS  
5.3.1 STUDY POPULATION 
The contact details for prescribers in the trust were obtained and emails sent to all 784 
with an explanatory letter, a demographic data form and the case vignette for 
completion.  The total number of completed replies received was 123 (15.7%), of which 
120 (97.6%) were returned by email and 3 (2.4%) anonymously in the post. Clinical and 
demographic characteristics of prescribers are detailed in Table 45 and 46.  The case 
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vignettes returned were approximately equal for both ethnicities i.e. those where the 
patient was described as white (n= 63 (51.2%)) and black (n=60 (48.8%)). 
 
Respondents often listed several possible antipsychotic treatment options in reply to the 
case study questions, for example olanzapine or aripiprazole or quetiapine or 
risperidone. These were labelled in the order written as antipsychotic 1 or antipsychotic 
2 or antipsychotic 3 or antipsychotic 4 for each outcome i.e. percentage maximum dose 
and type of antipsychotic. 
TABLE 45 CATEGORICAL CLINICAL AND DEMOGRAPHIC 
CHARACTERISTICS OF PRESCRIBERS 
 
Demographic Category Frequency 
n = 123 (%) 
Missing 
Cases (%) 
Gender Male 76 (61.8) 0 
Grade Consultant 50 (40.6)   
1 (0.8) Speciality Trainee 42 (34.1) 
Core Trainee 12 (9.8) 
Foundation Trainee 18 (14.6) 
Ethnicity White 88 (71.5)  
2 (1.6) Asian 18 (14.6) 
Black 8 (6.5) 
Mixed 4 (3.3) 
Other 2 (1.6) 
Chinese 1 (0.8) 
Case Ethnicity White 63 (51.2) 0 
 
 
TABLE 46 CONTINUOUS CLINICAL AND DEMOGRAPHIC 




Mean (Range) Missing 
Cases (%) 
Age (years) n = 115 39.7 (25-65) 8 (6.5) 
Percentage maximum antipsychotic 1, n=122* 42.66 (0.63-100) 0 
Percentage maximum antipsychotic 2, n=28 52.04 (3.13-100) 2 (1.6) 
Percentage maximum antipsychotic 3, n=12 46.69 (6.25-75) 1 (0.8) 
Total percentage maximum, n=120 49.32 (0.63 -175) 3 (2.4) 






Descriptive data for each of the categorical outcomes (high dose, type, polypharmacy 
and route) are listed in Table 47 and continuous outcomes (total percentage maximum 
dose, percentage maximum dose for antipsychotic 1, 2 and 3) in Table 48. Oral SGA 
were the most commonly prescribed type of antipsychotic and most respondents 
avoided using high doses or combinations of antipsychotics. 
 
TABLE 47 OUTCOMES OF CASE VIGNETTE 
 





Type of antipsychotic 1 
SGA 117 (95.1)  





Type of antipsychotic 2 
SGA 23 (18.7) 0 




None  95 (77.2) 
 
Type of antipsychotic 3 
SGA 12 (9.8) 0 
FGA 1 (0.8) 
None 110 (89.4) 
 
Type of antipsychotic 4 
SGA 1 (0.8)  
0 FGA 0 
None 122 (99.2) 
Polypharmacy (more than 
one antipsychotic prescribed) 
No 111 (90.2) 0 
High dose (more than 100% 
BNF maximum) 
No 114 (92.7) 3 (2.4) 
 
Route 
Oral 111 (90.2)  
0 IM 1 (0.8) 






5.3.2.1 TOTAL DOSE (PERCENTAGE MAXIMUM DOSE) 
Percentage maximum dose for antipsychotic 1 and total percentage maximum were 
broadly normally distributed (data were explored through P-P plots, histograms, 
Levene’s and Kolmogorov-Smirnov tests (Field, 2013)).  
 
The mean total doses for black and white patients were 47.7% and 50.9% respectively 
(Figure 13). There were no significant differences in total dose of antipsychotic by case 
ethnicity (p=0.567) (see Table 48).  
 
TABLE 48 TOTAL DOSE AND CASE ETHNICITY 




n Mean  
(% maximum) 
t P 
Antipsychotic 1 Black 60 41.82 0.481 0.632 
White 62* 43.46 
Antipsychotic 2 Black 11* 53.31 -0.196 0.846 
White 15* 51.10 
Antipsychotic 3 Black 4 62.50 -1.804 0.101 
White  9 38.78 
Total Dose Black 59 47.69 0.575 0.567 
White 61 50.89 





















FIGURE 13 TOTAL DOSE (PERCENTAGE MAXIMUM) BY CASE ETHNICITY 
 
The percentage maximum dose for antipsychotic 2 and 3 were not normally distributed, 
even after transformation. A 2-sided t-test is robust enough to allow use for non-normal 
variables if the sample size is large (Lumley et al., 2002). There were no significant 
differences in dose of antipsychotic 1, 2 or 3 by case ethnicity (see Table 48).  
5.3.2.2 HIGH DOSE 




























FIGURE 14 HIGH DOSE ANTIPSYCHOTIC BY CASE ETHNICITY 
 
 
5.3.2.3 CHOICE AND TYPE OF ANTIPSYCHOTIC 
The most frequently chosen antipsychotics were aripiprazole then olanzapine, 
accounting for 82.1% of choices (Figure 15). There were no differences by case 
ethnicity in type (FGA or SGA) of antipsychotic 1 (Figure 16), antipsychotic 2 or 
antipsychotic 3 (Tables 49 and 50). 
 
Fisher’s exact test was conducted on choice of antipsychotic 1, 2 and 3 to overcome the 
problem of small cell sample sizes.  Chi-squared tests were not possible for choice of 
antipsychotic 1, 2, 3 and high dose as more than 20% of some cells had expected 
frequencies of less than five cases. This invalidated the test as it ceased to approximate 
to the chi-squared distribution.  
 
 
47.5% (57) 47.5% (57)












FIGURE 15 CHOICE OF ANTIPSYCHOTIC BY CASE ETHNICITY (1ST 
ANTIPSYCHOTIC LISTED) 
 
* not an antipsychotic 




































2.5% (3) 1.6% (2)












TABLE 49 TYPE OF ANTIPSYCHOTIC 2 
 




3 0 3 
SGA 
 
12 11 23 
Not an antipsychotic 
 
1 1 2 
Total  16 12 28 
Fishers exact test 0.367 (exact significance 2-sided) 
 
 
TABLE 50 TYPE OF ANTIPSYCHOTIC 3 
 




1 0 1 
SGA 
 
8 4 12 
Total 
 
9 4 13 
Fishers exact test 1.000 (exact significance 2-sided) 
 
5.3.2.4 ANTIPSYCHOTIC POLYPHARMACY 
There were no differences in antipsychotic polypharmacy (p=0.37, Figure 17) by case 















TABLE 51 ANTIPSYCHOTIC POLYPHARMACY COMBINATIONS 
 
Polypharmacy combinations N Ethnicity 
Olanzapine and aripiprazole 2 1 black, 1 white 
Olanzapine, aripiprazole and quetiapine 2 1 black, 1 white 
Olanzapine, aripiprazole, quetiapine and amisulpride 1 1 black 
Olanzapine, aripiprazole and amisulpride 1 1 white 
Olanzapine, aripiprazole and trifluoperazine 1 1 white 
Olanzapine, aripiprazole and risperidone 1 1 white 
Olanzapine, aripiprazole and haloperidol 1 1 white 
Haloperidol and zuclopentixol decanoate 1 1 white 
Aripiprazole and quetiapine 2 1 black, 1 white  
Total 12 4 black, 8 white 
44.7% (55) 45.5% (56) 












5.3.2.5 ROUTE OF ADMINISTRATION 
There were no differences in route of administration (p= 0.53, Figure 18) by case 
ethnicity. 
 





5.3.3 PRESCRIBER VARIABLES AND OUTCOMES 
Each prescriber variable (age, gender, grade of staff and ethnicity) was examined to 
determine if associated with the outcomes (total dose, high dose, polypharmacy, type 
and route). 
 
Age was not normally distributed. All transformations were applied (natural log, 





















5.3.3.1 TOTAL DOSE 
Age was not normally distributed but three discrete categories were evident. It was 
divided into these 3 categories (32 or less, 33-44, 45 or more). Mid-aged (33-44 year 
olds) prescribers were more likely to use higher doses (p=0.01). Gender, grade of staff 
and prescriber ethnicity were not significantly associated with total dose (see Table 52). 
 
TABLE 52 TOTAL DOSE AND PRESCRIBER VARIABLES 
 









-1.116 0.27 -17.66 4.93 
Ethnicity 
(white or not 
white) 




























5.3.3.2 HIGH DOSE 
As with total dose, mid-aged prescribers were more likely to prescribe high doses 
(p=0.04). Gender, grade and prescriber ethnicity were not significantly associated with 
high dose (see Table 53). 
 








32 or less 37 0 37  
0.04 33 to 44 35 5 40 
45 or more 34 1 35 
Total 106 6 112 
Gender 
 
Male 69 4 73  
1.00 Female 45 2 47 
Total 114 6 120 
Grade 
 





39 3 42 
Core Trainee 12 0 12 
Foundation 
Trainee 
16 1 17 
Total 113 6 119 
Ethnicity 
 




Asian 16 1 17 
Black 7 1 8 
Mixed 4 0 4 
Other 2 0 2 
Chinese 1 0 1 







5.3.3.3 TYPE OF ANTIPSYCHOTIC 
No association was found between any prescriber variables for type of antipsychotic 
outcomes (see Table 54). 
 
TABLE 54 TYPE OF ANTIPSYCHOTIC AND PRESCRIBER VARIABLES 
 
Prescriber variable Type Total p 




32 or less 0 37 0 37  
0.31 33 to 44 3 38 0 41 
45 or more 2 34 1 37 
Total 5 109 1 115 
Gender 
 
Male 3 72 1 76  
1.00 Female 2 45 0 47 
Total 5 117 1 123 
Grade 
 
Consultant 3 47 0 50  
0.47 Speciality Trainee 2 40 0 42 
Core Trainee 0 12 0 12 
Foundation Trainee 0 17 1 18 
Total 5 116 1 122 
Ethnicity 
 
White 2 85 1 88  
 
0.393 
Asian 2 16 0 18 
Black 1 7 0 8 
Mixed 0 4 0 4 
Other 0 2 0 2 
Chinese 0 1 0 1 









5.3.3.4 ANTIPSYCHOTIC POLYPHARMACY 
Mid-aged prescribers were more likely to prescribe more than one antipsychotic 
concurrently (p= 0.001). Gender, grade and prescriber ethnicity were not significantly 
associated with polypharmacy (see Table 55). 
 
TABLE 55 POLYPHARMACY AND PRESCRIBER VARIABLES 
Prescriber 
variable  




32 or less 37 0 37  
0.001 33 to 44 31 10 41 
45 or more 35 2 37 
Total 103 12 115 
Gender 
 
Male 70 6 76  
0.53 Female 41 6 47 
Total 111 12 123 
Grade 
 





37 5 42 
Core Trainee 12 0 12 
Foundation 
Trainee 
17 1 18 
Total 110 12 122 
Ethnicity 
 
White 83 5 88  
 
0.06 
Asian 14 4 18 
Black 6 2 8 
Mixed 3 1 4 
Other 2 0 2 
Chinese 1 0 1 





5.3.3.5 ROUTE OF ADMINISTRATION 
No association was found between any prescriber variables for route of administration 
outcomes (Table 56). 
 
TABLE 56 ROUTE OF ADMINISTRATION AND PRESCRIBER VARIABLES 
 
Prescriber variable Route Total p 




32 or less 0 35 2 37  
0.22 33 to 44 1 38 2 41 
45 or more 0 31 6 37 
Total 1 104 10 115 
Gender 
 
Male 1 67 8 76  
0.71 Female 0 44 3 47 
Total 1 111 11 123 
Grade 
 
Consultant 1 44 5 50  
 
0.87 
Speciality Trainee 0 39 3 42 
Core Trainee 0 12 0 12 
Foundation Trainee 0 16 2 18 
Total 1 111 10 122 
Ethnicity 
 
White 1 83 4 88  
 
0.10 
Asian 0 15 3 18 
Black 0 7 1 8 
Mixed 0 3 1 4 
Other 0 1 1 2 
Chinese 0 1 0 1 












5.4.1 MAIN FINDINGS 
Antipsychotic prescribing did not differ between black and white ethnicity when tested 
using a theoretical case vignette method.  This study, unlike others previously, 
measured several outcomes of antipsychotic use including dose, antipsychotic 
combination, type and route of administration. The significant limitations of the study 
may have resulted in negative findings. 
 
Most prescriber variables were not associated with any of the outcomes. Prescribers 
aged between 33 and 44 years were more likely to prescribe larger total doses, high 
doses and more than one antipsychotic concurrently. Results may be influenced by the 
greater experience and thus prescribing confidence in this age group but the expectation 
would be that this experience would result in better prescribing. 
 
5.4.2 COMPARISON WITH PREVIOUS STUDIES 
Other studies have used similar methods to determine if treatment of mental ill-health 
differs by ethnicity. Lewis and colleagues (Lewis et al., 1990), in their challengingly 
titled study ‘Are British psychiatrists racist?’, used a case study of a black or white, 
male or female patient to measure effects of gender and ethnicity on a series of 
statements about the assessment, management and treatment of the patient in the case.  
These included three medication outcomes about antipsychotics, antidepressants and 
treatment compliance. White patients were rated by psychiatrists as significantly more 
likely than black to need ‘neuroleptic treatment’ but there were no differences by 
ethnicity for ‘antidepressant treatment not indicated’ and ‘unlikely to comply’. Ten 
years later Minnis and colleagues (Minnis et al., 2001) repeated the study in a similar 
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fashion using a case vignette accompanied by a photograph of a white or black man. As 
Lewis and colleagues had found before, white patients were more likely to have 
‘neuroleptic drug treatment indicated’ than black. So previous studies using similar 
methodology found, as did this study, that black patients were not judged more likely to 
need antipsychotic treatment. 
 
5.4.3 LIMITATIONS 
The case vignette design of this study was similar to that used in two previous studies as 
it contained a comparable level of detail but differed in that the patients in the earlier 
studies had first episode psychotic symptoms not a psychotic relapse. A relapse in 
psychosis may be more likely to be treated with more than one antipsychotic or a high 
dose compared with first episode psychosis where patients are usually antipsychotic 
naive and treated with a single agent.  
 
The return rate for questionnaires was lower than achieved by other studies using 
similar methods - 15.7% compared with 59% (Minnis et al., 2001) and 73% (Lewis et 
al., 1990). The survey was emailed to prescribers, this allowed them to be easily ignored 
or quickly deleted. The questionnaires should not have become ‘junk’ email as they 
were sent from an internal email address which the system would recognise as 
legitimate. Prescribers receive large volumes of unsolicited email perhaps accounting 
for the low response rate. Moreover questionnaires sent out by email usually receive 
responses much lower than those sent out on paper. Despite this, average email return 
rates are around 33% (Nulty, 2008), much higher than reached by this study. Survey 
platforms such as Survey Monkey (www.surveymonkey.com, (Nair & Adams, 2009)) 
are a common way of distributing questionnaires electronically. They are very user-
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friendly allowing rapid completion and return of information and even, with some 
packages, analysis of results. This approach was not used because of financial 
constraints. Respondents to the survey had to complete two documents (the 
questionnaire and demographic form), save them and then email them back. Indeed 
some prescribers’ initial replies were blank as they had not saved the completed forms. 
Anonymous replies could be sent through the post but this required several additional 
steps in the process perhaps accounting for the low postal return rate. The prescribers 
contacted with the questionnaire were largely unknown so there was a lower motivation 
to reply than if surveying colleagues (Nulty, 2008). A reminder email did elicit further 
responses. This is the third such study of its kind so a degree of questionnaire fatigue 
may have set in, reducing the return numbers. The prescribers’ ethnicity was requested 
directly whilst previous studies (Lewis et al., 1990; Minnis et al., 2001) either did not 
collect any respondent ethnicity data or collected indirect indicators i.e. medical school 
of graduation. This was due to a concern that inquiring about ethnicity would reveal the 
principal reason for the study and consequently affect outcome. Despite this, a small 
proportion (1.7% (Minnis et al., 2001)) of their respondents still guessed correctly or 
implied they had guessed by replying but refusing to participate (5.2% (Lewis et al., 
1990)).  
 
Some respondents may have known or suspected the reason for the survey but none 
informed me that they had deduced the purpose. Understandably (given the explanatory 
letter) many asked to be informed of the study’s intention when collection was 
complete. Others were worried that the survey was some sort of prescribing test set by 
the trust to measure prescribing competence and were anxious to provide ‘correct 
answers’. Despite this level of suspicion the prescribers’ ethnicity (despite the risks of 
 212 
study unmasking) was still requested to test comments by ethnic minority prescribers 
that they purposely prescribed differently by ethnicity.  
 
As in earlier chapters, classification of prescriber ethnicity using the Office of National 
Statistics groups masked the heterogeneity of the people in these categories and could 
have affected the results. Using a greater number of classifications of ethnicity may 
have resulted in a different outcome i.e. prescriber ethnicity could have been associated 
with dose, high dose, type of antipsychotic, polypharmacy or route of administration. 
 
A small amount of prescriber demographic data variables were missing. Age was most 
likely to be omitted then ethnicity and lastly grade of staff. It may have been that some 
of this information was personally sensitive or simply missing because of lack of 
attention by those completing the form. Antipsychotic polypharmacy results may have 
been due to prescribers not indicating on the questionnaire that their drug choices were 
alternatives to each other not additions. 
5.5 CONCLUSIONS 
Despite comments from ethnic minority prescribers rebutting the results of previous 
studies, this theoretical study of prescribers’ attitudes to antipsychotic prescribing by 
ethnicity yielded supporting results. That is that antipsychotic prescribing, when tested 
in both clinical and hypothetical studies, did not differ for black and white ethnicities. 
However it is important to note that the significant limitations of the study may have 
resulted in negative findings. 
  
 213 
CHAPTER 6   SUMMARY, CONCLUSIONS AND RECOMMENDATIONS 
6.1 SUMMARY OF THESIS AND CONCLUSIONS 
Prescribing of antipsychotics in patients of different ethnicities has been the focus of 
this thesis. The results of a multicentre study examining these issues for black and white 
patients separately, all ethnicities combined and the effects of each centre on study 
outcomes have been evaluated and reported. As well as this medical prescriber attitudes 
to prescribing by ethnicity using a case vignette have been explored. The results of these 
investigations did not find differences in prescribing by ethnicity in either real-life 
(clinical) and simulated (theoretical) circumstances. That is not to say that some centres 
do not have poorer prescribing by ethnicity that requires remedial action, but overall 
total data analysis showed no important differences. The significant limitations of the 
studies may have resulted in negative findings. 
 
Defining ethnicity can be difficult, and sometimes controversial. This is because few 
people have a single genetic identity, ethnicity is a fundamental part of most people’s 
individuality and the history of abuse by ethnicity. The description of ethnicity has 
developed from the collection of merely factual data i.e. country of birth or nationality 
to more complex descriptions encompassing heritage and national identity. Inevitably 
compromises are made to allow categorisation, masking heterogeneity of people in 
these categories. 
 
Ensuring all ethnic groups are involved in research studies is important for the 
generalisability of results and fairness of treatment. Research study abuses such as the 
Tuskegee syphilis study (Centers for Disease Control and Prevention, 1997) have 
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affected trust in researchers and greater efforts to engage and recruit ethnic minorities 
are, finally, being recognised as important in study outcomes. Accurate measurement of 
ethnicity is important to ensure health services are equitable and the self-assigned 
systematic and mandatory collection of ethnicity data by the UK NHS has allowed this 
to occur. Poverty and health inequality are strongly associated and ethnic minorities are 
overrepresented in lower socioeconomic groups. But not all health inequality within and 
between ethnic groups can be attributed to social groupings. 
 
Treatment of mental illness differs for ethnic minorities. Many reports, investigations, 
public enquiries and surveys have been conducted documenting differences in referral 
to specialist mental health services, admission rates to hospital, detention under the 
Mental Health Act and seclusion whilst in hospital. This is particularly so for black 
patients compared with white. Could this be because rates of psychosis and 
schizophrenia are much higher for black patients? Differences in symptom expression 
and presentation, social factors, routes of admission to hospital and racism are all 
suggested causes. Whatever the social and environmental causes, there is still some way 
to go to understand these ethnic variations. 
 
Research, predominantly from the US, showing differences in prescribing of 
antipsychotics for ethnic minorities raised concern in the UK that there may be 
prejudicial prescribing of antipsychotics. These suggested differences included use of 
high doses, more frequent use of older drugs and depot formulations, particularly for 
black compared with white patients. Ethnic groups may metabolise antipsychotics 
differently because of enzymatic genetic polymorphism. However, with the possible 
exception of Asian peoples, an individual’s own metabolising capacity is probably a 
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more important factor than their ethnicity alone. Nevertheless patients, carers and 
official reports demanded investigation into any potential differences in prescribing of 
antipsychotics by ethnicity. 
 
The multicentre study of antipsychotic prescribing of inpatients in eight UK mental health 
trusts conducted in this research programme did not find differences by ethnicity in dose, 
high dose, polypharmacy prescribed and polypharmacy administered, type of 
antipsychotic, route of administration, clozapine use and cost of antipsychotic treatment. 
However there were significant limitations as described in detail in each chapter and 
Section 6.2. This study fulfilled calls from reports into mental health services and 
ethnicity to investigate prescribing practices in the UK because of differences found in 
antipsychotic prescribing and ethnicity research studies (see Table 3). Most concerns 
about prescribing have been in black compared with white patients. These two ethnic 
groups have the largest proportions of inpatients in UK NHS mental health trusts and so, 
for these reasons, this was the first analysis. The outcomes were adjusted for over twenty 
different confounding factors and analysed in several ways (primary outcome-complete 
cases, complete cases, black compared with white ethnicity (Chapter 2), including centre 
as a confounder (Chapter 3), all ethnicities (Chapter 4)). Differences were not found by 
ethnicity in these adjusted analyses. However higher order grouping into broad ethnic 
categories can mask the heterogeneity of people and may conceal important differences 
in the results. 
 
Individual centre analysis for black and white patients (see Chapter 3) developed the 
Chapter 2 study by investigating variation in prescribing practice by centre to determine 
if prescribing practice differs between NHS Trusts not just within these ethnic groups.  
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This study did reveal differences in prescribing by ethnicity, particularly for one centre. 
These effects included higher doses, polypharmacy, greater use of FGAs and higher costs. 
For some of these outcomes it was not possible to adjust results for potential confounders 
because of small sample sizes and missing data. All centres where differences were found, 
whether adjusted or not, were informed of their results so enabling them to investigate 
reasons for any differences and make changes where needed.  
 
Analysis of data for all ethnicities in Chapter 4 develops the studies in Chapters 2 and 3 
by investigating a larger sample (through the inclusion of proportionally smaller ethnic 
groups) to discover if prescribing varies by these ethnicities. It did not find differences in 
antipsychotic prescribing although there were significant limitations. The study did find 
many variables associated with the study’s outcomes. Higher doses and combinations of 
antipsychotics were used for patients who were likely to have a more severe illness i.e. 
were detained, had longer lengths of admission and more previous admissions. Larger 
weight, not taking clozapine, using a depot antipsychotic and being poorly compliant with 
medication were also associated with these outcomes. The use of FGAs was associated 
with lower doses possibly because of the use of the percentage maximum dose method of 
expressing dose results. As expected and reported in previous studies, polypharmacy and 
high doses were closely related. SGAs were used for patients who had taken fewer 
previous antipsychotics and did not take (or need) anticholinergic medicines. Oral 
medicines were used for patients who were probably less chronically ill i.e. younger, not 
detained, had had fewer previous admissions, were taking a lower dose, did not have 
schizophrenia and taking a SGA. Some of these relationships were unexpected, for 
example lower doses and FGA, but most could be hypothesised rationally. 
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After publication of previous studies on antipsychotic prescribing and ethnicity, some 
ethnic minority prescribers informally challenged the results, suggesting that this practice 
was driven by clinical need, not inherent bias. The validity of these views were tested by 
surveying the prescribing intention of doctors in a single trust, using a case vignette 
method. This built on earlier studies by exploring antipsychotic prescribing by ethnicity 
using a different research design. The study did not find differences in antipsychotic 
prescribing intention by ethnicity for dose, high dose, polypharmacy, type and route of 
administration outcomes were found although there were significant limitations.  
 
Overall the clinical and theoretical studies in this thesis did not show differences in 
antipsychotic prescribing by ethnicity but there were significant limitations in study 
design and analysis. 
 
6.2 IMPROVEMENT OF STUDIES IN THESIS 
Description of the evolution of the studies in this thesis are described in Chapters 2 and 
5. Both were helped immeasurably by examining previous research work (see 
Appendices 2, 3 and 4), preliminary studies in this field (Appendices 6 and 9) and 
comments from peer-reviewers during the publication process. 
 
The clinical studies were limited by several factors that may have produced the negative 
findings - their cross-sectional design, broad categorisation of ethnic groups, smaller 
numbers of some ethnic groups (i.e. Asian, mixed, Chinese/other), no assessment of 
severity of mental state (CGI-S was collected previously but not measured at the time of 
antipsychotic prescription so was not a useful measure), some missing data, possible 
overadjustment of outcomes with multiple variables in regression models and an 
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inpatient population only. Despite these there was a large total sample size, multiple 
centres, collection of a large number of confounding variables, missing data was 
accounted for statistically and data analysed in several ways. 
 
Changes to the clinical studies that, with the benefit of hindsight, could have improved 
methodology include using more categories of ethnic group e.g. black African, black 
Caribbean, adding centres with low proportions of ethnic minority groups (to see effect 
of prescribing in a non-multicultural environment), powering the study so individual 
centre effects could be detected, using multilevel modelling for analysis of data by 
centre to measure cluster effects, collecting more confounding variables to improve the 
predictive power of regression models, extending the sample to include community 
patients, ensuring data collectors filled in the study forms properly, ensuring outcomes 
were not subject to the effects of overadjustment and using a different study design.  
 
For the case vignette study in Chapter 5 greater efforts could have been made to 
improve the questionnaire response rate by changing the way they were distributed, 
increasing the numbers of prescribers surveyed and having a more rigorous follow-up 
process. Improved validity of the clinical and theoretical studies with these changes 
would have required more time and consequently greater research funds. 
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6.3 CONTRIBUTION OF THESIS TO FIELD OF ANTIPSYCHOTIC 
PRESCRIBING AND ETHNICITY 
Some of the studies in this thesis have contributed substantially to the field of 
antipsychotic prescribing and ethnicity. The study described in Chapter 2 was the 
largest UK multicentre study of antipsychotic prescribing in black and white patients at 
the time of data collection and publication (there has since been a larger study by Das-
Munshi et al, 2018). The previous studies at the time did not include such a large 
sample and geographical spread and so the findings were therefore limited. Other UK 
studies of antipsychotics and ethnicity were also much smaller, older, single-centred and 
measured fewer prescribing outcomes and confounding variables than described in this 
thesis (Connolly et al., 2007; Lloyd & Moodley, 1992; Shubsachs et al., 1995; Stanley 
& Doyle, 1993; Tunnicliffe et al., 1992). The studies in Chapter 2 and 4 were published 
(see Appendices 14 and 15) in peer-reviewed journals and have been cited by other 
researchers in this field (Cook et al., 2015; Hassan et al., 2013; Takeshita et al., 2014; 
Thompson et al., 2016). 
 
The case vignette study of theoretical choice of antipsychotic by ethnicity in Chapter 5 
updated previous studies and took the premise further (Lewis et al., 1990; Minnis et al., 
2001). Previous studies had only analysed ‘antipsychotic use indicated’ whilst this study 
examined several outcomes of antipsychotic prescribing. This study was also published 
(see Appendix 20). 
 
The study was funded by the Equality and Human Rights Commission (formerly the 
Commission for Racial Equality at the time of study initiation). This was not via a grant 
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but a direct approach with a request to undertake the study as they recognised the 
importance of earlier work in this field and the value of a multicentre study of all 
ethnicities. 
6.4 RECOMMENDATIONS  
6.4.1 RECOMMENDATIONS FOR CLINICAL PRACTICE 
Overall antipsychotic prescribing was not affected by ethnicity in the studies described 
in this thesis but analysis of data by individual centre did reveal some differences. The 
significant limitations of the study may have resulted in negative findings. It is 
recommended that all providers of mental health services monitor antipsychotic 
prescribing by ethnicity and, if differences are found, investigate and remedy these 
discrepancies. 
 
6.4.2 RECOMMENDATIONS FOR PRESCRIBERS 
The UK studies described in this thesis found that antipsychotic prescribing does not 
vary by ethnicity for inpatients. It is recommended that prescribers reassure patients and 
carers that concerns about this issue have been recognised and investigated but that 
further studies are needed to overcome the limitations of research already undertaken. 
 
Prescribers are encouraged and educated to avoid, where possible, the use of high doses 
and combinations of antipsychotics and, where feasible, use clozapine in treatment-
resistant illness and long-acting injections where non-compliance is suspected. 
 
6.4.3 RECOMMENDATIONS FOR FUTURE RESEARCH 
The research studies undertaken for this thesis were thorough and, within the limits of 
their inherent design flaws, well conducted. A different design could have resulted in a 
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more rigorous study, for example using a prospective cohort study. This would allow 
assessment of illness severity on initiation of an antipsychotic – a limitation of this 
study design. Also using different methods of assessing dose, for instance CPZe or 
defined daily doses, could be employed as were done in earlier studies (see Appendix 
6), expanding the ethnic group categories to allow analysis of within not just between 
group differences and adjusting for fewer cofounding factors to avoid overadjustment.  
Completion of a meta-analysis of antipsychotic prescribing in ethnic minorities, 
incorporating the studies in Appendix 3, would be a robust method of analysing 
antipsychotic use by ethnicity. A meta-analysis has been performed before but only 
examined two outcomes (antipsychotic use and type) in a community sample (Puyat et 
al., 2013). 
 
Extending the reach of the study to a greater number of centres and including 
community patients could be achieved by adding ethnicity and antipsychotic prescribing 
to the audit topics of POMH-UK. This is because most NHS mental health trusts, along 
with private facilities and charitable institutions, are members of this quality 
measurement and improvement body. This would also allow collection of data from 
centres where ethnic groups are in the minority, in comparison to these studies where 
patients were recruited from NHS trusts with the largest proportions of ethnic minority 
patients. In addition re-auditing the centres in this study would be advised, particularly 
those where differences by ethnicity have been found, to determine if changes to the 
culture and quality of prescribing have occurred. 
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APPENDIX 2 CONFOUNDERS COLLECTED BY OTHER STUDIES OF 




(Dunn & Fahy, 1990) Receipt of an 
antipsychotic. 
No regression analysis. Chi-squared and 
t-tests by ethnicity and gender 
calculated. 
(Flaskerud & Hu, 1992) Treatment type. Age, gender, ethnicity, diagnosis, 
primary language, socioeconomic status 
(income and dependents), therapists 
discipline (professional/non-
professional), treatment modality 
(therapy with/without medication). 
(Jann et al., 1992) 
 







Haloperidol dose, haloperidol metabolite 
levels, age by ethnicity, weight. 
(Lloyd & Moodley, 1992) Type and dose of 
antipsychotic 
medication. 
Age, gender, ethnicity, diagnosis, 
section status. 
(Lin et al., 1996) Dose of 
antipsychotic 
Age, gender, ethnicity, diagnosis, type, 
dose, other psychotropics. 
(Segal et al., 1996) Antipsychotic 
received; dose 
(in CPZe); 
number of doses; 
number of 
injections. 
Ethnicity, psychotic diagnosis, GAS 
score (severity of psychiatric 
disturbance), dangerousness, psychiatric 
history, physical restraint used, hours 
spent in emergency service, clinicians 
efforts to engage patient in treatment.  
(Delbello et al., 2000) Use of 
antipsychotic 
treatment. 
No regression just comparison of groups 
for age, gender, diagnosis, length of 
hospitalisation. 
(Walkup et al., 2000) Dose; factors 
predicting dose. 
Ethnicity, length of stay, age, voluntary 
admission, weight, dangerousness, 
depression and substance misuse co- 
morbidity, BPRS (activation, 
withdrawal, depression/anxiety, 
paranoia subscales). 




Age, education, marital status, 
race/ethnicity, psychiatric co-morbidity 
(Axis 1 conditions), psychiatrist visits in 












patterns in a 
prison setting. 
Gender, age, race/ethnicity, violent 
offence status. 




illness; intake of 
psychiatric 
drugs. 
Age, race/ethnicity, country of birth, 
language (knowledge and 
understanding), marital status, 
employment, psychiatric illness, taking 
psychotropic drugs, housing, migration 
because of political/religious instability 
or war, family or friends in Sweden, 
desire to leave Sweden, need for talking 
treatment but not sought, as many or 
more immigrants than Swedes in 
residential area. 
(Owen, 2001) Type of 
antipsychotic 
prescribed. 
Centre, age, gender, ethnicity, marital 
status. 
(Covell et al., 2002) Type, route, 
polypharmacy. 
Gender, age, race/ethnicity, marital 
status, education. 




Race/ethnicity, gender, smoking status, 
age, hospital centre (there were 2 in the 
study), long hospitalisation (>3 years), 
weight (> 90kg), depot antipsychotics, 
high potency antipsychotics, 
carbamazepine or phenytoin use. 




response = 40% 
reduction in 
PANSS. 
Age, gender, race/ethnicity. 
(Fleck et al., 2002) Antipsychotics 
prescribed; 
compliance. 
Ethnicity, gender, weeks of follow-up, 
time in remission, time in psychosis 
during follow-up. 





Age, gender, service type e.g. inpatient, 
emergency room, provider setting, social 
security receipt, ethnicity, depot 
treatment. 
(Lelliott, 2002) Antipsychotic 
polypharmacy. 
Age, gender, bed type (forensic, 
rehabilitation, acute), polypharmacy, 
section status. diagnosis, ethnicity. 
(Moore et al., 2002) Psychotropic 
drug use. 







(Copeland et al., 2003) Type of 
antipsychotic 
prescribed. 
Age, gender, substance misuse, 
diagnosis, race/ethnicity. 
(Daumit et al., 2003) Type of 
antipsychotic 
prescribed. 
Age, gender, ethnicity, payment source 
(insurance/Medicare), geographic 
region, urban vs. rural practice location, 
physician practice setting, psychiatric 
diagnosis. 
(Kreyenbuhl et al., 2003) Dose, type, 




Age, gender, ethnicity, education, state, 
diagnosis, medical co-morbidity. 




Age, gender, ethnicity, income, 
insurance type, known to psychiatric 
services, mood anxiety and attention 
deficit hyperactivity disorder 
comorbidity. 






Race/ethnicity gender, age, regional 
location, other mental illness, co-
morbidities, prior antipsychotic use 
(previous clozapine use, previous depot 
use, previous SGA, number of previous 
antipsychotics in the last year), 
resources use (number of outpatient 
medical visits, emergency department 
visits, inpatient hospital days in last 
year). 








Diagnosis, age, race/ethnicity, bipolar 
type, concurrent anxiety or substance 
misuse or any concurrent diagnosis. 





day in use of 
clozapine. 
No regression only correlation 
coefficient and scatterplot. Looked at 
relationship between delay in clozapine 
use and gender, race/ethnicity, duration 
of illness separately. 




Age, education, gender, race/ethnicity, 





(Arnold et al., 2004) Effect of 
gender/ethnicity 
interaction on 
antipsychotic dose, high 
dose, route, type, 
polypharmacy. 
Age, ethnicity, education, 
income level, rating scale scores 




Dose; co-prescription of 
clozapine and 
olanzapine with other 
antipsychotics. 
No regression analysis only chi- 
squared tests done to compare 
co-prescription between paired 
ethnic groups. Demographics 
collected = age, race/ethnicity, 
gender. 
(Van Dorn et al., 2005) Effect of ethnicity and 
criminal arrest history 
on access to SGAs. 
Gender, race/ethnicity, 
insurance, initial treatment 
setting, no visits with 
psychiatrist, GAF rating scale, 
history of substance misuse, 
history of violent behaviour, 
history of arrest, psychotic 
symptoms, compliance. 
(Shi, 2007) Patient characteristics 
and antipsychotic use 
patterns for oral and 
depot antipsychotics. 
Age, gender, ethnicity, 
education, marital status, veteran 
status, insurance type, diagnosis, 
rating scales (PANSS, 
MADRAS, GAF), psychiatric 
hospitalisations in last year, 
arrest history, suicidal 
thoughts/attempts, substance 
misuse. 





Age, gender, race/ethnicity, 
insurance status, family income, 
employment status, diagnosis. 
(Grossman et al., 2008) Functional genetic 
variation in drug 
metabolising enzymes 
and effect on dose, 





Age, gender, race/ethnicity, 
weight, PANSS rating scale, 
smoking status, severe adverse 
effects, tardive dyskinesia status, 
antipsychotic use before study 
initiation, years since started 
treatment with antipsychotics, 
substance misuse, drug 






(Wheeler et al., 2008) Antipsychotic 
polypharmacy, type, route, 
dose, clozapine use at 2 
time points (baseline time 
1 in 2001 and time 2 in 
2004). 
Age, ethnicity and gender. 
(Busch et al., 2009b) Adherence to antipsychotic 
quality standards for 
receipt, continuity and 
dose. 
Age, gender, substance misuse, 
diagnosis, race/ethnicity, fiscal 
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Black patients were more likely than 
white to receive major tranquillisers 
(59% vs. 38%, p<0.01). Immigrant 
patients (black and white) were more 
likely than white British to receive 
intramuscular medication (71% vs. 49%, 
p<0.025). 
Difference in major 
tranquilliser use not 
owing to diagnosis. 
Unusual ethnicity 
classification. Black-
born British patient 







Survey USA Dose No significant difference in dose by 
ethnicity (values and statistics not listed, 
Asian vs. white or black). 
Study examining EPSE, 
dose secondary outcome. 







Survey USA Dose (CPZe) Asian patients treated with lower 
maximum (p < 0.05) and discharge (p< 
0.02) doses than whites even after 
adjustment for body weight. 
None 










No difference by ethnicity (ANOVA 
test) in oral or IM dosing of 
antipsychotics.  Polypharmacy was less 
likely in Hispanics than other ethnic 
groups (p<0.05). 
Does not state if 
polypharmacy less likely 
in Hispanics than blacks or 
Anglos or both these 
groups. 
(Price et al., 
1985) 
397 White, black Survey USA Predictors of use of 
depot fluphenazine 
decanoate vs. oral 
antipsychotics 
Black patients were 2.2 times more likely 
than white to be receiving fluphenazine 
decanoate depot, p< 0.001 (controlled for 




100 White, black Survey South Africa Dose Dose for whites 381mg, blacks 92mg 
difference not tested statistically. 









UK Receipt of an 
antipsychotic 
Black men were more likely to be given 
an antipsychotic than white men (90% 
vs. 63%, p<0.001). 
No differences between 
black and white women. 
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Authors Number Ethnicity Type of study Location Medication 
Outcomes 
Results Comments 











No difference in initial & cumulative 
dose by ethnicity. Afro-Caribbean 
patients more likely than non-Afro-
Caribbean to be prescribed high doses 
(i.e. > 2000mg CPZe, p<0.03) and depots 
(p<0.01). 









Survey USA Receipt of 
medication 
Black patients more likely than whites to 
be prescribed medication in psychosis 
(OR 1.44 (95% CI 1.28, 1.61, p< 
0.00001). 
None. 





















Hispanic patients were treated with 
higher doses than Caucasian and black 
(p<0.05). Black, Caucasian and Hispanic 
patients had higher doses than Chinese 
(p=0.01). 
Small numbers of non-






Survey UK Receipt, route, 
dose, 
polypharmacy 
Black patients more likely than white to 
receive a depot and oral antipsychotic 
(40.5% vs. 20.8%, p=0.019) but not 2 
oral antipsychotics. Black patients on a 
depot (but not oral) received higher 
median doses than white patients (180mg 
vs. 60mg CPZe, p=0.04). Black patients 
were as likely as white to receive an 
antipsychotic (OR 1.87, 95% CI 0.69, 










Survey UK Dose of depot 
antipsychotic 
No significant difference in dose by 







Survey UK High dose 
(>1000mg 
CPZe) 
No difference in high dose by ethnicity. 1 patient black, 1 mixed 
(black Asian) 
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173 Black, white Survey USA Antipsychotic 
dose 
Black patients received higher doses 
(haloperidol equivalents) than white 
(29.9mg vs. 15.3mg, p=0.001). 
None 







USA Dose (CPZe), 
depot use 
Non-white patients were more likely than 
white to have a higher dose of 
antipsychotic at baseline (p<0.001), a 
higher average dose during the study 
period (p<0.012) and a depot at baseline 
(p<0.001).  
Study of risk factors for 
tardive dyskinesia. Non-
white patients were almost 
all black (100/103 = 97%). 
Effect of ethnicity on dose 
was due to depot use. 
 









Mean daily dose (CPZe) was greater for 
African-Americans vs. white (389 mg 
and 280mg, p=0.05) Proportion of 
patients on ‘prn’ neuroleptics did not 









Survey UK Dose (CPZe) Afro-Caribbean patients were more 
likely than Caucasians to be taking 
higher doses of antipsychotics at 4 
weeks (882mg vs. 527mg, p<0.05) but 















Mean maximum actual and standardised 
CPZE doses; Hispanic (p<0.009) and 
Asian (p<0.002) lower than Anglo (no 
difference between Hispanic and Asian). 
Mean stabilised actual and standardised 
CPZE doses; Hispanic (p<0.036) but not 
Asian (p<0.056) lower than Anglo (no 
difference between Hispanic and Asian). 
No differences between groups on use of 
anticholinergic medication. 
Follow-up study of Ruiz et 
al, 1996. 
























Survey USA Dose of 
antipsychotic 
Non-Asian ethnicity associated with 











USA Dose of 
clozapine 
Korean-Americans were treated with 
lower daily doses of clozapine than 
Caucasians (366mg vs. 532mg, 
p<0.025). Plasma levels were also lower 
for Korean-Americans (212ng/L vs. 
376ng/L, p<0.05) 
Korean-Americans showed 
greater change in BPRS 
than Caucasians (48% vs. 
37.1%, p<0.05). 














Hispanic and Asians had lower actual 
(p<0.001) and standard (p<0.01) CPZe 
doses than General ethnicity. No 
difference in dose between Hispanic and 
Asian. Asians prescribed anticholinergic 
medication more often than Hispanic or 
General (p=0.0001), Hispanic vs. 
General not reported. 
General category poorly 
defined, 34 born outside of 
US. 





















African American patients were as likely 
to receive an antipsychotic (48% vs. 
35%, OR 1.27 (no CI), p=0.71) as non-
African Americans but a greater number 
of antipsychotic doses (3.1 vs.2.2, 
p=0.02); a higher 24-hour dose of 
antipsychotics (1321mg vs. 825mg, 
p<0.001); depot fluphenazine (8% vs. 
2%, p< 0.05); and a greater number of 
antipsychotic injections (p<0.04). 
 
Results were African 
Americans compared with 
non-African Americans. 
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719 White, African 
American, other  
Database 
study 
USA Receipt of an 
antipsychotic, 
dose, high dose 
(> 1000mg 
CPZe), length of 
treatment, depot 
use, use of 
anticholinergic 
agents 
No differences by race in receipt of an 
antipsychotic, dose, length of treatment 
and depot use. Minority patients more 
likely to be taking a high dose (27.4% vs. 
15.9%, p=0.01) and to be taking 
prophylactic anticholinergic agents (64% 
vs. 40.3%, p= 0.003) than Caucasians 
when inpatients. 





200 White, African 
American, 
Asian, Hispanic 
Survey USA Prescribing of 
an antipsychotic 
No significant difference African 
American and white (6% vs. 4.6%, 
p<0.05). 
None 





Survey USA Psychotropic 
use in children 
aged 5-14 years 
Caucasians (C) were twice as likely to be 
treated with an antipsychotic than 
African Americans (AA) (0.44% vs. 
0.21%, ratio AA/C 1:2.1, no p value). 
None 
(Ruiz et al., 
1999) 
204 Black (African 
American), 
white, Hispanic 
Survey USA Dose of 
antipsychotic 
Mean dose in black and white patients 
was higher than in Hispanic patients 
(16.2mg, 15.5mg and 7.6mg 
respectively, no statistical test of 
difference). Similarly weight/dose ratios 
of black and white patients were higher 
than for Hispanics (p=0.0001 and 
p=0.001 respectively). 
Doses converted to 
haloperidol equivalents. 









USA Use of 
antipsychotic 
treatment. 
African American patients were more 
likely than Caucasian to receive an 
antipsychotic (86% vs. 45%, p = 0.006). 
Adolescents with bipolar 
disorder. Only14 African 






Survey USA High dose African American patients more likely to 
be prescribed high doses (>1000mg 
CPZe) OR 2.67, p≤0.05 (no CI reported). 
This effect was not significant after 
controlling for depot use. Depot use 
increased risk of high dose by a factor of 
30. 
High doses in African 
American patients not 
explained by symptom 
severity at discharge.  
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154 Black, white, 
other 
Survey USA Type 
(risperidone or 
olanzapine use 
vs. non-use)  
White ethnicity associated with 
prescription of risperidone or olanzapine 
compared with other ethnicity (OR 0.11, 
95% CI 0.02, 0.73) but not black (OR 






3750 Black, white, 
Hispanic 
Survey USA Type of 
antipsychotic 
Black (but not Hispanic) patients 
prescribed SGAs less frequently than 






34,925 Black, Hispanic, 
?white (not 
listed)) 
Survey USA Antipsychotic 
polypharmacy, 
dose 
Doses for black and Hispanic patients 
were not more or less than 
recommended. Black patients, but not 
Hispanic were less likely than ?white to 
be prescribed more than one 
antipsychotic (OR 0.833, 95% CI 0.748, 
0.928). 
Depot information not 










Survey USA Type of 
antipsychotic 
prescribed 
Caucasian patients were more likely to 
receive SGAs than non-Caucasian 


























African-American patients more likely to 
receive a depot antipsychotic than whites 
(p=0.05; regression analysis controlling 
for clinician rated-compliance black vs. 
white, OR 1.5, p<0.05, no CI quoted). 
Estimated compliance differed between 3 
ethnicities (p<0.05). Black patients less 
likely to receive SGAs than whites 
(p<0.001). 
Vs. other ethnicities not 
reported 
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African-American patients were more 
likely to receive high dose antipsychotics 
(39% vs. 25% (white) vs. 47% (other), 
p<0.05). Other ethnicity patients were 
more likely to receive low doses of 
antipsychotics (43% vs. 21% (white) vs. 











USA Dose No difference by ethnicity in oral or 








Survey USA Type, route, 
polypharmacy 
Latino patients compared with non-
Latino patients were less likely to be 
prescribed a SGA (OR 0.54, no CI, p< 
0.05) and polypharmacy (OR 0.49, 
p<0.05), no data on depot use. Caucasian 
patients were more likely than non-
Caucasian to receive a SGA (OR 1.75, 
p<0.05) and less likely to receive a depot 
(OR 0.47, p<0.005), no data on 
polypharmacy. 
None. 










African American patients with 
schizophrenia high dose vs. white (not 
including high-potency antipsychotic 
variable) OR 1.55 (95% CI 1.02, 2.34, 
p≤0.05). 
 
High dose not associated 
with race in patients 
without schizophrenia & in 








Cohort USA Dose in CPZe African-Americans had a lower log dose 
vs. Caucasians (log -0.140, p<0.01)). 
African Americans on high potency 
antipsychotics had a higher log dose vs. 
Caucasians (log 0.269, p<0.001). 
Three models described, 
race not a factor in two of 
the three. 
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African American patients were more 
likely to receive antipsychotics for a 
significantly greater period of follow-up 
(p<0.007) and FGA (p<0.05). 
 
Poorer compliance for 
black patients compared 
with white (p=0.01). This 









RCT USA Dose No difference by ethnicity in baseline 
standardised (for weight) antipsychotic 
dose. 
Pilot study, non-Hispanic 
group not homogenous, 
consisted of Indian, 
Filipino, ‘American’, 








Survey USA Type, route Caucasian patients were significantly more 
likely than African-American to receive 
clozapine (OR 1.66, 95% CI 1.26, 2.18) 
and risperidone (OR 1.28, 95% CI 1.6, 
1.55). African-Americans were more likely 
to receive depot antipsychotics (p=0.001) 
and a ‘traditional’ antipsychotic (p=0.001) 
than Caucasian patients. 
White patients received 
mental health services 
more often and for 
longer, were more likely 
to have ICU management 
and less likely to have an 
emergency room contact 













Black patients visited psychiatry or 
primary care providers for antipsychotic 
prescription fewer times than white (13.3 
vs. 20.6, p<0.05). Hispanic no different to 
white. 
Difference accounted for 
by psychiatry providers 
as analysis of primary 
care providers showed no 
difference by ethnicity in 
antipsychotic 
prescription per visit. 
(Lelliott, 
2002) 
3576 Black, white, 
Asian, other 
Survey UK Antipsychotic 
polypharmacy 
and high dose 
No effect of ethnicity on either outcome. None.  






USA Type of 
antipsychotic 
prescribed 
White patients were more likely to receive 
a SGA than non-white (OR 2.335, 95% CI 
1.271, 4.365, p= 0.01). 
None 
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132 East Indian, 
African, mixed 
Survey Trinidad Psychotropic 
drug use 
No differences in prescribing of 
antipsychotic medication by ethnicity 
(p=0.390). 
African and East Asian 
patients were prescribed 
SSRI-type 
antidepressants less often 
than mixed ethnicity 
patients (p=0.005). 
(Copeland 








Hispanic (OR 0.77, 95% CI 0.73, 0.81) 
and African American (0.81, 95% CI 0.78, 
0.84) patients less likely to receive a SGA 
than white. African American (OR 0.35, 
95% CI 0.31, 0.39) and Hispanic (OR 
0.33, CI 95% 0.26, 0.41) patients less 











USA Type of 
antipsychotic 
prescribed 
In 1992-1994, 1995-1997 and 1998-2000 
African American patients were less likely 
than white patients to receive SGA for all 
diagnoses (1998-2000 OR 0.88, 95% CI 
0.78, 0.97). 
In 1992-1994, 1995-1997 and 1998-2000 
Hispanic patients had an equal chance of 
SGA use compared with white patients for 













African American patients were more 
likely than white and Hispanic to receive 
antipsychotic polypharmacy (p<0.001). 
None 
(Kreyenbuhl 




Survey USA Dose, type, 
route, use of 
anticholinergic 
medicines 
Black patients more likely to receive depot 
(OR 2.91, 95% CI 1.68, 5.01, p<0.0001); 
less likely to receive SGA (OR 0.24, 95% 
CI 0.12, 0.46, p=0.0001); more likely to 
receive anticholinergic medications (63% 
vs. 48%, p=0.008) compared with white 
patients.  Doses did not differ by ethnicity. 
Out-patient population. 
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Black patients less likely to be prescribed 
SGAs including clozapine (p<0.05). Black 
patients were more likely to be prescribed 
FGA (OR 1.64, 95% CI 1.27, 2.12, 
p=0.0002), anticholinergic agents (p<0.05), 
depots (p<0.05) and to be non-adherent 
(p<0.05). 
Difference in FGA 
use by ethnicity 











2 x 10 
month time 
periods. 






African American patients less likely than 
white to receive olanzapine (OR 0.614, 95% 
CI 0.495, 0.761, p<0.001). Effect was 
consistent over 2 x 10 month periods. 
Mexican Americans less likely than white to 
receive olanzapine in 1st 10-month period (OR 












No difference by race/ethnicity in route of 
administration or dose after regression 
analysis. 














USA Type of 
antipsychotic 
prescribed 
Non-Caucasian and Caucasian patients were 
as likely to be prescribed a SGA (86% vs. 









535 Black, white, 
Hispanic 
Survey USA Frequency of 
antipsychotic 
prescribing, type of 
antipsychotic 
White patients (OR 0.289, 95% CI 0.157, 
0.533) were less likely than black and 
Hispanic to be prescribed an antipsychotic. 

















Survey USA Predictors of 
conventional 
antipsychotic use 
African Americans were more likely to 
be prescribed a conventional 
antipsychotic (OR 3.40, no CI, p<0.001) 
than Caucasians. African American and 
other patients were more likely to be 
taking conventional antipsychotics (OR 










UK Theoretical time 
delay in use of 
clozapine 
Clozapine use not delayed by ethnicity 
















African American patients were more 
likely to receive a depot than non-
African American patients (OR 2.0, 95% 
CI 1.18, 3.41). No significant difference 
between African American and non-
African American patients for receipt of 
a SGA (OR 0.725, 95% CI 0.48, 1.10) or 




167 Black, white Survey USA Effect of gender 
and ethnicity on 
antipsychotic high 
dose, route, type, 
polypharmacy 
Black men more likely to be prescribed a 
depot antipsychotic than black women 
and white men and women (OR 2.6, 95% 
CI 1.19, 5.14, p<0.02). Black patients 
were more likely to be prescribed a high 
dose antipsychotic if they had a 
psychotic mood disorder (OR 8.1, 95% 
CI 1.15, 58.82, p<0.04).  
No effect of ethnicity on 
high dose antipsychotic 
use in patients with 
schizophrenia, type of 
antipsychotic or 
polypharmacy. Controlled 
for age, education, 
income level, rating scale 
(illness severity).  
(Bagchi et 
al., 2004) 
350 White, African 
American, 
Latino 
Survey USA Type of 
antipsychotic, 
receipt of an 
antipsychotic 
Latinos (OR 0.20 95% CI 0.07, 0.56), 
but not African Americans, were less 
likely than white patients to receive a 
SGA. There was no difference by 
ethnicity in use of an antipsychotic. 
Population were those 
with HIV and 
schizophrenia. 
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Survey USA Type of antipsychotic Black patients were less likely than 
whites to receive a SGA (OR 0.49, 95% 







(?white - not 
stated) 
Survey USA Average daily dose, 
high dose 
Black patients were more likely to 
receive both recommended doses (OR 
1.09, no CI, p=0.003) and high doses 
(OR 1.28, no CI, p<0.0001) than ?white. 
Hispanic dose and high dose did not 
differ from ?white. 
Depot information not 













African American patients but not 
Mexican American were less likely than 
white to receive olanzapine or 
risperidone compared to haloperidol (OR 
0.66, 95% CI 0.54, 0.80, p<0.001). 
Ethnicity was not a predictor of 
risperidone vs. olanzapine use.  
None 
(Sohler et al., 
2004) 
501 Black, white Cohort USA Dose (initial, 
discharge, maximum, 
average), route 
No differences by ethnicity in dose and 
route in fully adjusted model. 
Type of antipsychotic 
data collected but not 
analysed because of 
small numbers (SGA use 
black n=2, white n=23). 
(Taylor, 
2004) 
475 Black, white, 
Asian 
Survey UK Dose, polypharmacy 
of clozapine and 
olanzapine with other 
antipsychotics. 
Black patients were more likely than 
white to be prescribed olanzapine with 
other antipsychotics (33% vs. 20%, 
p=0.023). No difference by ethnicity in 
dose of olanzapine and clozapine and 
polypharmacy with clozapine. 
None. 
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RCT USA Efficacy (change in PANSS 
score), adverse effects 
(Extrapyramidal Symptom 
Rating Scale) and 
discontinuation rates of 
risperidone long-acting 
injection vs. placebo. 
No difference by race/ethnicity in 
dose, efficacy, tolerability and 









Survey USA Type of antipsychotic 
(olanzapine, risperidone or 
haloperidol) 
African American patients but not 
Mexican American were less likely 
than white to receive olanzapine or 
risperidone compared with 
haloperidol (OR 0.66, 95% CI 0.54, 
0.80, p<0.001). Ethnicity was not a 





501 Black, white Cohort USA Dose (initial, discharge, 
maximum, average), route 
No differences by ethnicity in dose 
and route in fully adjusted model. 
Type of antipsychotic 
data collected but not 
analysed because of 
small numbers (SGA 




475 Black, white, 
Asian 
Survey UK Dose, polypharmacy of 
clozapine and olanzapine with 
other antipsychotics 
Black patients were more likely than 
white to be prescribed olanzapine 
with other antipsychotics (33% vs. 
20%, p=0.023). No difference by 
ethnicity in dose of olanzapine and 
















RCT USA Efficacy (change in PANSS 
score), adverse effects 
(Extrapyramidal Symptom 
Rating Scale), discontinuation 
rates of risperidone long-
acting injection vs. placebo 
No difference by race/ethnicity in 
dose, efficacy, tolerability and 







Survey USA Type of antipsychotic FGA or 
SGA 
Black patients were less likely to 
receive SGAs than white (OR 0.58, 









Questionnaire USA Prescription of psychotropics 
for BPAD 
African-Americans were more 
likely to be prescribed an 
antipsychotic than Caucasians 







Survey UK Dose, high dose, co-
prescription (FGA + SGA) 
White patients were more likely 
than non-white to be prescribed a 
high dose antipsychotic (20.6% vs. 
13.9%, p=0.02) but not percentage 
maximum dose (p=0.05) or co-
prescription (p>0.05). 
None  







Clozapine dose, plasma levels Asian patients received a 
significantly lower mean dose of 
clozapine compared with 
Caucasians (175.6mg/day vs. 
432.5mg/day, p<0.001) but levels 
similar. Dose by mg/kg also 




patients were not 
surveyed in the 
same country.  
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USA Length of 
treatment with 
SGA, dose, 
receipt of an 
antipsychotic 
African American adolescents received 
antipsychotics for a greater percentage 
of time than Caucasians (79% vs. 40%, 
p= 0.05). No difference by 





Higher proportions of 
African American 
patients in this study 
diagnosed with 
psychotic features vs. 
Caucasian. 
(Staller et 
al., 2005)  
1292 White, non-white Survey USA Prescription of 
an antipsychotic 
No difference by ethnicity in being 
prescribed an antipsychotic (non-white 
vs. white OR 0.97, 95% CI 0.70, 1.34). 
Child and adolescent 












access to SGAs 
African American patients less likely 
than white/other to receive a SGA (OR 
0.41, 95% CI 0.19, 0.89, p< 0.05). Both 
African American and white/other 
patients with a criminal arrest history 
were less likely to receive SGA than 




1380 White, African 
American, other 
RCT USA Predictors of 





No significant difference between 
African American use of antipsychotics 
compared to white and other 
ethnicities. 
African American 
patients were more 
likely not to be taking 
any psychotropic 
medication (OR 0.42, 
95% CI 0.33, 0.54). 
(Dickey et 
al., 2006) 






USA Dose, high dose 
(> 1000mg 
CPZe) 











USA Use of 
psychotropic 
drugs 
Antipsychotics were prescribed more 
often to European American children 
than American Indian (p<0.05) but 
after Bonferroni adjustment not 
significant (p=0.28). 
African American and 
other ethnicities 
excluded because of 
low numbers in sample. 
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USA Prescription and 
type of antipsychotic 
in bipolar disorder 
Black patients were more likely than 
non-black to receive a SGA (p<0.001). 
No differences by race/ethnicity in 
receipt of FGA or receipt of two or 
more SGAs.  
More black than non-
black patients received 
two or more 
psychotropics (12.6% vs. 






Survey USA Proportion of each 
ethnicity receiving 
clozapine, dose, 
time to clozapine 
discontinuation. 
African Americans were treated with 
lower doses (p=0.008) and were less 
likely than whites to receive clozapine 
(10.3% vs. 15.3%, p<0.001). African 
Americans stopped clozapine during 
admission at a higher rate than whites 
(p=0.041). 
White patients had higher 
total baseline BPRS 
scores than black patients 
at time of clozapine 
initiation (p=0.005). 
Black patients had greater 
improvement in BPRS 
scores initially than 
whites (p=0.03). Rates of 
hospital discharge did not 







Survey USA Medication use in 
patients with BPAD 
Black patients were more likely to 
receive a FGA than non-black (OR 
1.42, 95% CI 1.04, 1.94) or any 
antipsychotic (OR 1.32, 95% CI 1.04, 
1.67) and as likely to receive a SGA. 
Adjusted for multiple 
confounders. 
(Mallinger 
et al., 2006) 





USA Treatment with 
SGA, clozapine use, 
combination of FGA 
and SGA 
White patients were more likely to be 
treated with a SGA (OR 6.45, 95% CI 
2.37, 17.54, p< 0.001), were more 
likely to be treated with clozapine (OR 
2.70, 95% CI 1.58, 4.63, p<0.001) than 
black. Black patients were numerically 
more likely to receive a combination of 








Survey USA Receipt of an 
antipsychotic during 
physician visit 
No difference by ethnicity in physician 
visits with or without antipsychotic 
treatment. 
Population examined 
were youth < 20 years 
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Survey USA Ziprasidone use 
and dose over 3 
fiscal years 
African American (OR ranged from 
0.60 to 0.76; p<0.001) and Hispanic 
(OR ranged from 0.64-0.76; p range < 
0.05, p<0.001) patients were less 
likely to receive ziprasidone than 
white patients over all 3 years. No 




153 White, black Cross-
sectional 
Survey 
UK Dose, high dose, 
polypharmacy, 
type, cost 
No differences in all outcomes by 
ethnicity except cost. Cost of 
treatment was higher in black patients 
compared with white (£182.79 vs. 
£143.08 p=0.02;OR > £150/month, 









USA SGA use in 
children 
African Americans were as likely as 
white patients to use a SGA (OR 1.34, 
95% CI 0.98, 1.83). 
None 




1875 African American 
and Caucasian 
Cohort  USA Discontinuation of 
clozapine. 
No difference by ethnicity in 
proportions stopping clozapine 
overall. More black patients stopped 
because of leucopenia than whites 
(5.3% vs. 2.4%, p=0.001). 










USA Polypharmacy African-American patients were less 
likely to be prescribed polypharmacy 
than whites (OR 0.81, 95% CI 0.75, 
0.87). Hispanic and other ethnicities 










USA Polypharmacy Asian (not black or Hispanic) patients 
were more likely to be prescribed 
antipsychotic polypharmacy than 
white (OR 1.55, 95% CI 1.17, 2.04).  
None 
(Pogge et al., 
2007) 




USA Receipt of SGA 
vs. no 
antipsychotic 
No difference by ethnicity in use of 


















USA Depot use Black patients more likely to 
be treated with depot 
antipsychotics (OR 1.53, 95% 
CI 1.12, 2.09, p = 0.007) than 
‘other’ ethnicity. White 
patients were less likely than 
‘other’ ethnicity to be treated 
with depot than oral (OR 0.67, 
95%CI 0.49, 0.92, p=0.012). 
White vs. black not compared. 
Other predictors of greater 
use of depot than oral = 
PANSS disorganised 
thought, PANSS anxiety 
and depression, psychiatric 
hospitalisation in last year 
(yes), ever arrested (yes), 
















Dose of olanzapine or 
haloperidol in acute 
mania 
No significant difference 
between ethnicities in mean 
modal doses of both drugs. 









UK Dose, high dose, 
polypharmacy, type 
No differences in all outcomes 
by ethnicity except 
polypharmacy (white 25.7% 
vs. black 31.1%, OR 3.05, 
95% CI 1.44, 6.46, p=0.004). 
Polypharmacy driven by 
centre differences, 1 of the 
3 centres had very high 













African Americans and 
Latinos were less likely to 
receive an antipsychotic alone 
than non-Latino whites 
(p<0.001 and p = 0.011 
respectively). 
























No difference between 
ethnicities in probability of 
antipsychotic medication use 










et al., 2008) 





USA Functional genetic 
variation in drug 
metabolising enzymes 
(DME) and effect on 
dose, efficacy and safety 
of antipsychotics. 
No effect of genetic 
variation in DME and 
dosing, efficacy and safety 
(including tardive 
dyskinesia) for olanzapine, 
perphenazine, quetiapine, 
risperidone, ziprasidone.    
Analysis of CATIE 
study group. 
(Jano et al., 
2008) 
621,719 White, Non-white Survey USA SGA use No difference in SGA use by 
ethnicity (white vs. non-
white OR 1.14, 95% CI 0.54, 
2.52, p=0.73) 
Older adult (60 years 
and over) population  
(Thorens et 
al., 2008) 
92 Swiss, EU, non-EU Questionnaire Switzerland Receipt of an 
antipsychotic 
No difference by ethnicity in 
receipt of an antipsychotic 
p=0.26. No further details. 
Patients defined by 
country of origin, 
Poland and Romania 
included in non-EU 
countries. 
(West et al., 
2008) 
304 White, non-white Questionnaire USA Depot initiation Non-white (OR 1.14, 95% 
CI 0.53, 2.46) patients were 
as likely as white to receive 
a depot. 
Non-white vs. white 
psychiatrists were 
more likely to 
initiate depots 










Survey USA Type of antipsychotic Black (OR 0.754, 95% CI 
0.622, 0.913) and Hispanic 
(OR 0.713, 95% CI 0.565, 
0.899) patients (not other) 















Survey New Zealand Antipsychotic 
polypharmacy, type, 
route, dose, clozapine 
use at 2 time points 
(baseline T1 in 2001 
and T2 in 2004) 
Antipsychotic monotherapy = 
numerical differences at T1 between 
ethnic groups but not at T2; type = 
SGA use increased, FGA use 
decreased, no differences between 
ethnicities at T2; route = depot use 
decreased - no differences between 
ethnicities at T2; clozapine = Asian 
patients lower use than other 
ethnicities; dose = significant 
difference between ethnicities at both 

























Extension study (2 
randomised 










Being African-American was a 
predictor of increased use of oral 
supplementation with depot 
olanzapine (OR 1.85, 95% CI 1.004, 








Re-analysis of data 
from 3 audits 
UK Use of long-acting 
antipsychotic 
injections 
No association between use of 
antipsychotic long-acting injections 









USA Filled prescription for 
an antipsychotic 
No differences in use of 
antipsychotics for bipolar disorder for 
black (OR 0.93, 95% CI 0.87, 1.00) 
and Hispanic (OR 0.96, 95% CI 0.90, 
1.03) compared with whites. 
None. 
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(Busch et al., 
2009b) 





USA Adherence to 
antipsychotic quality 
standards for receipt, 
continuity and dose 
(PORT standards) 
Acute phase: medication 
prescribing (dose, 
continuous supply) worse 
for black vs. white (OR 
0.86, 95% CI 0.79, 0.94), 
Hispanics same as whites.  
Maintenance phase: 
medication prescribing 
worse for black vs. white 
(OR 0.75, 95% CI 0.71, 
0.79), Hispanics same as 
whites. 
Acute phase: dose (PORT 
standards) similar for black 
vs. white; better for 
Hispanic vs. white patients 
(OR 1.69 (95% CI 1.04, 
2.72). 
Maintenance phase: no 
difference in dose standard 
for black vs. white; better 
for Hispanic vs. white (OR 




3480 Black, white Longitudinal 
study 
USA Type, receipt of 
antipsychotic 
Black patients were less 
likely to be prescribed SGA 
(p=0.03) than whites. 
Overall black patients were 





178 Asian, white Retrospective 
case-note 
review 
UK Switching from FGA to 
SGAs 
Asian patients were as 
likely to be switched to 
SGAs as whites (p=0.489). 
Minimal study details as 
published letter. 
(Constantine 
et al., 2010b) 
23,183 White, black, 
Hispanic, 
other 
Database study USA Prevalence of 
antipsychotic 
polypharmacy 
Other ethnicity more likely 
than white to receive 
antipsychotic polypharmacy 
(OR 1.18, 95% CI 1.04, 
1.34, p<0.001). 
Black and Hispanic as 
likely as white ethnicity to 
receive antipsychotic 
polypharmacy. 









USA Effect of race/ethnicity 
and smoking on 
pharmacokinetics of 
perphenazine  
Mean daily dose of 
perphenazine for African 
American patients did not 
differ from other ethnicities 
(25.04mg vs. 23.63mg, 
p>0.05) 
Pharmacokinetic study of 
CATIE patients. African 
American mean clearance 
was significantly faster than 
non-black patients (p<0.05). 
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type, route of 
antipsychotic 
Black patients were more likely to be 
prescribed a depot antipsychotic than white 
patients (OR 2.06, 95% CI 1.18, 3.59, 
p=0.011), and more likely to be prescribed a 
depot as the only antipsychotic ever taken 
(OR 2.71, 95% CI 1.13, 6.53, p=0.026). No 
difference by ethnicity in type or prescription 
of an antipsychotic. 
None 
 








Malaysia Dose (CPZe) No differences in dose by ethnicity (actual 
values not stated). 
None 
(Sleath et al., 
2010) 




USA Receipt of an 
antipsychotic 
Black patients were as likely and Unknown 
race/ethnicity (p<0.001) more likely than 
white to receive an antipsychotic.  
Sample were 














No difference in antipsychotic use for 
white vs. non-white (reference) patients 
(OR 1.14, 95% CI 0.9, 1.46, p=0.27). 
No difference by ethnicity in 
appropriate (p=0.16), potentially 
appropriate (p=1.0) and no appropriate 




aged 60 and 
over. 
(Wittkampf 










Moroccan (OR 1.15, 95% CI 1.10, 1.21) and 
Turkish (OR 1.12, 95% CI 1.05, 1.18) 
patients were more likely than Native to be 









UK Dose, high dose, 
polypharmacy, 
type, cost 
No differences in all adjusted outcomes by 
ethnicity. 
8 centre study. 
(Degenhardt 








USA Mean modal 
dose 
No differences by ethnicity for dose.  Small number of 
African American 
patients in the 
study (n=41). 
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No significant differences for 
treatment outcome, polypharmacy 
and type of antipsychotic (chi-
squared and Mann Whitney). 
Most of immigrant group 







Database study New 
Zealand 
Dose, length of 
treatment on 
clozapine 
No differences in these outcomes 





157 White, other  Cohort study 
secondary 
analysis 




White patients were more likely to 
be prescribed an antipsychotic 
than other ethnicity (OR 2.32, 95% 
CI 1.37, 3.91). 
Ethnicity defined as white 










Canada Prescription of an 
antipsychotic 
Chinese patients (OR 0.49, 95% 
CI 0.25, 0.98, p<0.05) were less 
likely and mixed patients (OR 
2.97, 95% CI 1.30, 6.80) were 
more likely than white to be using 
antipsychotic medication. Other 
Asian and non-white/Non-Asian 
did not differ from white. 
Non-white included black 
patients. 







Survey USA Management of 
antipsychotic 
medication  
Non-Hispanic blacks were more 
likely to have management of 
antipsychotic medication than non-
Hispanic whites in 3 of the 4 
regression models (OR range 1.66 
to 1.88, p<05). Hispanic and other 
ethnicity did not differ from 
whites. 
Outcome defined as 
medications prescribed, 
ordered, supplied, 
administered or continued. 
Non-Hispanic blacks had 
greater risks of 






102 Black, white, 
Hispanic, 
other 




White less likely than non-white to 
use long-acting injections (OR 
0.52, 95% CI 0.33, 8.3, p<0.007). 
Race/ethnicity not associated with 
type of injectable antipsychotics 
(1st or 2nd generation). 
CI for odds ratio cross 1 
but p value highly 
significant. 
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124 Black, white, Hispanic + 
mixed, other 
Survey USA Antipsychotic 
polypharmacy  (oral 
treatment in those on 
long-acting IM 
injections) 
Greater use of oral 
antipsychotics with depot in 
Hispanic patients (OR 3.8, 95% 
CI 1.3-10.8). Other comparisons 
not quoted. 
Reference category for 
logistic regression not 
listed. Author contacted no 
reply. Hispanics grouped 









USA Rates of 
psychotropic use in 
children and 
adolescents 
Hispanic/Latino patients were 
less likely to receive a SGA 
than non-Hispanic/Latino 
patients (p<0.03). Caucasian vs. 
non-Caucasian not significantly 
different. 
None 
(Cruz et al., 
2012) 
206,603 Native-born, immigrants 
(Eastern Europe, 
Maghreb (North Africa), 
Latin America, Sub-




Spain Proportions of each 




Native-born were numerically 
more likely to be treated with 
antipsychotic than immigrants 
(1.9% vs. 0.4%). No observed 
differences for type of 
antipsychotic. 
No statistical analysis of 
between group differences 





217 Caucasian, other 






Ethnicity not a factor after 
regression analysis however 
before adjustment Caucasians 
were less likely than other 
races/ethnicities to receive a 
long-acting injection (47.9% vs. 
55.4%, p=0.03). 
Abstract only available so 




13,992 Black, Latino, white Cohort study USA Use of RLAI Black (OR 1.09, 95% CI 0.89, 
1.33) and Latino (OR 0.90, 95% 
CI 0.72, 1.12) patients were not 









UK Theoretical delay in 
time to prescription 
of clozapine 
No difference by ethnicity in 
delay in time to prescribe 
clozapine (white mean 48.3 
months; other mean 47.4 
months; p=0.9). 
Ethnicity (black, Asian and 
mixed) was a significant 
factor in patients excluded 
from the study because of 
missing data. 
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USA Prescribing of 
FGA and SGAs 
after CATIE 
study. 
African-American patients were more 
likely than Caucasians to be prescribed a 
FGA (OR 2.36, 95% CI 1.61, 3.48) but 










USA Prescribing of 
FGA and SGAs 
after CATIE 
study. 
African-American patients were more 
likely than Caucasians to be prescribed a 
FGA (OR 2.36, 95% CI 1.61, 3.48) but 





214,113 White, black, 
Hispanic, other 
Cohort study USA Use of ‘off-label’ 
antipsychotic 
medications 
Black (OR 0.90, 95% CI 0.88, 0.91) and 
Hispanic (OR 0.80, 95% CI 0.79, 0.82) 
patients were less likely than white to be 
prescribed any ‘off-label’ antipsychotics. 
other ethnicity did not differ from white. 
‘Off-label’ was 
defined as not 




144 Black, white, 
Hispanic, other 
Survey USA Factors associated 
with starting 
clozapine 
Black (OR 0.57, 95% CI 0.38, 0.86) and 
Hispanic (OR 0.47, 95% CI 0.24, 0.91) 
patients were less likely than whites to 
















African American men received similar 
doses of antipsychotic as white men 
(p=0.257). Doses for black women were 
also similar to white women (p = 0.921). 
White men received higher doses than 
African American women (p=0.034). 
None 
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USA Use of an 
antipsychotic, dose, 
polypharmacy, cost 
Use of an antipsychotic was lower for 
blacks (OR 0.84, 95% CI 0.75, 0.93) and 
higher for Hispanics (OR 1.54, 95% CI 
1.42, 1.68) and other (OR 1.34, 95% CI 
1.20, 1.50) than whites. Black (OR 0.77, 
95% CI 0.65, 0.91), Hispanic (OR 0.71, 
95% CI 0.63, 0.80) and other (OR 0.81, 
95% CI 0.68, 0.96) had a higher risk of 
non-recommended doses than whites. Rates 
of polypharmacy were not significantly 
different between black Hispanic and others 
vs. white. Costs were lower for black (-
1.183, p<0.001), greater for Hispanic 
(1.436, p<0.001) and other (0.890, p<0.001) 
than whites. 













USA Use of olanzapine 
pre and post FDA 
metabolic effect 
warnings 
Hispanic patients had a greater use of 
olanzapine than white both pre (risk 
difference 0.17, 95% CI 0.13, 0.20) and 
post (risk difference 0.03, 95% CI 0.1, 0.4) 
FDA warning. There was no difference for 
black vs. white use pre and post warning. 
Excluded Asian 











USA Dose of 
antipsychotic 
Prescribed daily dose differed by ethnicity 
(which not stated) for risperidone only (not 
other antipsychotics) (p=0.04). Non-
Hispanic whites had the highest average 
dose (4.4mg) followed by African 
Americans (4mg) then Hispanics (3.9mg). 












Survey Canada Chlorpromazine 
equivalent (CPZe) 
dose by ethnicity 
No difference by ethnicity (white CPZe 
dose 515.72mg vs. non-white 516.08, 
p=0.972). 












20,122 Black, Latino, non-
Latino white 
Survey USA Clozapine use Proportions of blacks (2.3%) and 
Latinos (2.1%) using clozapine 
were lower than non-Latino whites 
(5.9%). 
Differences not tested 
statistically. My 
analysis (chi-squared) 
p<0.01 Black vs. 













USA SGA use in 
children 
Black patients more likely 
than Latino (OR 5.10, 95% CI 
1.15, 9.19, p<0.001) and 
mixed/other (OR 3.26, 95% 
CI 1.9, 13.67, p<0.05) to be 
prescribed SGAs. 
In mixed group 
69% were Latino 











Greater number of excess 
prescriptions dispensed for 
depot older antipsychotics and 
a shortfall in prescriptions for 
oral newer antipsychotics for 






















No significant differences in 
odds of using antipsychotics 
for African Americans vs. 
non-African Americans; 
Latinos vs. non-Latinos; 
Asians, Maoris and Pacific 
Islanders vs. non ethnic 
minority; black/black British 
vs. white. 
African Americans (OR 0.62, 
95% CI 0.50, 0.78) vs. non-
African Americans and 
Latinos (OR 0.77, 95% CI 
0.73, 0.81) vs. non-Latinos 




and OR quoted, 










(Teo et al., 
2013) 
497 White European 
and non-white 
European 





Polypharmacy more likely in 
white patients than non-white 
(p=0.05).  Clozapine use 
(p=0.979) and clozapine use in 
polypharmacy (p=0.502) did not 
differ by ethnicity.  
Treatment 
resistance more 











numerically more likely to 
receive depot antipsychotics 
than Caucasian and other 
ethnicities (quoted by individual 
US state). 
Descriptive 







Survey  USA ‘Off label’ use of 
antipsychotics 
White/non-Hispanics  (OR 0.28, 
95% CI 0.16, 0.51) were less 
likely to use ‘off label’ SGAs 
than other. 













Survey USA Factors associated 
with clozapine 
initiation 
African Americans (OR 0.663, 
95% CI 0.61, 0.72), Hispanic  
(OR 0.788, 95% CI 0.71, 0.87) 
and other ethnicities (OR 0.889, 
95% CI 0.84, 0.94) were less 
likely to start clozapine 













Survey USA Antipsychotic use White patients had a shorter time to 
antipsychotic prescription (p<0.001 
for all except Hawaiian/multiracial 
p<0.05) and also had a higher 
antipsychotic fill probability than all 
other ethnicities (p<0.01). 
Children and 
adolescents (ages 
2 to 20). 
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of stimulant with 
SGA 
Black patients were more likely than 
white to be prescribed concurrent 
stimulants and SGA (OR 1.34, 95% CI 
1.26, 1.41) but not other ethnicity (OR 
1.00,95% CI 0.94, 1.05).  
Concurrent use 
of stimulants 
and SGA in 
children (aged 6 









use, type, route 
No difference between black and white 
patients antipsychotic use (OR 1.0, 95% CI 
0.90, 1.12, p=0.952). In 2012 black patients 
(reference category) were less likely than 
white to receive oral SGA (OR 1.43, 95% 
CI 1.32, 1.56, p<0.001) and more likely to 
receive oral FGA (OR 0.87, 95% CI 0.79, 
0.96, p=0.003), LAI FGA (OR 0.47, 95% 
CI 0.42, 0.53, p<0.001) and LAI SGA (OR 








Survey UK Antipsychotic 
plasma levels 
Black patients were more likely to 
have low antipsychotic plasma levels 









Survey USA Outcomes of 
clozapine use vs. 
antipsychotic 
polypharmacy 
Fewer white vs. non-white patients in 
clozapine monotherapy group vs. 
polypharmacy group (52% vs. 61%, 
no p value). Polypharmacy group 
differs by race/ethnicity (not specified 
which) from clozapine group 
(p<0.001). 
None 






Survey USA Antipsychotic 
use and 
administration in 
end of life care 
African Americans were less likely than 
whites to have an antipsychotic 
administered 
(OR 0.73, 95% CI 0.62,0.86, p= 
0.004) but not an antipsychotic 






















No differences in dose by 
ethnicity (p=0.09) but Maori 
were prescribed clozapine 
more frequently than non-
Maori (24% vs. 13%, 
p=0.007). No difference by 











exposure to and 
discharge on an 
antipsychotic  
Black patients were less likely than 
white to receive an antipsychotic 
RR 0.8 (95% CI 0.6, 0.96). 
 
Scope of use of 
antipsychotics for 
delirium. Small 
sample size for 
Asian, Hispanic and 







Survey USA Antipsychotic use White patients (with and 
without psychological 
impairment) were more likely 
to be prescribed SGA than 
black and Latino (1.2% vs. 
0.8% vs. 0.6%, p<0.05). 
Children and 










Survey  USA Psychotropic use 
(including 
antipsychotics) 
Antipsychotics used for white 
1.7%, black 1.9%, Asian 0.7% 
and Hispanic 1.3%. White 
patients used psychotropics 
more frequently than Hispanic 
(OR 3.1, 95% CI 2.7, 3.5) but 
not Asian (vs. Hispanic) or 
black (vs. Hispanic). 







* same dataset; ADHD = attention deficit hyperactivity disorder; B= black; BPAD = bipolar affective disorder; BPRS = Brief Psychiatric Rating Scale; CATIE = Clinical Antipsychotic Trials for Intervention 
Effectiveness; CGI-S = Clinical Global Impression – Severity; CI = confidence interval; CPZe = chlorpromazine equivalents; EPSE = extrapyramidal side effects; GAF = Global Assessment of Functioning; 
IM = intramuscular; LAI = long-acting injection; PANSS = Positive and Negative Syndrome Scale; PORT = Patient Outcomes Research Team; RCT = randomised controlled trial; RR = risk ratio; RLAI = 
risperidone long-acting injection; SUD = substance misuse disorder; UK = United Kingdom; United States of America = USA.  
 
 











USA Clozapine use, antipsychotic 
polypharmacy (³90 days, 
non-clozapine 
combinations) 
Prescribers with higher 
percentages of ethnic minority 
patients were less likely to 
prescribe clozapine and 
polypharmacy than those with 
lower percentages. Hispanic 
patients clozapine use (OR 0.97, 
95% CI 0.96, 0.98, p=0.001), 
polypharmacy use (OR 0.99, 95% 
CI 0.98, 0.99, p<0.001). Non-
Hispanic black clozapine (OR 
0.99, 95% CI 0.99. 0.99,p<0.001) 





high and low 
proportions of 
ethnic minorities 













UK Antipsychotic receipt, type 
(FGA or SGA), depot use, 
clozapine use, high dose, 
prescribed 2+ antipsychotics 
(excluding clozapine), 
involvement of service-user 
in antipsychotic choice, 
provided with written 
information on 
antipsychotic, benefits/side 
effects of antipsychotic 
explained 
Depot use was more likely in 
black patients than white (OR 
1.56, 95% CI 1.33, 1.84). 
Clozapine use less likely in black 
vs. white patients (OR 0.56, 95% 
CI 0.39, 0.79. High dose 
antipsychotic use more likely in 
mixed vs. white patients (OR 
1.58, 95% CI 1.05, 2.38). No 
differences between ethnic groups 








for 7 confounders 
including ethnicity. 
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APPENDIX 4 STUDIES OF ANTIPSYCHOTIC PRESCRIBING AND ETHNICITY, SUMMARY TABLE 
Notes 
• Worse = greater receipt of/length of treatment of an antipsychotic; greater depot use; lesser use of clozapine; lesser use of SGAs; 
greater FGA use; greater use of ‘off label’ antipsychotics; more than one antipsychotic concurrently; lower cost 
• Some references appear in more than one grouping because of multiple ethnic comparisons 
 
Black vs. white (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Littlewood & Cross, 
1980) 
Antipsychotic use    None 
Depot use    
(Adams et al., 1984) Dose    None 
Polypharmacy    
(Price et al., 1985) Depot use    None 
(Holden, 1987) Dose     None 
(Dunn & Fahy, 1990) Antipsychotic use    None 
(Chen et al., 1991) Dose    Non-Caribbean 
assumed white Depot use    
High dose    
(Flaskerud & Hu, 
1992) 
Antipsychotic use    Medication receipt in 
psychosis 
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Reference Outcome Worse No Difference Better Comments 
(Lloyd & Moodley, 
1992) 
Depot use    None 
Antipsychotic use    
Polypharmacy - depot 
and oral 
   
Depot dose    
Oral dose    
Polypharmacy -2 oral    
 (Stanley & Doyle, 
1993) 
High dose    Included 1 patient of 
mixed race 
(Strakowski et al., 
1993) 
Dose    None 
(Glazer et al., 1994) Dose    None 
Depot use    
(Chung et al., 1995) Dose    None 
PRN antipsychotics    
(Shubsachs et al., 1995) Dose 4 weeks after 
admission 
   None 
Dose 1 year and 3 years 
after admission 
   
(Jeste et al., 1996) Dose    None 
(Storch & Storch, 
1998) 
Antipsychotic use    None 
(Zito et al., 1998) Antipsychotic use    None 
(Delbello et al., 2000) Antipsychotic use    None 
(Walkup et al., 2000) High dose    None 
(Wang et al., 2000) Type of antipsychotic 
(2nd generation) 
   None 
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Type of antipsychotic 
(2nd generation) 
   None 
(Leslie & Rosenheck, 
2001) 
Dose    None 
Polypharmacy    
(Valenstein et al., 
2001a) 
 
High dose    None 
(Valenstein et al., 
2001b) 
Depot use    None 
Type of antipsychotic 
(2nd generation) 
   
(Diaz & De Leon, 
2002) 
High dose    In patients with 
schizophrenia  
(dosReis et al., 2002) Dose – low and high 
potency antipsychotic 
   None 
Dose - high potency 
antipsychotic 
   
(Fleck et al., 2002) Length of treatment    None 
Type (1st generation)    
(Kuno & Rothbard, 
2002) 
Type (2nd generations)    None 
Clozapine use    
Depot use    
(Lasser et al., 2002) Antipsychotic use    Visit rates for 
antipsychotic 
prescription 
(Copeland et al., 2003) Type (2nd generation)    None 
Clozapine use    
(Daumit et al., 2003) Type (2nd generation)    None 
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Reference Outcome Worse No Difference Better Comments 
(Jaffe & Levine, 2003) Polypharmacy    None 
(Kreyenbuhl et al., 
2003) 
Dose    None 
Type (2nd generation)    
Depot use    
Anticholinergic agent 
use 
   
(Opolka et al., 2003) Type (2nd generation)    None 
(Owen et al., 2003) Dose    None 
Depot use    
(Valenti et al., 2003) 
 
Type (1st generation)    None 
(Arnold et al., 2004) High dose    Depot use worse for 
black men not black 
women 
Depot use    
Type (2nd generation)    
Polypharmacy    
(Bagchi et al., 2004) Type (2nd generation)    None 
Antipsychotic use    
(Herbeck et al., 2004) Type (2nd generation)    None 
(Leslie & Rosenheck, 
2004) 
Dose    None 
High dose    
(Opolka et al., 2004) 
 
Type (2nd generation)    None 
(Sohler et al., 2004) Dose    None 
Route   
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Reference Outcome Worse No Difference Better Comments 
(Taylor, 2004) Dose    None 
Polypharmacy (with 
clozapine) 
   
Polypharmacy (with 
olanzapine) 
   
(Hudson et al., 2005) Type (2nd generation)    None 
(Kupfer et al., 2005) Antipsychotic use    None 
(Patel et al., 2005) Length of treatment    None 
Antipsychotic use    
Dose    
(Chakos et al., 2006) Antipsychotic use    None 
(Dickey et al., 2006) Dose    None 
High dose    
(Kelly et al., 2006) 
 
Antipsychotic use    Clozapine use 
Dose    
(Mallinger et al., 2006) Type (2nd generation)    Polypharmacy = FGA 
+ SGAs Clozapine use    
Polypharmacy     
(Valenstein et al., 
2006) 
 
Type (2nd generation)    Ziprasidone use 
(Connolly et al., 2007) Dose    None 
High dose    
Polypharmacy    
Type (2nd generation)    
Cost    
(Gersing et al., 2007) Type (2nd generation)    None 
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Reference Outcome Worse No Difference Better Comments 
(Kelly et al., 2007) 
 
Clozapine cessation    None 
(Kreyenbuhl et al., 
2007b) 
Polypharmacy    None 
(Morrato et al., 2007) Polypharmacy    None 
(Connolly & Taylor, 
2008) 
Dose    None 
High dose    
Type (1st generation)    
Polypharmacy    
Antipsychotic use    
Type (2nd generation)    
Polypharmacy - 
olanzapine depot plus 
oral 
   
(Busch et al., 2009b) Medication quality 
(acute and maintenance)  
   Medication quality = 
dose, continuous 
supply Dose  (acute and 
maintenance) 
   
Antipsychotic use    
(Hanlon et al., 2009) Antipsychotic use    None 
Type (2nd generation)    
Polypharmacy    
(Pinto et al., 2010) Depot use    None 
Type (2nd generation)    
Antipsychotic use    
(Sleath et al., 2010) Antipsychotic use    None 
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Reference Outcome Worse No Difference Better Comments 
(Connolly et al., 2011) Dose    None 
High dose    
Polypharmacy (2nd 
generation) 
   
Type    
Cost    
(Degenhardt et al., 
2011) 
Dose    None 
(Rost et al., 2011) Antipsychotic use    None 
(Horvitz-Lennon et al., 
2012) 
Depot use     Risperidone long-
acting injection 
(Koranek et al., 2012) Type (1st generation)    None 
(Leslie & Rosenheck, 
2012) 
‘Off label’ use of SGAs    ‘Off label’ = not for 
schizophrenia or 
bipolar 
(Manuel et al., 2012) Clozapine use    None 
(Nejtek et al., 2012) Dose    None 
(Robst, 2012) Antipsychotic use    None 
Dose    
Polypharmacy    
Cost    
(Dusetzina et al., 2013) Type (2nd generation - 
olanzapine use) 
   None 
(Horvitz-Lennon et al., 
2013) 
Clozapine use    Differences not tested 
statistically. My 
analysis (chi-squared) 
p<0.01 black vs. 
white. 
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Reference Outcome Worse No Difference Better Comments 
(Brown et al., 2014) Depot use    None 
(Stroup et al., 2014) Clozapine use    None 
(Kamble et al., 2015) Stimulant and SGA use    None 
(Lawson et al., 2015) 
 
 
Antipsychotic use    None 
Oral SGA    
Oral FGA    
Depot SGA    
Depot FGA    
(Cataife & Weinberg, 
2015) 
Antipsychotic use    None 
(Burgio et al., 2016) Antipsychotic prescribed    None 
Antipsychotic 
administration 
   None 
(Herzig et al., 2016) Antipsychotic use     None 
(Cook et al., 2017) Antipsychotic use (SGA)    None 
(Das-Munshi et al., 
2018) 
 
Antipsychotic use    None  
Type of antipsychotic    
Depot use    
Clozapine use    
High dose     
Polypharmacy    
Choice of antipsychotic    
Written information     
Benefits/side effects    
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Black vs. non-black (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Tunnicliffe et al., 
1992) 
Dose of depot    Non-Caribbean 
assumed white 
(Segal et al., 1996) Antipsychotic use    Non-black = white, 
Asian, Hispanic, other 
ethnicities 
Dose    
Depot use    
Doses of antipsychotic    
Antipsychotic injection 
number 
   
(Valenstein et al., 
2001a) 
 
Low dose (<300mg 
CPZe) 
   Non-black were other 
ethnicities (no other 
details) 
(Mark et al., 2003) Type (1st generation)    None 
Type (2nd generation)    
Clozapine use    
Depot use    
Anticholinergic agent 
use 
   
(Woods et al., 2003) Type (2nd generation)    Non-black = white, 
Hispanic, other Depot use    
Polypharmacy     
(Van Dorn et al., 2005) Type (2nd generation)    Non-black = 
white/other 
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Reference Outcome Worse No Difference Better Comments 
(Garver et al., 2006) 
 
Type (2nd generation)    Polypharmacy classed 
as two 2nd generation 
antipsychotics 
Type (1st generation)    
Polypharmacy (two 2nd 
generation 
antipsychotics) 
   
(Kilbourne & Pincus, 
2006) 
 
Type (1st generation)    None 
Type (2nd generation)    
Antipsychotic use    
(Shi, 2007) Depot use    Non-black = other 
(not white) 
(Jin et al., 2010) Dose    None 
(Linares et al., 2013) Type (2nd generation)    Non-black = mixed 
other (Asian, white) 
(Puyat et al., 2013) Antipsychotic use    None 
Type (2nd generation)    
(Brown et al., 2014) Depot use    Non-black = other 
(Kamble et al., 2015) Stimulant and SGA use    Non-black = other 
















White vs. non-white (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Lehman & Steinwachs, 
1998) 
Antipsychotic use    Non-white were black 
and other, analysed as 
white vs. Minority 
Dose    
High dose    
Length of treatment    
Depot use    
Anticholinergic agent 
use 
   
(Wang et al., 2000) Type (2nd generation)    Non-white = other 
ethnicity 




(Valenstein et al., 
2001a)  
High dose    Non-white =. other 
(no further details) Low dose (<300mg 
CPZe) 
   
(Covell et al., 2002) 
 
Type (2nd generation)    Non-white = black 
and Hispanic Depot use    
(Luo et al., 2002) 
 
Type (2nd generation)    Non-white = not 
stated 
(Pinninti et al., 2003) Type (2nd generation)    None 
(Szarek & Goethe, 
2003) 
 
Antipsychotic use    Non-white = black 
and Hispanic 
(Taylor et al., 2003) Clozapine use    Non-white =black, 
Asian, mixed 
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Reference Outcome Worse No Difference Better Comments 
(Valenti et al., 2003) 
 
Type (1st generation)    Non-white = black + 
other 
(Mace & Taylor, 2005) Dose    None 
High dose    
Polypharmacy    
(Staller et al., 2005) Antipsychotic use    None 
(Olfson et al., 2006) Antipsychotic use    Non-white = other 
(Valenstein et al., 2006) Type (2nd generation)    Ziprasidone use. Non-
white = other (Asian, 
native American) 
(Kreyenbuhl et al., 
2007b) 
Polypharmacy    Non-white = other 
ethnicity 
(Shi, 2007) Depot use    Non-white = other 
(not black) 
(Jano et al., 2008) Type (2nd generation)    None 
(West et al., 2008) Depot use    None 





(Constantine et al., 
2010b) 
Polypharmacy    Non-white = other 
(Sleath et al., 2010) Antipsychotic use    Non-white = 
Unknown race 
(Wittkampf et al., 2010) Antipsychotic use    Non-white = 
Moroccan or Turkish 
(Findling et al., 2011) Antipsychotic use    Non-white = other 
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Reference Outcome Worse No Difference Better Comments 
(Valenstein et al., 2006) Type (2nd generation)    Ziprasidone use. Non-
white = other (Asian, 
native American) 
(Kreyenbuhl et al., 
2007b) 
Polypharmacy    Non-white = other 
ethnicity 
(Shi, 2007) Depot use    Non-white = other 
(not black) 
(Jano et al., 2008) Type (2nd generation)    None 
(West et al., 2008) Depot use    None 





(Constantine et al., 
2010b) 
Polypharmacy    Non-white = other 
(Sleath et al., 2010) Antipsychotic use    Non-white = 
Unknown race 
(Wittkampf et al., 2010) Antipsychotic use    Non-white = 
Moroccan or Turkish 
(Findling et al., 2011) Antipsychotic use    Non-white = other 
(Puyat et al., 2011) Antipsychotic use    Non-white = mixed 
(Puyat et al., 2011) Antipsychotic use    Non-white = non-
white/non-Asian 
(Rost et al., 2011) Antipsychotic use    Non-white = other.  
(Aggarwal et al., 
2012a)* 
Depot use    None 
Type of depot (2nd 
generation) 
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Reference Outcome Worse No Difference Better Comments 
(Coury et al., 2012) Type (2nd generation)    Non-white = non-
Caucasian 





Type (not stated)    
(Fastenau et al., 2012) Depot use    Non-white = other – 
no details 
(Howes et al., 2012) Delay in clozapine use    Non-white = black, 
Asian, mixed other 
(Koranek et al., 2012) Type (1st generation)    Non-white = other 
(Robst, 2012) Antipsychotic use    Non-white = other 
Dose    
Polypharmacy    
Cost    
(Hassan et al., 2013) Dose    Non-white = non-
white European 
(Teo et al., 2013) Polypharmacy    Non-white = non-
white European Clozapine use    
Clozapine 
polypharmacy 
   
(Rodday et al., 2014) ‘Off label’ 2nd 
generation 
antipsychotic use 
   Non-white = other 
(Stroup et al., 2014) Clozapine use    Non-white = other 
 300 
Reference Outcome Worse No Difference Better Comments 





   
    
 
Asian vs. white (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Binder & Levy, 1981) Dose    None 
(Lin & Finder, 1983) Dose    None 
(Jann et al., 1992) Dose    Asian = Chinese 
(Collazo et al., 1996) Dose    Asians = Chinese 
subjects Anticholinergic agent 
use 
   
(Matsuda et al., 1996) Dose (clozapine)    None 
(Taylor, 2004) Dose    None 
Polypharmacy (with 
clozapine) 
   
Polypharmacy (with 
olanzapine) 
   
(Ng et al., 2005) Dose clozapine    Clozapine use 
(Morrato et al., 2007) Polypharmacy    None 
(Hashmi et al., 2009) Switching from FGAs 
to SGAs 
   None 
(Puyat et al., 2011) Antipsychotic use    Asian = Chinese 
(Puyat et al., 2011) Antipsychotic use    Asian = other Asian 
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Reference Outcome Worse No Difference Better Comments 




   None 
(Das-Munshi et al., 
2018) 
Antipsychotic use    None 
Type of antipsychotic    
Depot use    
Clozapine use    
High dose     
Polypharmacy    
Choice of antipsychotic    
Written information    
Benefits/side effects    
 
Asian vs. black (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Binder & Levy, 1981) Dose    None 
(Jann et al., 1992) Dose    Asian = Chinese 
 
Asian vs. Hispanic (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Jann et al., 1992) Dose    Asian = Chinese 
(Collazo et al., 1996) Dose    Asians = Chinese 
subjects Anticholinergic agent 
use 
   




Asian vs. non-Asian (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Lin et al., 1996) Dose    Non-Asian = white, 
black, Hispanic) 
(Ruiz et al., 1996) Dose    Non-Asian = general 




   
 
Mixed vs. white (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Das-Munshi et al., 
2018) 
Antipsychotic use    None 
Type of antipsychotic    
Depot use    
Clozapine use    
High dose    
Polypharmacy    
Choice of antipsychotic    
Written information    









Chinese/Other vs white (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Das-Munshi et al., 
2018) 
Antipsychotic use    None 
Type of antipsychotic    
Depot use    
Clozapine use    
High dose    
Polypharmacy    
Choice of antipsychotic    
Written information    
Benefits/side effects    
 
Hispanic vs. white (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Adams et al., 1984) Dose    None 
Polypharmacy    
(Jann et al., 1992) Dose    None 
(Collazo et al., 1996) Dose    None 
Anticholinergic agent 
use 
   
(Ruiz et al., 1999) Dose    None 
(Baillargeon & 
Contreras, 2001) 
Type of antipsychotic 
(2nd generation) 
   None 
(Leslie & 
Rosenheck, 2001) 
Dose    None 
Polypharmacy    
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Reference Outcome Worse No Difference Better Comments 
(Lasser et al., 2002)     Visit rates for 
antipsychotic 
prescription 
(Copeland et al., 
2003) 
Type (2nd generation)    None 
Clozapine use    
(Daumit et al., 2003) Type (2nd generation)    None 
(Bagchi et al., 2004) Type (2nd generation)    None 
Antipsychotic use    
(Leslie & 
Rosenheck, 2004) 
Dose    None 
High dose    
(Valenstein et al., 
2006) 
Type (2nd generation)    Ziprasidone use 
(Kreyenbuhl et al., 
2007b) 
Polypharmacy     None 
(Morrato et al., 2007) Polypharmacy    None 
(Tamayo et al., 2007) 
 
Dose    None 
(Depp et al., 2008) Antipsychotic use    None 
(Yang et al., 2008) Type (2nd generation)    None 
(Busch et al., 2009a) Antipsychotic use    None 
(Busch et al., 2009b) Medication quality 
(acute and 
maintenance) 
   Medication quality 
= dose, continuous 
supply 
Dose (acute and 
maintenance) 
   
(Constantine et al., 
2010b) 
Polypharmacy    None 
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Reference Outcome Worse No Difference Better Comments 
(Rost et al., 2011) Antipsychotic use    None 
(Horvitz-Lennon et 
al., 2012) 
Depot use    Risperidone long-
acting injection 
(Koranek et al., 
2012) 
Type (1st generation)    None 
(Leslie & 
Rosenheck, 2012) 
‘Off label’ use of 
SGAs 
   ‘Off label’ = not for 
schizophrenia or 
bipolar 
(Manuel et al., 2012) Clozapine use    None 
(Robst, 2012) Antipsychotic use    None 
Dose    
Polypharmacy    
Cost    
(Dusetzina et al., 
2013) 
Type (2nd generation - 
olanzapine use) 
   None 
(Horvitz-Lennon et 
al., 2013) 
Clozapine use    Difference not 
tested statistically. 
My analysis (chi-
squared) Latino vs. 
white p<0.01. 
(Stroup et al., 2014) Clozapine use    None 
(Cataife & 
Weinberg, 2015) 
Antipsychotic use    None 
(Cook et al., 2017) Antipsychotic use 
(SGA) 





Hispanic vs. black (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Adams et al., 1984) Dose    None 
Polypharmacy    
(Jann et al., 1992) Dose    None 
(Ruiz et al., 1999) Dose    None 
(Jaffe & Levine, 
2003) 
Polypharmacy    None 
(Linares et al., 2013) Type (2nd generation)    None 
 
Hispanic vs. non-Hispanic (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Ruiz et al., 1996) Dose    Non-Hispanic = 
general i.e. not 
Hispanic not Asian 
(Covell et al., 2002) 
 
Type (2nd generation)    None 
Polypharmacy    
    










(Coury et al., 2012) Type (2nd generation)    None 
(Puyat et al., 2013) Antipsychotic use    None 
Type (2nd generation)    
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Mexican American vs. white (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Opolka et al., 2003) Type (2nd generation) 
1st 10 months 
 
 
  None 
Type (2nd generation) 
2nd 10 months 
   
(Opolka et al., 2004) 
 
Type (2nd generation)    None 
 
American Indian vs. white (reference category)   
 
Reference Outcome Worse No Difference Better Comments 
(Ferguson et al., 
2006) 
Antipsychotic use    None 
(Cataife & 
Weinberg, 2015) 




Maori vs. Non-Maori (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Metcalfe et al., 
2013) 
Type (2nd generation 
oral) 
   None 
Depot (1st generation)    
(Dey et al., 2016) Antipsychotic dose 
(CPZe) 
   Non-Maori = New 
Zealand European, 
Asian, Pacific 
Islander and other.  
Type  (not stated)    
Route (not stated)    
Clozapine use    
 
Asian, Maori and Pacific Islanders vs. Non-Ethnic Minority (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Puyat et al., 2013) Antipsychotic use    None 
 
Hawaiian or multiracial vs. white (reference category) 
 
Reference Outcome Worse No Difference Better Comments 
(Cataife & Weinberg, 
2015) 
Antipsychotic use    None 
 
 309 
Unclassifiable Papers  
 

















USA Dose No difference by 
ethnicity in oral dose or 








Survey UK Antipsychotic 
polypharmacy 
and high dose 
No effect of ethnicity 






132 East Indian, 
African, 
mixed 
Survey Trinidad Psychotropic 
drug use 




ethnicity. No further 
details. 
African and East Asian 
patients were prescribed 
SSRI-type 
antidepressants less often 
than mixed patients 
(p=0.005). 
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Authors Number Ethnicity Type of 
study 







RCT USA Efficacy (change in 
PANSS score), adverse 
effects (Extrapyramidal 
Symptom Rating Scale) 
and discontinuation rates 
of risperidone long-acting 
injection vs. placebo 
No difference by 














USA Receipt of SGA vs. no 
antipsychotic 
No difference by 
ethnicity in use of 


























in probability of 
antipsychotic 





















USA Functional genetic 
variation in drug 
metabolising 
enzymes (DME) and 
effect on dose, 
efficacy and safety 
of antipsychotics. 
No effect of genetic 
variation in DME and 














92 Swiss, EU, 
non-EU 
Questionnaire Switzerland Receipt of an 
antipsychotic 
No difference by 
ethnicity in receipt of 
an antipsychotic 
p=0.26, no further 
details. 
Patients defined by 
























use at 2 time 
points (baseline 
time (T1) in 
2001 and time 
(T2) in 2004) 
Antipsychotic monotherapy= 
numerical differences at T1 
between ethnic groups but not at 
T2; type = SGA use increased, 
FGA use decreased, no 
differences between ethnicities 
at T2; route = depot use 
decreased - no differences 
between ethnicities at T2; 
clozapine = Asian patients less 
likely to receive than other 
ethnicities; dose = significant 
difference between ethnicities at 
both T1 and T2 (lowest mean 




































No association between use of 
antipsychotic long-acting 

















Malaysia Dose (CPZe) No differences in dose by 

















No significant differences for 
treatment outcome, 
polypharmacy and type of 
antipsychotic (chi-squared and 




















No differences in these 













USA Dose of 
antipsychotic 
Prescribed daily dose differed by 
ethnicity (which one not stated) 
for risperidone only (not other 
antipsychotics) (p=0.04). Non-
Hispanic whites had the highest 
average dose (4.4mg) followed 
by African Americans (4mg) 
then Hispanics (3.9mg). 
None 
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2919 White, black, 
other 
Survey USA Outcomes of 
clozapine use vs. 
antipsychotic 
polypharmacy 
Fewer white vs. non-white 
patients in clozapine 
monotherapy group vs. 
polypharmacy group (52% 
vs. 61%, no p value). 
Polypharmacy group 
differs by race/ethnicity 












Survey  USA Psychotropic use 
(including 
antipsychotics) 
Antipsychotics used for 
white 1.7%, black 1.9%, 
Asian 0.7% and Hispanic 
1.3%. White patients used 
psychotropics more 
frequently than Hispanic 
(OR 3.1, 95% CI 2.7, 3.5) 
but not Asian (vs. 
Hispanic) or black (vs. 
Hispanic). 
Sample size for 
all psychotropics. 
Numerical 




* same dataset; B= black; BPAD = bipolar affective disorder; BPRS = Brief Psychiatric Rating Scale; CATIE = Clinical Antipsychotic Trials for Intervention 
Effectiveness; CGI-S = Clinical Global Impression – Severity; CI = confidence interval; CPZe = chlorpromazine equivalents; EPSE = extrapyramidal side effects; 
GAF = Global Assessment of Functioning; IM = intramuscular ; PANSS = Positive and Negative Syndrome Scale; PORT = Patient Outcomes Research Team; RCT = 
randomised controlled trial; RR = risk ratio; RLAI = risperidone long-acting injection; SUD = substance misuse disorder; UK = United Kingdom; United States of 



























Prescribers with higher 
percentages of ethnic minority 
patients were less likely to 
prescribe clozapine and 
polypharmacy than those with 
lower percentages. Hispanic 
patients clozapine use (OR 0.97, 
95% CI 0.96, 0.98, p=0.001), 
polypharmacy use (OR 0.99, 
95% CI 0.98, 0.99, p<0.001). 
Non-Hispanic black clozapine 
(OR 0.99, 95% CI 0.99. 
0.99,p<0.001) polypharmacy 





high and low 
proportions of 
ethnic minorities 
not vs. another 
ethnic group. 
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(E or UE) 
 
Education                          





















          




Mental State  
 
Current diagnosis 







Duration of illness 













































































































      
** Count regular and prn.  For prn record amount given in last full day. If more than 3 antipsychotics, add together all maxima and put in 
brackets the number of antipsychotics prescribed. 
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Drug Therapy – other factors 
 




































Drug Therapy – other factors continued 
 
Previous antipsychotic treatment 
(names of drugs) 
 
 
Cost of current 
treatment (as per 
BNF) 
 
Patient influence on drug 
choice (Y/N) 
 












































































APPENDIX 7 DATA COLLECTION FORM, ETHNICITY STUDY 2 
Name data collector …………………………………………….   Ethnicity of data collector …………………………………………………. 
































When not in 




E; Unemployed = 
UE; Retired = R; 
student S) 
Education 
When did you 
leave school? Did 
you do further 
study after 
school?**                          
(primary, 
secondary, 6th form 
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Parental ethnic origin 
 
 






Did you receive 



























































































(from SHO or 





























Clinical Global Impression 
 
 
Severity of Illness 
 
Considering your total clinical experience with this particular population, what is the 
severity of illness of this patient now? 
 
0 = Not assessed 
1 = Normal, not ill at all 
2 = Borderline mentally ill 
3 = Mildly ill 
4 = Moderately ill 
5 – Markedly ill 
6 = Severely ill 






































(0,1, 2-5 or 
>5) 
 
Length of current 
admission (to day 
of data collection) 
(days) 
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Current Antipsychotic Therapy.  Count regular (including depot) and prn.  For ‘prn’ record amount given in last full day, if none drug 
dose is 0%.  If more than 3 antipsychotics, add together all maxima and put in brackets the number of antipsychotics prescribed. For 






Antipsychotic 1 Antipsychotic 2 Antipsychotic 3  
Total dose 
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Length of current antipsychotic treatment  




























































APPENDIX 8 PROCEDURE, ETHNICITY STUDY 2 
Research procedure 
Antipsychotic prescribing in black and white patients 
 
1. Call wards before data collection to check is convenient to visit for the audit. 
2. Print off list of patients on acute adult ward (including PICUs) that you are visiting 
(if you have computerised lists). 
3. Check ethnicity of the patients on the ward on the electronic notes system or in 
patients’ notes (usually on clerking form). Patients who are black (African or 
Caribbean descent) or white (NOT mixed or Asian) can be included in the study. 
You will need to check what codes your trust uses for ethnicity – usually Office of 
National Statistics ones – I have provided a print out. 
4. Go through drug charts on ward and write list of patients who are prescribed and are 
receiving a regular antipsychotic. 
5. You now have your list of patients to approach i.e. those who are black or white and 
on a regular antipsychotic. 
6. Ask nurses to highlight who on your list is safe to approach. 
7. Ask nurse to introduce you to each patient 1 at a time. 
8. Explain to each patient what study is about e.g. ‘we are doing a study to make sure 
that medicines are used fairly for black and white patients. I need to ask you a few 
questions about you and your ethnic origin, weigh and measure how tall you are. 
This should take about 5 minutes. Would this be ok with you?’ 
9. For those who do not want to take part in the study record the following information 
from notes on the sheet provided: 
• Persons initials 




• Ethnic origin  
Patients who are asleep or off the ward are not classed as ‘refusers’. 
10. Ask patient questions from the data collection form about  
• Smoking status 
• Employment – e.g. when you are not in hospital are you currently working? 
• Education – e.g. when did you leave school? Did you go on to further study? 
• First language – e.g. what languages do you speak – which is your ‘best’/most 
fluent one? 
• Ethnic origin – e.g. what would you describe your ethnicity as? 
• Parental origin – e.g. and your parents were they both white British/black 
African etc.? If parents’ ethnicity is white and black then patient is excluded as 
they are classed as mixed. 
• Choice of antipsychotic – e.g. did you have a choice of your antipsychotic 
treatment? 
• Information – e.g. did you get any written (e.g. a leaflet) or did anyone discuss 
the good and not so good things about your antipsychotic treatment?   
• Substance misuse – e.g. do you use or have you used street drugs or excess 
alcohol now or in the past? 
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11. Measure height and weight. Use cm and kg. Use the treatment room for the data 
collection as the height and weighing scales are there.  If no height measurer then 
use a mark on the wall and tape measure. Some patients like to know their weight in 
stones too, switch on back of scales to change to stones. Get patient to take their 
shoes off for accurate measurement. 
12. Ask named nurse or SHO for CGI-S as on questionnaire. 
13. Collect rest of information for the data collection form from notes 
• Significant physical illness e.g. heart disease, asthma - if unsure record 
• Forensic history – currently charged with an offence or a history of conviction 
for an offence 
• Race/ethnicity of prescriber (on current chart and consultant – use same 
classification as used for patients). If you can’t find out from staff or prescriber 
medical staffing will have this information.  
• Current diagnosis – if no ICD-10 code then write current diagnosis (may be 
more than 1) 
• Current Mental Health Act section  
• Mean percentage maximum dose = daily dose ÷ maximum daily dose of drug x 
100 to get % (or for depots – weekly dose of depot ÷ maximum weekly dose of 
depot x 100 to get %). 
• Easiest to get previous antipsychotic treatments from Part 1 and 2 summaries but 
you will need old notes for patients who have been ill for decades. 
• If you are not sure about anything then please call Anne on 07905315371 
 
• It is very important to fill in the whole table with information.  If the entire 
table is not completed we cannot use that patient’s data. 
 
• Sections that can take time to find full data on include: previous antipsychotics, 
number of previous admissions, length of illness – may need old notes or good part 



























Patients prescribed at least one regular (or when required ‘prn’ dose received in last 24 hours) oral or injectable 





Data Title Data Definition Location of data 
Age On date of data collection Notes 
Ethnicity As 2001 ONS Census (see below) i.e. white or mixed or Asian/Asian British or black/black British 
or Chinese or other (state what) 
Notes 
Employment Employed = working when not in hospital 
Unemployed = not working when not in hospital 
Retired  
Student 
Notes, nursing staff 
Education Record highest completed – primary; secondary; A level/6th form college; degree level Notes, nursing staff 
First Language Language spoken at home  Notes, nursing staff 
Smoking status Current cigarette smoker i.e. smoker or non smoker Notes, nursing staff 
Substance Misuse Excessive current use of street drugs and/or alcohol Notes, nursing staff 









F00-F09 organic, including symptomatic, mental disorders e.g. dementia 
F10-F19 mental and behavioural disorders because of psychoactive substance use 
F20-F29 schizophrenia, schizotypal and delusional disorders 
F30-F39 mood (affective) disorders e.g. bipolar affective disorder, recurrent depressive disorder 
F40-F48 neurotic, stress related and somatoform disorders e.g. agoraphobia, panic disorder 
F50-F59 behavioural syndrome associated with physiological disturbance and physical factors e.g. 
anorexia 
F60-F69 disorders of adult personality and behaviour e.g. paranoid personality disorder 
Notes 
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F70-F79 mental retardation 
F80-F89 disorders of psychological development 
F90-F98 behavioural and emotional disorders with onset during/occurring in childhood/adolescence 
F99 unspecified mental disorder 
Not known - the clinical team has not yet reached a diagnosis 
Forensic history 
 
Currently charged with an offence or a history of conviction for an offence Notes 
Ethnicity of patient’s 
consultant 
Use same classification as used for patients i.e. Office for National Statistics (ONS) 2001 Census 
definitions below 




Current Mental Health 
Act section? 
Record if 
Sectioned (any type) or 
Informal 
Notes, nursing staff 
Duration of illness Time since 1st contact with psychiatric services 
In days, years or months depending duration 
Notes 
Number of previous 
admissions 
To inpatient or home treatment care 
Categorised into 0, 1, 2-5 or >5 
Notes  
Length of current 
inpatient admission 
Time in days of inpatient admission (not just on current ward as they may have moved) to day of 
data collection 
Notes or nursing 
staff (if patient only 
been on 1 ward) 
History of or current 
non-compliance with 
medication 







Count regular (including depot) and prn.  For ‘prn’ record amount given in last 
full day, if none drug dose is 0%.  If more than 5 antipsychotics, add together 
all maxima and put in brackets the number of antipsychotics prescribed. If 
written prn PO/IM write PO (oral) and IM (intramuscular) as separate 




(%) maximum dose 
(Current daily dose ÷ maximum daily dose of drug) x 100 = % 




Regular anticholinergic? Benzatropine, orphenadrine, procyclidine, trihexyphenidyl (i.e. benzhexol) Medicine chart 
Length of current 
antipsychotic treatment 
In days, applies to main (highest percentage dose) antipsychotic treatment 
Look at previous (not only current) chart(s) 
Medicines chart(s) 
or notes if long-term 
treatment 
Previous treatment with 
any of current regular 
antipsychotic(s) 
Has the patient taken any of their regular current antipsychotic treatments before for previous 




Names of antipsychotics had previously Notes 
Current all other regular 
drug therapy 
As written on current drug chart(s) Medicine chart 
 





Any other white background 
 
Mixed 
White and black Caribbean 
White and black African 
White and Asian 









Any other Asian background 
 
Black or black British 
Caribbean 
African 
Any other black background 
 
Chinese or other ethnic group 
Chinese 
Any other ethnic group 
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APPENDIX 11 ANTIPSYCHOTIC NAMES AND DOSES 
Generic name Brand name(s) Maximum dose  
(daily dose for oral and 
weekly dose for IM) 
Amisulpride Solian 1200mg 
Aripiprazole Abilfy tablets and 
injection 
Tablets or aqueous injection 
= 30mg 
Benperidol Anquil 1.5mg 
Chlorpromazine Largactil 1000mg 




(or flupenthixol) tablets or 
decanoate depot injection 
Depixol Tablets = 18mg 
Depot injection = 400mg per 
week 
Fluphenazine tablets or 
decanoate depot injection 
Moditen - tablets 
Modecate – depot 
injection 
Tablets = 20mg 
Depot injection = 50mg per 
week 
Haloperidol tablets and 
decanoate depot injection 
Dozic - oral liquid  




Tablet/liquid = 30mg 
Aqueous injection = 18mg 





Olanzapine Zyprexa tablets and 
velotabs, injection 
Tablets and injection 20mg 
Pericyazine Neulactil 300mg 
Perphenazine Fentazin 24mg 
Pimozide Orap 20mg 
Pipotiazine (pipothiazine) 
palmitate 
Piportil Injection 50mg per week 
Promazine No branded product 800mg 
Quetiapine (doses depend 
on indication) 
Seroquel 750mg = psychosis or 
schizophrenia 
800mg = bipolar disorder 
Risperidone Risperdal – tablets, 
quicklets; Risperdal 
Consta – long-acting 
injection 
Tablets = 16mg 
Injection = 25mg weekly 
(50mg 2 weekly) 
Sertindole Serdolect  24mg 
Sulpiride Dolmatil, Sulpitil, 
Sulpor 
2400mg 
Trifluoperazine Stelazine 50mg 






Zuclopentixol  (or 
zuclopenthixol) 
Clopixol Depot and 
Clopixol Accuphase 
Tablets = 150mg 
Decanoate depot injection = 
600mg/week 
Acetate intramuscular 
injection (Accuphase) (not 
depot) = 400mg 
 
Drugs now discontinued 

























APPENDIX 12 DATA COLLECTION FORM, ETHNICITY STUDY 3  
Name of data 
collector…………………………………………………………………………………………    
 
Each patient’s information is collected in 1 vertical column. See data collection 
definitions for full explanation. 
 1 2 3 
Patient’s 
Initials 
   
Date of data collection    
NHS 
Number (or hospital 
number if no NHS number) 
   
Ward Name 
 
   
Gender (male or female) 
 
   
Age (years) 
 
   
Ethnicity 
white or mixed or 
Asian/Asian British or 
black/black British or 
Chinese or other (state 
what) 
   
Employment status 
(Employed = E; 
Unemployed = UE; Retired 
= R; student S) 
   
Education 
 (Primary or Secondary or 
A level/6th form college or 
Degree level) 




   
Smoking status 
(Smoker = S or Non-
Smoker = NS) 
   
Substance Misuse? (Yes/No)    
Weight (kg) 
 
   












 1 2 3 




   
Forensic history (Yes/No) 
 
   
Race/ethnicity of patient’s 
Consultant (coded as 2001 
ONS Census) 
   
Current Mental Health Act 
section? (sectioned or 
informal) 
   
Duration of illness 
(In days or years or 
months) 
   
Number of previous 
admissions 
(0 or 1 or 2-5 or >5) 
   
Length of current inpatient 
admission (to day of data 
collection) 
(days) 
   
History of or current non-
compliance 
Yes/No 






Antipsychotic number 1 – 
total daily dose (mg/day po 
or depot dose/week) 
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2 – total daily dose 
(mg/day po or depot 
dose/week) 
   
Route (oral or 
intramuscular) 
 
   












3 – total daily dose 
(mg/day po or depot 
dose/week) 
   
Route (oral or 
intramuscular) 
 
   











4 – total daily dose 
(mg/day po or depot 
dose/week) 
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Antipsychotic number 5 
– total daily dose 
(mg/day po or depot 
dose/week) 
   
Route (oral or 
intramuscular) 
 
   




   
Total dose as % 
maximum 










   
Length of current 
antipsychotic treatment 
in days (for highest % 
max dose antipsychotic 
administered) 
   
Previous treatment with 
any of current regular 
antipsychotic medication 
(Yes/No) 
   
Previous antipsychotic 
treatments 





   




   
Contact details for any questions - Anne Connolly 0790 531 5371 or 020 3228 2317 
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APPENDIX 13 HEALTH CARE COMMISSION BME GROUP DISTRIBUTION 
Number of patients by trust and percentages Count Me In Census 2007          0   
Healthcare Commission, Mental Health Act Commission, National Institute for Mental 
Health England          




Black or black British + 




       
         
1 South London And Maudsley NHS Trust NHS England 399 990        
2 West London Mental Health NHS Trust NHS England 259 875        
3 East London and The City Mental Health NHS Trust NHS England 234 637        
4 Barnet, Enfield and Haringey Mental Health NHS Trust NHS England 193 693        
5 Central and North West London Mental Health NHS Trust NHS England 189 780        
6 Birmingham and Solihull Mental Health NHS Trust NHS England 147 783        
7 South West London and St George's Mental Health NHS Trust NHS England 117 645        
8 Nottinghamshire Healthcare NHS Trust NHS England 111 940        
9 Camden And Islington Mental Health and Social Care Trust NHS England 101 373        
10 Oxleas NHS Foundation Trust NHS England 75 450        
11 North East London Mental Health NHS Trust NHS England 62 404        
12 Mersey Care NHS Trust NHS England 57 633        
13 Manchester Mental Health and Social Care Trust NHS England 51 269        
14 Avon and Wiltshire Mental Health Partnership Trust NHS England 45 679        
15 Bolton, Salford and Trafford Mental Health Services NHS England 39 570        
16 Oxfordshire and Buckinghamshire Mental Health Partnership NHS Trust NHS England 37 458        
17 Leicestershire Partnership NHS Trust NHS England 26 433        
18 Kneesworth House Hospital PVH England 23 99        
19 Leeds Mental Health Teaching NHS Trust NHS England 22 365        
20 Hampshire Partnership NHS Trust NHS England 18 655        
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Categories included 
Black or black British Caribbean 
Black or black British African 
Black or black British Any other black background 
Mixed White and black Caribbean 
Mixed White and black African 
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APPENDIX 15 FACTORS ASSOCIATED WITH NON EVIDENCE-BASED 




































































































APPENDIX 16 CASE VIGNETTE 
A 23-year-old, unemployed man presents to psychiatric services after being brought in 
by police having been found wandering in busy traffic.  
 
He is somewhat agitated and confused and shows poor self-care. Since admission three 
days before, he says he has been hearing voices telling him to direct traffic and then 
discussing his inability to do this.  
 
During interview he is markedly thought-disordered. On the ward he has been eating only 
takeaways, having told staff that he believes the hospital food to be poisoned. Nursing 
staff say that he has been isolating himself in his room during the day, coming out only 
when prompted to do so. There are no other mental state changes and he is taking no 
medication. The working diagnosis is of a relapse of schizophrenia. 
 
He is a physically fit, white/black* man of average height and weight (about 75Kg) with 
no family history of mental illness. His mother and father are in good health as are his 
two siblings. He has had one other hospital admission. This was a year ago when he was 
treated with risperidone which he apparently stopped soon after discharge because of 
sexual side effects.  
 
During this first admission he was assessed by a psychiatrist and diagnosed with 
schizophrenia. At that time he had been using cannabis heavily. However he claims he 
has not used any street drugs in the recent past – his urine drug screen confirms this. 























*vignettes used white or black 
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APPENDIX 17 DEMOGRAPHIC DETAILS CASE VIGNETTE STUDY 
 














(please tick as 
appropriate) 
Senior House Officer 
(Foundation Trainee) 
 





(please tick as 
appropriate, from 








Asian or Asian British  
Other ethnic group  
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APPENDIX 20 CASE VIGNETTE STUDY 
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